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Abstract
Aspirin has long been used as a prophylactic against thrombotic coronary events,
acting through inhibition of cyclooxygenase (COX)-l mediated platelet aggregation.
Unfortunately, gastrointestinal disorders are a common side-effect of aspirin that
limit its use.
A novel range of hybrid drugs in which a furoxan nitric oxide (NO)-donating moiety
is joined by ester linkage to the aspirin molecule were developed in the hope that the
cytoprotective actions of drug-derived NO would overcome the gastric side-effects
of aspirin. In addition, the presence of the NO group instils the potential for them to
have additional cardiovascular benefit over the parent compound. These effects are
investigated in this thesis and compared to that of an established nitrooxy-ester
derivative of aspirin (NCX4016).
A novel electron paramagnetic resonance assay was developed in order to investigate
whether the esterification had impacted on the ability of the compounds to inhibit
COX-1. Results indicated that the furoxan-aspirin hybrids and their NO-free furazan
counterparts all retained an aspirin-like action in vitro.
The NO-mediated effects in the vasculature were investigated via their capability to
cause relaxation of phenylephrine-constricted isolated rat aortic rings. The furoxan
hybrids were found to be powerful vasodilators and the effect was shown to be NO-
mediated on account of the lack of effect with their NO-free equivalents and a
susceptibility to the guanylate cyclase inhibitor, ODQ. Myography also revealed the
phenomenal potency of the stand-alone furoxan compound B13, which was
demonstrated to cause vasorelaxation in the picomolar range - approximate 300-fold
more potent than an established powerful NO donor, DEA/NO.
Antiplatelet studies in both platelet rich plasma (PRP) and washed platelets (WP)
revealed the furoxan-aspirin hybrids to inhibit platelet aggregation in both WP and
PRP. The effects were attenuated in PRP, likely due to the acetyl instability in
plasma. The comparatively weak effect of the NO-free counterparts, along with the
susceptibility to ODQ, is indicative of the dominant role of NO over aspirin in this
arena. However, in contrast to NCX4016, an aspirin-like action is retained, especially
in WP.
Electrochemical detection of NO release revealed the compounds to be stable in
solution and to only release significant amounts of NO in response to intracellular
concentrations of antioxidant elements glutathione and ascorbate, raising a potential
for primarily intracellular delivery of NO.
Finally, the capability of the compounds to inhibit release of pro-inflammatory
cytokines from monocytes and monocyte-derived macrophages was investigated.
Following LPS stimulation, cells treated with furoxan-aspirin hybrid, B8, displayed
reduced TNFa release. Immunofluorescence studies suggested that the mechanism
behind the reduction in TNFa release involved inhibiting the translocation of its
transcription factor, NF-kB, to the nucleus.
Taken together these studies reveal that both elements of the furoxan-aspirin hybrids
are active in vitro. Whilst chemical modification is likely required to improve
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EL1SA Enzyme-linked immunosorbent assay
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ERK Extracellular signal-regulated kinases
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HEPES (4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid)
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iNOS Inducible nitric oxide synthase
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LDH Lactate dehydrogenase
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L-NMMA L-arginine; NG-methyl-L-arginine
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NADPH nicotinamide adenine dinucleotide phosphate
NANC Non-adrenergic non-cholinergic (neurone)
NCX4016 2 acetoxy-benzoate 2-(2-nitroxymethyl)-phenyl ester
NCX4215 2-acetoxybenzoate 2-(2-nitroxy)-butyl ester
NF-KB Nuclear factor kappa B
nNOS Neuronal nitric oxide synthase
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NOS Nitric oxide synthase
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NSA1D Non-steroidal antiinflammatory drug





PGHS Prostaglandin F1 synthase (COX)
pgi2 Prostaglandin i2 / prostacyclin
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PPP Platelet poor plasma
PRP Platelet rich plasma
RT Room temperature
SA Salicylic acid
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SERCA Sarcoplasmic/endoplasmic reticulum Ca~ -ATPase
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Chapter One: General Introduction
1. General Introduction
1.1 Introduction
Cardiovascular disease is the leading cause of death in the world (Murray & Lopez,
1997). The most common clinical manifestations of the disease are myocardial
infarction (MI) and angina. Common prophylactic treatments for MI and angina
include the antithrombotic drug, aspirin, and the nitric oxide (NO)-yielding
vasodilator compounds, glyceryl trinitrate (GTN) and isosorbide dinitrate (ISDN).
This study investigates a set of compounds that combine a novel NO-containing
moiety with aspirin and, therefore, have the potential to provide a multi-faceted
approach to treating heart disease.
1.2 Platelet Function
1.2.1 Platelets
Platelets are small, discoid cell fragments that are heavily involved in haemostasis.
They originate from megakaryocytes in the bone marrow, but circulate in the blood.
Platelets are anuclear and lack replicative machinery. They do, however, possess
ribosomes and mRNA and so can synthesise some proteins (Bugert el al., 2003;
Lindemann et al, 2001). In the resting state, platelets are approximately 2 pm in
size, however, once activated they rapidly adopt a larger irregular shape
characterized by protruding filopodia (Winokur & Hartwig, 1995).
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1.2.2 Activation Mechanisms and Consequences
Platelets become activated in response to factors such as thrombin or adenosine
diphosphate (ADP), but also by exposure to collagen and von Willebrand factor
(vWF) following damage to the blood vessel endothelium. Once activated, platelets
release a number of factors involved in further activation and recruitment of
platelets, as well as activation of the coagulation cascade. Platelets adhere to the
vessel wall and to each other to form a haemostatic plug.
Initial weak interaction of platelets with collagen of the vessel wall occurs via vWF.
It binds collagen to platelet GPIb-V-IX complex (Alevriadou et al., 1993; Ruggeri,
1997; Savage et al, 1996). A more stable interaction follows, binding the platelets
directly to collagen via GPVI collagen receptors (Moroi et al., 1996; Saelman et al.,
1994). Thrombus growth is associated with binding of platelet fibrinogen to
glycoprotein (GP) Ilb/IIIa receptors which are expressed by activated platelets.
These receptors bind fibrinogen and thus link adjacent platelets, generating an
aggregate. At this stage, NO and prostacyclin (PGI2) are also released by the
endothelial cells and by activated platelets in order to act as negative feedback
mechanisms for the thrombus formation (Coughlin et al., 1980; Freedman &
Loscalzo, 2003).
1.2.3 Endogenous Inhibitory Mechanisms
A number of endogenous inhibitory mechanisms modulate platelet function and can
act in a synergistic manner to prevent pathologic thrombus formation. These
endogenous factors are produced by the endothelium and include NO and PGI2.
3
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NO, acting via its second messenger, cyclic guanosine monophosphate (cGMP),
inhibits both platelet adhesion and aggregation, through mechanisms discussed
further in section 1.4.4.1. Depression of NO in a dog model of endothelial injury was
demonstrated to increase thrombus formation, whereas an infusion of L-arginine
delayed it (Yao et al., 1992). NO also controls thrombus formation in the
cerebrovascular and renal systems (Shultz & Raij, 1992; Stagliano et al., 1997).
PGD acts to prevent platelet cytosolic calcium increase, platelet ATP secretion and
aggregation, but, unlike NO, PGI2 is poor at preventing adhesion (Doni el al., 1988;
Krishnamurthi et al., 1984; Radomski et al., 1987d). PGI2 is formed by the action of
the enzymes cycloooxygenase (COX, section 1.5.2) and prostacyclin synthase in
endothelial cells. Shear stress increases PGI2 production and upregulates COX
mRNA transcription (Frangos el al., 1985; Okahara et al., 1998). PGI2 acts locally
(on platelets and smooth muscle cells), but is rapidly converted to the inactive
metabolite, PGF|a. PGI2 is a powerful inhibitor of platelet aggregation and the
antiaggregatory effect of PGI2, together with the antiplatelet effects of NO, is
important in the regulation of platelet-vessel wall interactions (Radomski et al.,
1987a; Radomski et al., 1987c). Further evidence for the involvement of PGI2 in
protection against thrombosis came with the development of IP-receptor knockout
mice. Inhibition of platelet aggregation is not seen in these animals when a stable
PGI2 analogue is administered (Murata et al., 1997). PGI2 is utilised experimentally
in the preparation of washed platelets, where it transiently prevents activation and
prolongs viability of the platelets (Blackwell el al., 1982; Read et al., 1985).
4
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1.2.4 Current Pharmacological Interventions
Several antithrombotic treatments are available for use in patients at risk of stroke or
MI. Of these, the most commonly used today is aspirin (discussed further in section
1.5.2.2). Unfortunately, the use of aspirin is limited by its gastrotoxic side effects and
consequently alternative antithrombotic therapies are still being developed.
Clopidogrel acts to irreversibly block the adenosine diphosphate (ADP) receptor
(P2Y12) on platelet cell membranes. The P2Y12 receptor is responsible for the
completion and amplification of the response to ADP and to all platelet agonists,
including thromboxane A2 (TXA2), thrombin, and collagen (Storey, 2001).
Clopidogrel is a powerful antithrombotic agent (Uchiyama et al., 1992). The
CAPRIE study (1996) demonstrated that clopidogrel had superior clinical benefit
over aspirin for secondary prevention of atherothrombotic disease, with reduced risk
of MI and stroke (CAPRIE, 1996). Furthermore, its use in combination with aspirin
gives synergistic inhibitory effects (Moshfegh et al., 2000). However, a recent study
showed evidence of a relationship between the use of clopidogrel and surgical
bleeding among patients undergoing coronary artery surgery (Kapetanakis et al.,
2006). There is also a recently ignited debate over whether or not clopidogrel
resistance can develop, a factor which may limit its future use (Morel et al., 2005).
Glycoprotein (GP)IIb/IIIa inhibitors (e.g. abciximab and tirofiban) bind to GPIIb/IIIa
receptors exposed 011 the surface of activated platelets, thus preventing aggregate
formation. Drugs of this class administered percutaneously have been shown to be
safe and beneficial in preventing acute coronary syndromes (Bhatt & Topol, 2000;
Kong et al., 1998: White, 1999). However, studies have demonstrated increased
5
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mortality following oral delivery of GPlIb/IIIa antagonists (Chew el al., 2001). There
is also a major risk of bleeding associated with use of GPllb/IIIa receptor inhibitors
in some patients (Sitges & Villa, 1997; SoRelle, 2001; Trivedi el al., 2002).
1.3. Inflammation
Atherosclerosis is a major cardiovascular disease of the western world, characterised
by plaque build-up in arterial walls. It is now generally considered to be a chronic
inflammatory disease and so drugs with anti-inflammatory action may bring about
beneficial effects (Shaw et al., 2006; Shaw et al., 2005; Stoll & Bendszus, 2006).
1.3.1 Inflammatory Cells in Atherosclerosis
The first evidence for the involvement of inflammatory cells in the process of
atherosclerosis came from the observation of infiltrating T-cells in atherosclerotic
plaque tissue (Stemme et al., 1995; Zhou et al., 1996). The T-cells are thought to
play a role in the activation of inflammatory cells such as monocytes and
macrophages within the plaque (Hansson et al., 1989a; Hansson et al., 1989b).
Further evidence for the stimulation of inflammatory cells via an immune response
was obtained from experiments using transgenic immunodeficient mice crossed with
atherosclerotic-prone mice. This cross led to a dramatic reduction in development of
the earliest lesion, the fatty streak. Subsequent reintroduction of T-cells led to
increased circulating levels of the pro-inflammatory cytokine interferon-y and
accelerated atherosclerosis (Whitman el al., 2000; Zhou et al., 2000).
Atherosclerosis is characterised by formation of lipid-rich plaques in the sub-
endothelial space of arterial walls. Atherosclerosis progresses from a fatty streak,
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which, in itself, is not clinically significant. The fatty streak occurs due to the
movement of lipoprotein into the arterial wall via the damaged endothelium
(Celermajer, 1997). The lipoprotein likely becomes trapped in the intima by matrix
components (Fry, 1987; Schwenke & Carew, 1989a; Schwenke & Carew, 1989b)
and then modified by oxidation (Steinberg & Witztum, 1990). At this stage,
inflammatory cells such as monocytes also migrate into the fatty streak (Fig. 1.3c).
Monocytes are mononuclear leukocytes that demonstrate migratory, chemotactic,
pinocytic and phagocytic activities. They typically circulate in the blood for a few
days before migrating into other tissue types and maturing into macrophages. The
monocytes are recruited to lesion sites via endothelial cell-cell adhesion molecules
(CAMs, fig. 1.3c). CAMs, such as VCAM and ICAM are upregulated at
atherosclerotic-prone sites during endothelial dysfunction (section 1.4.4.2) and also
in patients with hypercholesteraemia (Celermajer, 1997; Iiyama et al., 1999; Shi et
al., 2005; van de Stolpe & van der Saag, 1996; Walpola et al., 1995). Monocytes
differentiate into macrophages, which are phagocytic leukocytes whose function is to
protect against infection and noxious substances. Macrophages also act to release
cytokines in order to attract further inflammatory cells, such as the highly motile
phagocytes, neutrophils. Macrophages subsequently take up the oxidised lipid via
specific scavenger receptors (Yamada et al., 1998) to become foam cells, which have
characteristic cytoplasmic droplets of cholesterol esters (Steinberg, 1987).
Further complexities arise on the migration of smooth muscle cells into the
subendothelial space. Here they contribute to formation of the fibrous cap via
synthesis of extracellular matrix (ECM) proteins. The advanced lesion is formed
following deposition of collagen and elastin in the fibrous cap region. This advanced
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lesion also displays a characteristic necrotic core, comprising an acellular region of
cell debris, lipid and calcium deposits.
It is from here that clinical events are manifest, either when increases in lesion size
impact on the lumen size, resulting in ischaemia or angina, or in the event of plaque
erosion or rupture. Plaque stability is a balance between the actions of inflammatory
cells (such as macrophages) and smooth muscle cells. Macrophages release
proteolytic enzymes named matrix metal loproteases that degrade the ECM laid down
by smooth muscle cells (Jones el al., 2003; Shah et al., 1995). Plaque rupture most
commonly occurs at the site of greatest haemodynamic stress; erosion or rupture
exposes lipid contents of the plaque to the lumen. This in turn may initiate the
coagulation cascade, leading to formation of a thrombus and predisposing to
complications such as MI or stroke (Fuster et al., 1990).
1.3.2 Inhibitory Mechanisms & Current Interventions
NO is an endogenous inhibitor of atherosclerosis. The various NO-mediated anti¬
inflammatory mechanisms that control atherosclerosis are discussed in section
1.4.4.3.
Pharmacological interventions for patients at risk of atherosclerosis-induced
cardiovascular disease are also available. Statins (or 3-hydroxy-3-methylglutaryl
coenzyme A (IIMG-CoA)-reductase inhibitors) were first used clinically in patients
with hypercholesterolemia to lower cholesterol in those at risk of cardiovascular
disease (Blauw et al., 1997). However, as patients with normal serum levels of
cholesterol also benefit from statin treatment, it is likely that they possess alternative
therapeutic mechanisms. Several studies provide evidence that this further effect of
8
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statins is likely to be an anti-inflammatory action; statins have been demonstrated to
significantly lower levels of the inflammatory marker C-reactive protein (Chan et al.,
2004; Milionis et al., 2005). Intensive treatment with atorvastatin decreased
inflammatory activity in carotid atherosclerotic plaques - possibly through inhibition
of inflammatory activity of macrophages (Martin-Ventura et al., 2005). Statins
downregulate the activation of the transcription factor, NF-kB, involved in the
inflammatory response (Dichtl et al., 2003; Martin-Ventura et al., 2005). Other
reported effects of statins include inhibition of platelet activation (Colli et al., 2004)
and antioxidant activity (Kowalski et al., 2005; Mason et al., 2006). Finally, statins
also enhance endothelial NO production by directly upregulating expression and
activity of its synthase, thus providing increased NO, which itself has anti¬
inflammatory actions, such as attenuating endothelium-leukocyte interactions
(section 1.4.4.3; Laufs et al., 1998).
The anti-inflammatory drug, aspirin, has therapeutic benefit in atherosclerosis
through its anti-inflammatory actions. It decreases the adherence of monocytes and T
cells to human coronary artery endothelial cells (Khan & Mehta, 2005). It can also
reduce expression of proinflammatory cytokines such as TNFa by inhibiting the
function of its transcription factor, NF-kB. NF-kB is normally kept in an inactive
state in the cytoplasm by being bound to an inhibitory subunit named IkB.
Phosphorylation of IkB. leads to its degradation, releasing NF-kB, which translocates
to the nucleus and stimulates expression of TNFa. Aspirin impacts upon this process
by inhibiting NF-kB mobilisation (Hachicha et al., 1999; Khan & Mehta, 2005).
Furthermore, aspirin prevents IkB degradation by inhibiting function of the IkB
kinase (IKK; Kopp & Ghosh, 1994; Tegcder et al., 2001; Yin et al., 1998).
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The antiplatelet action of aspirin (discussed in detail in section 1.5) also indirectly
contributes to its anti-inflammatory action. Platelets can be considered inflammatory
cells due to their release of pro-inflammatory agents. The release of IL-1B and
CD40L by platelets is thought to play a role in triggering atherogenesis (Gawaz et
al., 2005).
1.4 Nitric Oxide
NO is a ubiquitous signalling messenger molecule involved in diverse physiological
and pathophysiological processes. These include various effects in cardiovascular
and inflammatory processes including inhibition of platelet and inflammatory cell
adhesion, inhibition of platelet activation and also control of vascular tone
(Ahluwalia et al., 2004; De Caterina et al., 1995; Gruetter et al., 1981; Ignarro el al.,
1987; Radomski et al., 1987c; Radomski et al., 1987d). Furthermore, NO also
functions as a neurotransmitter at non-adrenergic, non-cholinergic (NANC) neurones
(Rand, 1992).
NO is composed of a single atom each of nitrogen and oxygen, is uncharged and has
an unpaired electron. Due to its free radical nature, it can rapidly react with reactive
oxygen species (ROS) and molecular oxygen at high NO concentrations, forming a
variety of biologically active species, which may go some way to explaining
paradoxical effects of NO observed in some systems (Shaw, 2006).
1.4.1 Historical Overview
During the early 1980s, the vasodilator endothelium-derived relaxation factor
(EDRF) was discovered to be released in response to agonists such as acetylcholine
(ACh), bradykinin and thrombin (Busse et al., 1985; Furchgott, 1984; Furchgott &
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Zawadzki, 1980). It was several years later that independent studies revealed that NO
accounted for at least some of the actions of EDRF (Furchgott, 1988; Ignarro et al.,
1988; Moncada et al., 1988; Palmer et al., 1987). Whilst some of those studies
merely suggested that NO and EDRF had similar physical, chemical and
pharmacological properties, Palmer el aVs work was definitive in that they directly
measured NO release from cultured endothelial cells using chemiluminescence
(Palmer et al., 1987).
1.4.2 Synthesis of NO
NO is produced by a group of enzymes known as NO synthases (NOS), of which
there are three recognized isoforms: endothelial (Pollock el al, 1991), neuronal
(Bredt et al., 1991) and inducible (Yui et al., 1991). NOS converts arginine and
oxygen to citrulline and NO in a process that requires tetrahydrobiopterin (BEfi) in
addition to other co-factors; flavin adenine dinucleotide (FAD), flavin
mononucleotide (FMN) and nicotinamide adenine dinucleotide phosphate (NADPH;
Mayer et al., 1989; Siddhanta et al., 1996). NO synthases can be separated into two
types: the constitutive isoforms (neuronal and endothelial) and the inducible isoform.
The constitutive isoforms are calcium-dependent, whilst the inducible isoform is not
due to calcium being permanently bound (Alderton et al., 2001). The three NOS
isozymes are fairly homologous: they are all homodimers, with each monomer
containing a reductase domain linked to a haem oxygenase (Griffith & Stuehr, 1995).
The former contains binding sites for FAD, FMN and NADPH, and the latter binds
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The constitutive forms of NOS are always present in neuronal or endothelial cells
and remain inactive until a rise in intracellular calcium is stimulated. Calcium binds
calmodulin, forming a complex that forms an electron bridge between the reductase
and oxygenase domains and thus, activates NOS. The production of NO will
continue until calcium levels subsequently decrease. Calmodulin then dissociates and
the enzyme reforms its complex with caveolin (Forstermann et al, 1991). More
recently, a calcium-independent phosphorylation of the synthase has been described
as a mechanism that stimulates the activity of endothelial NOS (eNOS; Ming et al.,
2002).
eNOS is membrane-bound and associated with membrane structures called caveolae
(Forstermann et al., 1991). On encountering an increase in Ca2+ mobilization caused
by agonists such as bradykinin or during shear stress, eNOS is activated to generate
NO, which subsequently diffuses in three dimensions away from its source (Govers
& Rabelink, 2001). The position of the endothelium at the interface between flowing
blood and the vessel wall means that the NO generated will encounter a number of
different cell types, depending on the direction in which it diffuses: NO that diffuses
abluminally passes into vascular smooth muscle cells where it causes vascular
relaxation; that which diffuses into the vessel lumen encounters platelets and
leukocytes, whereupon it inhibits their aggregation and adhesion to the vessel wall. It
will also encounter red blood cells where it is scavenged by haemoglobin (section
1.4.3.3).
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NO synthesized by neuronal NOS (nNOS) in the neurones of the central nervous
system acts as a neuromodulator involved in processes such as memory formation,
pain modulation and neuronal control of blood flow (Moore & Handy, 1997).
1.4.2.2 Inducible NOS
Unlike the constitutive isoforms, which only bind calmodulin when the intracellular
calcium concentration increases, inducible NOS (iNOS) tightly binds calmodulin
even at resting calcium concentrations, and so is active once synthesized (Cho et al.,
1992). Instead, regulation of iNOS occurs at the transcriptional level; iNOS is
normally absent in most cells but is stimulated in cells such as macrophages during
inflammation, immunological defence, or infection. Substances such as cytokines
(e.g. TNF-a, IL-lfl or IFN-y) and bacterial products (lipopolysaccharides; LPS) are
known to regulate iNOS by stimulating binding of transcription factors such as NF-
kB to promoter regions of the iNOS gene (Aktan, 2004; Galea et al., 1992; Hibbs et
al., 1992; Lee et al., 1993; Nathan, 1992; Xie & Nathan, 1994). A mechanism of
post-transcriptional regulation of iNOS has also been reported whereby LPS and
IFN-y act to stabilise iNOS mRNA (Xie & Nathan, 1994).
Once expressed, the enzyme begins to synthesise large quantities (pM) of NO which
can result in host tissue damage (Nathan & Xie, 1994). The deleterious effects of
iNOS-derived NO persist and can last for days because the enzyme does not rely on
calcium to function (Nathan & Xie, 1994).
The large quantities of NO produced by iNOS result in inflammation, cell damage
and apoptosis (Lowenstein & Snyder, 1992; Moncada & Higgs, 1995; Nathan,
1992). Increased NO has been demonstrated in patients with chronic inflammatory
13
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conditions such as asthma (Persson el al., 1994), arthritis (Farrell et al., 1992) and
ulcerative colitis (Boughton-Smith et al., 1993), thought to be due to the induction of
iNOS (Aktan, 2004; Moncada & Higgs, 1995). iNOS has been localised in human
atherosclerotic lesions to macrophages and smooth muscle cells, suggesting it plays a
role in oxidative damage during the disease progression (Luorna et al., 1998). With
the increased presence of ROS, as is common with endothelial dysfunction, it is
likely that the reaction of iNOS-derived NO with superoxide (O2") to form
peroxynitrite (ONOO") may occur. The deleterious effects of peroxynitrite are likely
to play a role in atherosclerotic disease progression (Shaw, 2006).
Despite commonly being thought to be involved in pathological roles, there is some
evidence of favourable effects of iNOS-derived NO. It has been demonstrated to be
an anti-bacterial agent (Nozaki et al., 1997), to be involved in wound healing
(Yamasaki et al., 1998), to have a protective response to intestinal injury
(McCafferty et al., 1997) and to have possible roles in cardioprotection (Muller et
al., 2000; Parratt & Szekeres, 1995).
1.4.2.3 NOS Inhibitors
There are many NOS inhibitors available for use as experimental tools to help
investigate the contribution of NOS in vasodilator responses. These compounds are
mainly analogues of the endogenous substrate, L-arginine. The most commonly
used non-selective NOS inhibitors include: N°-monomethyl-L-arginine (L-NMMA),
L-nitroarginine (L-NNA), N°-nitro-L-arginine methyl ester (L-NAME) and the
endogenous asymmetric dimethylarginine (ADMA; Leiper & Vallance, 1999; Moore
& Handy, 1997; Palmer et al., 1988; Yallance et al., 1992).
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Fig. 1.1. Synthesis and targets of NO.
1.4.3 Targets of NO
1.4.3.1 Soluble Guanylate Cyclase
Soluble guanylate cyclase (sGC. Fig. l.l) is the primary target for NOS-derived NO.
sGC is a heterodimeric enzyme consisting of two subunits (a and (3), in addition to a
prosthetic haem group (Kamisaki el al., 1986; Karow et al., 2005). Each subunit can
be divided into three domains: the N-terminal haem-binding domain, a central
dimerisation domain and a C-terminal catalytic domain. NO has a high affinity for
the haem domain and so binds to it forming a NO-haem complex which undergoes a
subsequent conformational change resulting in a 400-fold increase in the rate of
enzyme catalytic activity (Stone & Marietta, 1996).
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Activated sGC converts guanosine-5'-triphosphate (GTP) to 3', 5'- cyclic guanosine
monophosphate (cGMP; Ishii et al., 1991; Moro et al., 1996; Wolin et al., 1982).
There are a number of cGMP-dependent effector pathways that rely on stimulation of
cGMP-dependent protein kinases, cGMP-regulated phosphodiesterases or cGMP-
gated ion channels. For instance, NO-induced vasorelaxation is brought about by
2+
cGMP-dependent protein kinases activating Ca -activated potassium channels
leading to membrane hyperpolarisation. This then closes voltage-dependent Ca2+
channels resulting in a decrease in intracellular calcium which brings about the
vasorelaxation (Fukao et al., 1999; Lucas et al., 2000; Robertson et al., 1993).
In addition to reducing intracellular calcium, NO-donors also induce relaxation by an
unknown mechanism which uncouples 'stress' from the phosphorylated myosin light
chain of the smooth muscle (McDaniel et al., 1992). The stress is defined as
'force/cell cross-sectional area' (Flai & Murphy, 1989) and refers to the shortening of
the filament. Furthermore, it has been demonstrated that the relaxation of vascular
smooth muscle caused by NO involves the activation of myosin light chain
phosphatase (MLCP), correlated with a decline in light chain phosphorylation and
force (Etter et al., 2001).
1.4.3.1.1 sGC Deactivation
The first suggestion of a quick reactivation of sGC came from the observation that
NO-induced relaxation of aortic rings could be repeated within two minutes of the
first stimulus (Palmer et al., 1987). NO dissociation from the sGC haem triggers
deactivation.
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Studies have shown the half-life of NO-sGC to vary between five seconds and a few
minutes (Brandish et al., 1998; Kharitonov et al., 1997a; Kharitonov el al., 1997b;
Margulis & Sitaramayya, 2000; Russwurm el al., 2002), depending on the presence
of factors such as GTP, oxy-haemoglobin and glutathione (GSH). Furthermore, in
intact cells, the half-life has been estimated to be 190 ms (Bellamy & Garthwaite,
2001).
1.4.3.1.2 sGC Inhibitors
1 H-[ 1,2,4]oxadiazolo[4,3-a|-quinoxalin-l-one (ODQ) inhibits sGC (Garthwaite et
al., 1995) and is therefore a useful experimental tool in determining the cGMP-
dependent and -independent effects of NO. ODQ is the preferred alternative to the
non-specific inhibitors methylene blue and LY-83583, which have been shown to
interfere with NO synthesis (Mayer et al., 1993). ODQ binds in a competitive
manner and inhibits NO-stimulated activity leaving basal enzymatic activity. The
mechanism of ODQ-mediated inhibition involves sGC haem oxidation (Schrammel
et al., 1996; Zhao et al., 2000).
1.4.3.2 cGMP-lndependent Effects of NO
A rise in intracellular cGMP has been shown not to be necessary for several NO-
dependent effects. Such cGMP-independent effects show an interesting correlation
with extracellular NO generation (Crane et a/., 2005; Miller et al., 2004; Sogo et al.,
2000a) and appear to be particularly relevant in the inhibition of platelet aggregation
(Beghetti et al., 2003; Crane et al., 2005; Gordge et al., 1998; Homer & Wanstall,
2002; Trepakova et al., 1999; Tsikas et al., 1999). In platelets, the evidence is fairly
strong in support of NO-mediated activation of the sarcoplasmic/endoplasmic
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reticulum Ca2+-ATPase (SERCA), leading to refilling of Ca2+ stores and thus a
decrease in intracellular calcium (Trepakova et al., 1999).
It has also been reported that S-nitrosocysteine inhibits collagen-induced
thromboxane A2 (TXA2) synthesis in platelets by a cGMP-independent mechanism
(Tsikas et al., 1999). This effect is likely due to NO-mediated inhibition of COX-1 as
has been previously reported (Kanner el at, 1992; Tsai el al., 1994). Alternatively it
could occur via inhibition of TXA2 synthase (Wade & Fitzpatrick, 1997).
1.4.3.3 NO Scavengers
NO can be scavenged by various agents which are used experimentally. Of these
scavengers, two are commonly used: haemoglobin and carboxy-2-phenyl-4,4,5,5-
tetramethyl-imidazoline-l-oxyl-3-oxide (cPTIO).
The stable radical compound cPTIO reacts with NO to form nitrite. It has been
demonstrated to antagonise effectively the effects of NO in biological systems; it
significantly inhibits vasorelaxation (Akaike et al., 1993), inhibits endothelial cell
mitogenesis and proliferation (Sarkar et al., 1995), reverses inhibition of neutrophil
adherence to the coronary artery endothelium (Sato et al., 1996) and significantly
inhibits NO-induced accumulation of cGMP in endothelial cells (Pfeiffer et al.,
I 997).
NO also reacts with haemoglobin in its oxygenated state (oxyHb) to form
methaemoglobin and nitrate. The rapid reaction of NO with oxyHb is a confounding
factor for in vivo NO delivery. However, this issue is considerably complicated by
the possibility of NO transport on haemoglobin as S-nitrosohaemoglobin, resulting
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from S-nitrosation of Cys 93 residue (McMahon et al., 2002; Pawloski et al., 2001;
Stamler et al., 1992). The existence of such a pathway and its relevance to human
physiology is the topic of heated debate (Hobbs et al., 2002), and is disputed by the
counter-argument that the role of haemoglobin is to release NO from NO2 (Gladwin
et al., 2004; Gladwin & Schechter, 2004).
NO displays antithrombotic actions through its ability to inhibit platelet adherence
(Radomski et al., 1987b; Radomski et al., 1987d) and aggregation (Pasqui et al.,
1991; Radomski et al., 1990; Radomski et al., 1987b; Radomski et al., 1987c).
Radomski el al. first demonstrated that when aetivated, a constitutive NO synthase in
platelets is stimulated to produce NO (Radomski et al., 1990). This gives a
subsequent increase in cGMP which is responsible for the antiaggregatory effect
(Fig. 1.2; Mellion et al., 1981).
1.4.4 Physiological Effects of NO




Fig. 1.2. Anti-platelet actions of NO and aspirin
19
Chapter One: General Introduction
1.4.4.2 NO and the Endothelium
The endothelium (Fig. 1.3) is a single layer of cells that lies between the smooth
muscle cell layer and the lumen of blood vessels that was, until recently, regarded to
be inert. Within the past two decades the endothelium has been shown to be an
antithrombogenic surface involved in diverse roles related to metabolic, synthetic
and regulatory pathways (Rubanyi, 1993).
The normal function of the endothelium is to help control vascular homeostasis. The
important role of the endothelium to release a substance (later identified as NO) that
brings about vasodilatation was first reported in 1980 (Furchgott & Zawadzki, 1980).
However, in addition, the endothelium produces a powerful vasoconstrictor peptide,
endothelin (ET-1; Fig 1.3a). The substances released by the endothelium act directly
on the adjacent smooth muscle cells to bring about relaxation or contraction.
Endothelial dysfunction or the loss of normal function of the endothelium, is a
consequence of the decreased activity or bioavailability of endothelium-derived NO.
Endothelial dysfunction is known to precede the development of atherosclerosis
(section 1.3.1; Celermajer, 1997; Suwaidi et al., 2000) and has been associated with
the following risk factors: hypercholesterolemia (Drexler & Zeiher, 1991), obesity
(Shankar & Steinberg, 2005) and hypertension (Taddei et al., 2001; Zhu et al.,
2002).
Fig. 1.3. Function of the endothelium, (a) shows function of agonist and shear stress action
on the endothelium and the consequences on the adjacent smooth muscle cells, (b) shows
the role that NO plays in endothelium-dependent relaxation of smooth muscle cells, (c)
shows a dysfunctional endothelial cell expressing CAMs such as ICAM and VCAM and the
resulting recruitment of monocytes. Monocytes migrate into the subendothelial space where
they differentiate into macrophages and later take up LDL (lipoprotein) that has been
oxidised by free radical species, to become foam cells, an important constituent of the
atherosclerotic plaque. EC = endothelial cell, SMC = smooth muscle cell, FC = foam cell,
mon = monocyte, mac = macrophage (P)= phosphorylation.
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NO brings about smooth muscle cell relaxation in a process relying upon cytosolic
guanylate cyclase to increase cGMP. (Fig 1.3b; Gruetter et al., 1981; Ignarro et al.,
1987; Liu et al., 1992; Rapoport et al., 1983). NO also stimulates synthesis of PGL,
a potent vasorelaxant and inhibitor of platelet aggregation. NO has been
demonstrated to increase the production of eicosanoids such as PGh through
activation of COX in endothelial cells by a cGMP-independent mechanism (Davidge
et al., 1995). Interestingly, the Davidge results are in contrast to other studies where
NO has been demonstrated to inhibit COX activity (discussed in section 1.4.3.2). It is
plausible that these opposing effects occur due to differing intermediary pathways
and not as a result of a direct interaction of NO with COX (Tsai et al., 1994). A
further possible explanation is that the NO-related species, peroxynitrite, is
responsible for the effect, an occurrence that would not be observed in the studies
with purified enzyme (Davidge et al., 1995).
Prostaglandins, such as PGL, are also released by endothelial cells (Fitzgerald,
2004). PGL, along with PGE2, brings about endothelium-dependent vasorelaxation
by action on specific receptors, named IP receptors (Coleman el al., 1994). These
receptors are G-protein-coupled receptors that act to increase levels of cyclic
adenosine monophosphate (cAMP; Coleman et at., 1994; Halushka et al., 1989) via
the Gs subunit (Jaschonek et al., 1988) coupling to adenylate cyclase (Gorman et al.,
1977). IP receptors have been localised to platelets (Oliva & Nicosia, 1987), where
they bring about their antiaggregatory effects, and also to vascular smooth muscle
cells.
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After inhibition of the synthesis of NO and prostaglandins, an endothelium-
dependent, hyperpolarisation-mediated vasodilatory mechanism can still be observed
following stimulation by ACh or bradykinin. The mediator of this action has been
named endothelium-derived hyperpolarizing factor (ED1IF).
Several studies have shown in vitro evidence for the existence of EDHF in human
arteries (Bussemaker et al., 2003; Kemp & Cocks, 1997; Miura et al., 1999;
Nakashima et al., 1993). The action of EDFIF relies upon the release of intracellular
calcium as occurs under shear stress or following receptor activation. Calcium-
activated potassium channels are then stimulated, resulting in an endothelium-
derived hyperpolarisation, or release of an 'EDHF'(Ding & Triggle, 2003; Griffith,
2004). EDFIF may be a purely electrical contact-mediated event, or it may rely upon
a diffusible mediator, of which several candidates have been suggested, including
potassium ions themselves (Edwards et al., 1998; Griffith, 2004), C-type natriuretic
peptide (Chauhan et al., 2003b), derivatives of the cytochrome-P450-
monooxygenase, the epoxyeicosatrienoic acids (Fulton el al., 1998) or even L-
NAME insensitive NO (Chauhan et al., 2003a; Cohen et al., 1997).
1.4.4.3 NO and Inflammatory Cells
NO has various anti-inflammatory actions in the vasculature. It plays a role in
endothelial cell-mediated inhibition of leukocyte recruitment to a site of injury (i.e.
during atherosclerosis) or infection. P-selectins are contained within Weibel Palade
bodies in the endothelium (Merten & Thiagarajan, 2004; Smith, 1993). The
expression of selectins on the surface of the endothelial cell is upregulated following
stimulation, for example, by histamine during an infection, or by the presence of
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activated platelets (Dole et al., 2005; Smith, 1993). Here they can bind with
complementary L-selectins on the leukocyte surface (Kansas et al., 1993).
Leukocytes are loosely bound and so are free to 'roll' along the endothelium. Firmer
bonds between leukocytes and endothelial cells are soon formed via endothelial
molecules such as ICAM and VCAM expressed by the endothelial cells (Fig. 1.3c),
but also by integrins expressed by the leukocytes. The integrins are heterodimeric
glycoproteins such as CD11 or CD 18 (Tonnesen, 1989). NO impacts on this process
in a number of ways. It reduces expression of P-selectin and thus leukocyte
recruitment in a cGMP-dependent process (Ahluwalia et al., 2004). The
administration of NOS inhibitors, L-NMMA and L-NAME, both increased adherent
leukocytes by 15-fold in a process abolished by administration of the CD 18
antibody, IB4 (Kubes et al., 1991). NO has also been demonstrated to inhibit ICAM
and VCAM expression (Berendji-Grun el al., 2001; De Caterina et al., 1995;
Spiecker et al., 1997).
In addition, NO has anti-inflammatory effects in macrophages. Immunological or
inflammatory stimuli (such as activation by cytokines and bacterial products)
stimulate macrophages to express iNOS and produce NO (Moneada & Higgs, 1995).
NO inhibits production of inflammatory cytokines such as the interleukins (IL-1 and
IL-12; Huang et al., 1998; Obermeier et al., 1999; Thomassen et al., 1997). NO also
downregulates the proinflammatory cytokine TNFa in macrophages (Sinha el al.,
1998; Thomassen et al., 1997). It has been further shown in vitro and in vivo that L-
NMMA treatment increases TNFa production, whereas L-arginine treatment reduces
it (Iuvone el al., 1996). As discussed in section 1.3.2, phosphorylation of IkB is
required for NF-kB to become activated and induce TNFa production. It has been
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shown that NO can impact on this process by inhibiting IicB-phosphorylation, thus
inhibiting the activation of NF-kB (Hattori el al., 2004). Furthermore, NO-donors can
directly inhibit the DNA binding activity of NF-kB preventing it from activating
genes (Matthews et al., 1996; Sekkai et al., 1998).
Interestingly, under certain conditions, NO can have pro-inflammatory actions
(Grisham et al., 1999). For example, in asthma and during pulmonary disease, the
high concentrations of iNOS-derived NO may produce various deleterious effects such
as increased vascular permeability, damage to the airway epithelium, and promotion of
inflammatory cell infiltration (Flak & Goldman, 1996; Laskin et al., 2001; Mulrennan
& Redington, 2004). Pro-inflammatory effects of excessive NO production have also
been implicated in neurodegenerative diseases such as Parkinson's, Alzheimer's and
multiple sclerosis (Liu et al., 2002; Santiago et al., 1998). It is possible that the
inflammatory effects of NO are actually due to the generation of peroxynitrite which is
causing these inflammatory actions (Shaw, 2006).
NO has been reported to have other paradoxical actions (such as being pro- and anti¬
oxidant, pro- and anti-apoptotic and also cytotoxic and cytoprotective) and it is
suggested that the opposing effects of NO are due to the method of synthesis, the
NO-related species involved, its concentration and the cell type involved (Grisham et
al., 1999; Shaw, 2006; Taylor et al., 2003).
1.4.5 Current NO Donors and their Limitations
NO-donors are used as experimental tools in the quest to understand the complex
physiological processes in which NO plays a role. In addition, some NO-donor drugs
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are used clinically to treat the symptoms of vascular disease and thrombotic
disorders.
1.4.5.1 Organic Nitrates
Organic nitrate compounds are still the most widely used therapeutic NO donors,
despite having been used for over 125 years (Murell, 1879). These include
compounds such as GTN and ISDN, commonly used in the symptomatic treatment
of angina. They rapidly bring about their effect by dilating veins and coronary
arteries, thus reducing cardiac work and improving blood supply to the heart
(Abrams, 1885). However, the use of compounds such as GTN is limited by the
development of tolerance to the haemodynamic effects with long-term use or high
dosage (Stewart, 1888). Nitrate tolerance is characterized by a loss of nitrate-
induced, cGMP-mediated vasodilation and tolerance has been demonstrated to lead
to the loss of antiplatelet actions of nitrates, even at low doses (Chirkov et al., 1997;
Schwemmer & Bassenge, 2003). The mechanism behind tolerance is highly
controversial, but is likely due to the interruption of the bioactivation pathways that
are required to release NO from these compounds. Nitrate-mediated inhibition of
vascular mitochondrial aldehyde dehydrogenase, the enzyme that accomplishes
bioactivation of GTN has been suggested as a mechanism of tolerance (Chen et al.,
2002; Sydow et al., 2004). Possible additional mechanisms for the tolerance may be
oxidative stress (Munzel et al., 1995), desensitization of sGC (Artz et al., 2002), or
an induction of reflex sodium retention, and thus plasma volume (Parker et al.,
1991). Another potential drawback for the clinical use of nitrates is their poor
antiplatelet effects. This is explained by the poor capability of platelets to release NO
from organic nitrates (Weber el al., 1996).
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Diazeniumdiolates (NONOates) are compounds with the general formula X-
|N(0)N0]" which are formed by the process of exposing nucleophiles to pressurised
NO gas (Morley & Keefer, 1993). Diazeniumdiolates do not require bioactivation,
are generally stable when in solid form, but will spontaneously release NO when in
solution at a rate that is dependent on pH, temperature and the nature of the
nucleophile (Horstmann et al., 2002; Keefer et al., 2001; Ramamurthi & Lewis,
1997). Unlike the organic nitrates, diazeniumdiolates do not induce tolerance (Homer
& Wanstall, 1998).
Diethylamine diazeniumdiolate (DEA/NO) is a commonly used experimental
diazeniumdiolate. It has a short half-life (around 2 min) at physiological temperature
and pH (Homer & Wanstall. 1998) and inhibits platelet activation by a cGMP-
independent mechanism (Sogo et al., 2000a).
1.4.5.3 Sydnonomines
Molsidomine is converted in the liver to its active metabolite, 3-
morpholinosydnonomine (SIN-1; Reden, 1990). SIN-l releases NO spontaneously in
a two-step process in the blood (Feelisch et al., 1989). It was originally thought that
SIN-l was an NO-donor drug, but as SIN-l is known to simultaneously generate O2",
it is now more correctly regarded as a peroxynitrite generator (Feelisch et al., 1989;
Hogg et al., 1992).
It was originally hoped that sydnonomines would provide tolerance-free alternatives
to the nitrates, but despite being considerably more potent than nitrates at inhibiting
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platelet activation (Bult et al., 1995; Gerzer et al., 1988), in a large-scale clinical trial
molsidomine failed to show any benefit in MI (ESPRIM, 1994).
1.4.5.4 S-Nitrosothiols
S-Nitrosothiols have the general formula RSNO. They are synthesised by S-
nitrosation of reduced thiols (Williams, 1985), but are also produced endogenously
(e.g. S-nitrosoalbumin and S-nitrosoglutathione).
Release of NO from S-nitrosothiols in vivo likely takes place by utilising Cu2+-
containing enzymes (Al-Sa'doni et al., 1997; Dicks el al., 1996), although other
enzymes can also achieve the release of NO (Freedman et al., 1995; .lourd'heuil et
al., 1999; Zai et al., 1999). S-Nitrosothiols have been demonstrated to be more
selective for platelets over blood vessels (Crane et al., 2002; de Belder el al., 1994;
Ramsay et al., 1995) and are known to mediate their effects via both cGMP-
dependent (Mellion et al., 1983; Radomski et al., 1992) and cGMP-independent
effects (Crane et al., 2005; Gordge et al., 1998; Sogo el al., 2000a; Tsikas et al.,
1999).
The stability of older S-nitrosothiols can be unpredictable and their half-life can vary
depending on the R-group present, the solvent and the pFI. However, more recently
developed S-nitrosothiols may offer improvement (Crane et al., 2005; Megson et al.,
1997; Miller et al., 2003; Sogo el al., 2000b).
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1.5 Aspirin
1.5.1 Historical Overview
Aspirin (acetylsalicylic acid) was first synthesized in 1899 by Felix Hoffman of
Bayer Corp. It was the first drug of the family of nonsteroidal anti-inflammatory
drugs (NSAIDs) on the market and it is used today in the treatment of headache,
rheumatic pain, inflammation, and as a prophylactic against thrombotic events in the
cardiovascular system. Over 40 billion aspirins are taken per year in the United
States (Schiffmann et al, 2005). Despite being used for many years, it took until
1971 for Vane to discover that inhibition of prostaglandin synthesis was the
mechanism for the therapeutic effect of aspirin (Vane, 1971).
1.5.2 Pharmacological Mechanism of Action
Prostaglandins are derived from arachidonic acid (AA) in a pathway dependent on
the COX family of enzymes, where aspirin has its effect. There are two structurally
similar COX isoforms named COX-l and COX-2 (discussed in sections 1.5.2.2 and
1.5.2.3 respectively), which are encoded by different genes. The expression of the
COX isozymes varies between tissues.
In contrast to other NSAIDs, such as naproxen and ibuprofen, which reversibly bind
at the active site of COX (Garcia Rodriguez et al., 2004), aspirin causes an
irreversible inhibition. It selectively and rapidly (within minutes) acetylates the
hydroxyl group of a serine residue (Scr 530) near the C-terminus of COX, forming
an impediment to the binding of AA (DeWitt & Smith, 1988; Roth & Majerus, 1975;
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Roth el al.. 1975). Acetylation causes irreversible COX inhibition and a requirement
for new COX to be synthesised for subsequent production of prostaglandins. As
platelets are widely thought to lack the necessary cellular machinery to synthesise
new proteins, the effect of aspirin will last for the lifetime of the platelet
(approximately 10 days); indeed a recovery of COX activity of 10 % per day has
been observed, in-line with platelet turnover (Altman el al., 2004).
1.5.2.1 Arachidonic Acid Metabolism
AA is an essential fatty acid found amongst membrane phospholipids. Activation of
the enzyme, phospholipase A2, liberates AA from the membrane, making it available
for two further pathways. AA can either be utilized by COX-1 or COX-2 to form
prostaglandins and thromboxanes, or it can be utilised by another enzyme called 5-
lipoxygenase (5-LO) to form leukotrienes (Fig. 1.4). The lipoxygenases, which
comprise three major types (5-, 15-, and 12-LO), are compartmentalized within
different cell types of peripheral blood and act to transform AA to biologically active
compounds (Serhan et al., 1990).
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Fig. 1.4. Arachidonic acid metabolism. AA is either metabolized by one of the COX enzymes
to form prostaglandins and thromboxanes or by 5-LO to form the leukotrienes.
5-LO is a calcium- and ATP-dependent enzyme which catalyses the conversion of
AA to (5S)-trans-5,6-oxido-7,9-trans-l 1,14-cis-eicosatetraenoic acid (5-HPETE) and
also the subsequent conversion to the fairly unstable leukotriene A4 (LTA4), the first
of a series of leukotrienes formed. LTA4 is the substrate for two enzymes;
leukotriene A4 hydrolase and leukotriene C4 synthase, which form LTB4 and LTC4
respectively (Bertolini el al., 2001). LTB4 is a potent chemotaxin and LTC4, along
with the subsequent leukotrienes, LTD4 and LTE4, formed from it, is involved in
bronchoconstriction and increased vascular permeability (Parente, 2001).
31
Chapter One: General Introduction
1.5.2.1.1 Lipoxins
Lipoxins (LXs) and aspirin-triggered lipoxins (ATL) are endogenously produced
anti-inflammatory agents. Lipoxins are short-lived eicosanoids whose appearance in
inflammation signals the resolution of inflammation. LXs were first identified in
human leukocytes by Serhan et al. in the early 1980s, who proposed that LXs were
formed via interactions of the 5- and 15-lipoxygenase pathways in leukocytes
(Serhan el al., 1984). The common mammalian forms of LXs are LXA4 and its
positional isomer LXB4 (McMahon & Godson, 2004).
LXs are typically formed through cell-cell interactions. The most common pathway
identified within the vasculature is viaplatelet-polymorphonuclear neutrophil (PMN)
interaction. This pathway involves the activities of 5-LO, present in cells such as
neutrophils, and 12-LO, present in platelets. 5-LO generates LTA4 from AA that is
rapidly taken up by platelets. Platelets then convert LTA4 to LXA4 through the
oxygenase activity of their 12-LO (Serhan et al., 1990).
LXs are also formed in a process triggered by aspirin, known as the 15-epi-LX
pathway. In environments rich in cytokines, aspirin will acetylate COX-2, prompting
it to act as a lipoxygenase rather than an endoperoxide and thus, converting AA to
15-HETE which is subsequently transformed by 5-LO to 15-epi-LXA4 or 15-epi-
LXB4 (Claria & Serhan, 1995).
ATLs are thought to bring about beneficial effects of aspirin further to the
antithrombotic action, particularly in the resolution of inflammation (McMahon et
al., 2001). Recent evidence has shown that LXA4 regulates the production of the
32
Chapter One: General Introduction
inflammatory mediator IL-12 (Machado el al., 2006). In the absence of LXA4 and the
consequent cessation of IL-12 production, inflammation would persist, resulting in
host damage. Machado et al. demonstrated that LXs activate two receptors (AhR
and LXAR) in dendritic cells, causing expression of a suppressor of cytokine
signalling (SOCS-2), which in turn, regulates the inflammatory response. They
further demonstrated that SOCS-2-deficient mice display uncontrolled inflammation
(Machado et al., 2006). A further LX-mediated mechanism has been proposed which
helps explain some of the actions of aspirin that cannot be attributed to the inhibition
of prostanoids - such as how aspirin inhibits cell accumulation during inflammation.
In two separate studies aspirin has been demonstrated to trigger production of NO
through eNOS and iNOS (Paul-Clark et al., 2004; Taubert et al., 2004). The NO acts
to provide anti-inflammatory effects such as inhibition of leukocyte-endothelial
interactions (Paul-Clark et al., 2004) and preservation of endothelial function
(Taubert et al., 2004).
1.5.2.2 COX-1 and its Inhibition
COX-l is often referred to as the 'house-keeping' isoform due to its functions in
many tissues. It has high-profile regulatory roles in the gastric mucosa, the kidneys
and platelets.
In platelets, the effect of aspirin is irreversible, due to the inability of platelets to
generate new COX. This means that there is a cumulative inhibition of platelet TxA2
production (Patrignani et al., 1982), leading to a prolonged antithrombotic effect. As
depicted in figure l .2, the antithrombotic action of aspirin comes about through its
ability to inhibit platelet COX-l. The normal coagulation pathway relies on the
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production of TxA2 as described above (Fig. 1.4). TxA2 was first identified in the
guinea pig lung during anaphylaxis. It was known to cause vasoconstriction of rabbit
aortic smooth muscle and consequently, was known as rabbit aorta-contracting
substance (Piper & Vane, 1969).
A few years later, endoperoxides (PGG2 and PGH2), which induced platelet
aggregation, were found to be generated when platelets were incubated with AA
(Hamberg & Samuelsson, 1974; Hamberg et al., 1974). It was soon noted that these
agents alone could not account for the activity of rabbit aorta-contracting substance
and it was later realised that incubation of PGG2 or PGFI2 with platelets resulted in
the formation of a very unstable compound that induced irreversible platelet
aggregation and was degraded to the inactive, but stable, TxB2 (Hamberg et al.,
1975). The unstable compound was named TxA2.
TxA2 exerts its effect by action on G-protein coupled receptors called TP receptors,
of which different types exist in platelets and vascular smooth muscle (Masuda et al.,
1991). It has been reported that two different effector systems are involved in TxA2-
induced platelet signalling. Phospholipase C activation is primarily involved in
mediating platelet aggregation and Ca2+ mobilisation controls platelet shape change
(Brass et al., 1987). TP receptor mutations, and defective signal transduction by the
TP receptor have both been linked to bleeding disorders (Hirata et al., 1994; Mitsui
etal, 1997).
Unstable TxA2 has a half-life of-30 seconds (Bhagwat et al., 1985) so it is not
surprising that most experimental studies of TXA2 activity are carried out with the
longer-lasting TP receptor agonist, U46619. U46619 studies have revealed that the
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TxA2 receptor is located on the platelet membrane (Hung et al., 1983), that U46619
directly stimulates platelet shape change (Parise et al., 1982), that it induces platelet
aggregation in humans but not in sheep (Leach & Thorburn, 1982) and that sickle-
cell anaemia patients have decreased aggregation in response to U46619, but not
thrombin (Foulon et al., 1993).
As aspirin is nearly 170-lold more selective for inhibiting COX-1 than COX-2 (Vane
el al., 1998), low dose aspirin (75 mg) can be taken daily and is effective at
inhibiting platelet thromboxane without affecting vascular PGI2 or having an anti¬
inflammatory effect (Forster & Parratt, 1997; Vane et al., 1998).
1.5.2.3 COX-2 and its Inhibition
In contrast to COX-l, COX-2 is virtually undetectable under normal conditions in
most tissues. It is often referred to as the 'inducible' isoform because of its tendency
to be expressed in response to inflammatory stimuli.
The COX-2 gene is commonly stimulated by both growth factors and mediators of
inflammation such as IL-1, TNFa and LPS. Furthermore, its expression is suppressed
by anti-inflammatory cytokines and glucocorticoids. With the development of COX-
2 selective inhibitors, it was shown that COX-2 plays a critical role in inflammation,
pain, and fever (DeWitt, 1999).
The regulation by growth factors suggests that COX-2 has a role in mitogenesis, or
perhaps wound repair. Indeed, colon cancers have been demonstrated to produce
high levels of the COX-2-derived prostaglandins that act to enhance tumour growth
(Karim & Rao, 1976; Lirn et al., 2001; Lupulescu, 1996; Sano et al., 1995;
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Sinicrope, 2006; Yona & Arber, 2006) The implication of COX-2 in the
development of cancers further suggests a role for COX-2 in control of cell growth.
COX-2 also performs various specific functions in specialised cell types. For
example, it is involved in reproduction. In granulosa cells it is stimulated by follicle-
stimulating hormone and luteinizing hormone (Sirois & Richards, 1992; Sirois et al.,
1992) where it impacts on ovulation, fertilisation, implantation, and decidualisation
(Lim et al., 1999; Lim el al., 1997). COX-2 is also stimulated in the kidney macula
densa by lumenal salt concentrations (Harris et al., 1994) to play a role in renal
physiology, where it mediates renin production (Cheng et al., 1999).
Prostaglandins produced by cytokine-stimulated COX-2 within the spinal cord are
important mediators of inflammatory pain and hyperalgesia (Vane et al., 1998).
COX-2 upregulation occurs in endothelial cells of the brain vasculature following
inflammatory stimuli and is responsible for production of the fever-inducing PGE2
(Cao et al., 1996).
Due to the numerous activators of COX-2 and the many different conditions that lead
to transcriptional activation of the COX-2 gene, it is difficult to identify specific
signaling pathways. However, two pathways are heavily implicated in the regulation
of COX-2 gene expression. The NF-icB signaling pathway is involved in the
stimulation by inflammatory components and the MAPK signaling pathway in
growth factor-mediated signaling (for review see Smith et al., 2000).
The suggestion that the gastrotoxic effects of aspirin (discussed further in section
1.3.3) are due to the inhibition of housekeeping COX-1, whereas its anti¬
inflammatory effects are a consequence of inhibition of COX-2, led to the
36
Chapter One: General Introduction
development of selective COX-2 inhibitors in the hope that the beneficial effects
could be retained without injury to the gastric mucosa (Crofford, 1997).
However, it is important to recognise that selective COX-2 inhibitors lose the
cardiovascular benefit observed with aspirin as these are primarily mediated through
COX-1. In addition, COX-2 has a role in sustaining vascular PGI2 production
(McAdam et al., 1999). Recently, several of the new COX-2 inhibitors have been
withdrawn due to mounting evidence of an increased risk of stroke, thought to be due
to inhibition of COX-2 in endothelial cells leading to reduced generation of the
antithrombotic and vasodilator agent, PGH, in relation to the unaffected COX-1
derived, TXA2 (Fitzgerald, 2004).
1.5.3 Limitation of Use of Aspirin
The long term use of aspirin for pain and inflammation associated with conditions
such as rheumatism and arthritis is limited because of its serious side-effects in the
gastro-intestinal tract, reported to cause 16,000 deaths each year in the USA (Keeble
& Moore, 2002). The first evidence for gastric damage caused by aspirin was
presented in 1938 (Douthwaite & Lintott, 1938) and there is now clear evidence for
an association between gastric and duodenal ulcers and NSA1D use (AMIS, 1980;
Levy, 1974; Silvoso et al., 1979; Sun et al., 1974; Wolfe et al., 1999).
NSAIDs cause gastric mucosal injury through their topical irritant effect, but more
importantly, through suppression of gastric prostaglandin synthesis (Rainsford &
Willis, 1982; Wallace et al., 1993a). Many components of mucosal defence rely on
prostaglandins including mucus and bicarbonate secretion, blood flow (Ashley et al.,
1985; Gana et al., 1987), epithelial cell turnover and repair, as well as mucosal
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immunocyte function. It is believed, therefore, that inhibition of prostaglandin
synthesis by aspirin depresses these defences, providing an opportunity for further
damage by endogenous agents such as acid, pepsin and bile salts (Wolfe et al.,
1999).
1.5.3.1 Overcoming Gastrotoxicity
As mentioned above, COX-2-selective inhibitors were developed to avoid the gastric
side-effects of aspirin under the assumption that the inhibition of housekeeping
functions is COX-1-mediated and the anti-inflammatory effects are COX-2-
mediated. The COX-2 selective inhibitor celecoxib has been demonstrated to have a
more favourable gastric profile than other NSAIDs (Bensen et al., 2000). The
selective COX-2 inhibitor, NS-398 was shown to block pro-inflammatory
prostaglandin synthesis in the air pouch model of inflammation without inhibiting
gastric prostaglandin production, therefore avoiding gastric ulceration (Masferrer et
al., 1994). However, whilst celecoxib and rofecoxib were demonstrated to not
produce gastric lesions in healthy rat mucosa when administered in animals without
compromised gastrointestinal mucosa, they have been shown to aggravate and
complicate existing ulcers (Laudanno et al., 2001).
Interestingly, it has been more recently proposed that gastric damage is due to the
dual inhibition of COX-1 and COX-2. A study demonstrated that whilst nonselective
COX inhibitors produced severe gastric lesions, the selective COX-2 inhibitor,
rofecoxib, did not induce damage and neither did the selective COX-1 inhibitor, SC-
560. However, a combination of SC-560 and rofecoxib reintroduced the gastric
lesions. The authors proposed the damage induced by conventional NSAIDs requires
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both COX isoforms to be inhibited as inhibition of COX-1 alone led to an
upregulation of COX-2 expression in the gastric mucosa (Tanaka el al., 2001).
Other approaches in the quest to improve the cost : benefit balance of NSAIDs
include enteric coating of drugs, aspirin pro-drugs (Ankersen & Senning, 1989;
Carter et al., 1980; Truelove et al., 1980) and dual COX/5-LO inhibitors (Fiorucci et
al., 2001). Enteric-coated aspirin has a barrier that controls the location at which it is
absorbed and so it passes through the stomach and is dissolved in the small intestine.
Enteric-coated aspirin has been demonstrated to have no risk of peptic ulcer bleeding
(Weil et al., 1995), but whether or not it causes ulceration to the lower intestine is
still under debate (Grossman, 1995; Weil et al., 1995). The main disadvantage of the
enteric coating is the time taken to obtain peak plasma levels of the drug. For normal
formulations it is around 30 - 40 min, but for the enteric-coated drug, this increases
to around 3-4 h (Patrono el al., 2004). Reasons behind this are likely to include the
fact the pH in the small intestine is much less acidic than the stomach and therefore
the compound will be less ionised and absorbed more slowly, and also resulting in a
reduction in the peak plasma concentration. The increased time taken to reach the
point of absorption may also contribute to slower response.
Since it is becoming generally accepted that the 5-LO pathway is involved in the
development and maintenance of inflammation, dual inhibitors of both the COX-2
and 5-LO pathways are being developed. A new dual COX-2/5-LO inhibitor has
been shown to be effective in animal models of arthritis without being ulcerogenic
(Inagaki, 2003). It remains to be seen, however, if these inhibitors will encounter the
same problems as the COX-2 selective inhibitors.
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A further novel target may be the newly discovered ALX receptor for LX and ATL
(section 1.5.2.1.1) ALX receptor agonists may provide resolution-targeted anti¬
inflammatory therapies (Chiang et al., 2005).
1.5.4 NO-Aspirin Hybrids
More recently, hybrid drugs, linking a cytoprotective molecule such as NO
(Takeuchi et al., 1998b) to the aspirin molecule have been developed (Cena et al.,
2003; del Soldato el al., 1999) and appear to be promising in the search for a gastric-
friendly NSAID.
NO has various effects on the gastric mucosa to increase mucosal defence. It
increases blood flow in the gastric mucosa, promoting repair and removal of toxins
(Wallace & Miller, 2000). It also increases secretion of protective gastric mucus
(Brown et al., 1993) and is thought to promote healing of gastric ulcers by promoting
angiogenesis (Ma & Wallace, 2000). NO from NO-aspirins, like PGL, can inhibit
neutrophil adhesion to the blood vessel wall (Lefer & Lefer, 1996). It is therefore
possible that NO replaces the aspirin-inhibited PGL as an inhibitor of neutrophil
adherence and also of mucosal vasodilatation (Keeble & Moore, 2002). Wallace and
colleagues documented the role of neutrophils in gastropathy (Asako et al., 1992;
Wallace, 1997). They reported neutrophil adherence to the vascular endothelium of
the gastric microcirculation as one of the earliest events following NSAID
administration to laboratory animals (Asako el al., 1992). Furthermore, they showed,
with the use of antibodies, that mucosal injury was avoided by preventing neutrophil
adherence (Wallace et al., 1993b). Since NO is known to prevent neutrophil
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adhesion, the idea of combining an NO group to an NSA1D was suggested to prevent
gastropathy (Wallace, 1997).
The toxic effects of aspirin have previously been linked to actions of the carboxylic
acid moiety (Rainsford & Whitehouse, 1976). NO-aspirin hybrids have been shown
to have reduced acute gastric toxicity, thought to be primarily due to prevention of
the carboxylic acid effect, rather than a direct protective effect of NO, although the
latter may contribute (Cena el al., 2003).
NCX4016 (section 1.4.1) and the related compound, NCX4215, (Wallace et al.,
1995) were the first NO-aspirins to be released, but now another family of NO-
aspirin hybrid drugs named the furoxans (section 1.4.2) has been developed.
Various other NO-NSAID hybrids have been produced such as NO-flurbiprofen,
NO-naproxen, NO-diclofenac, NO-ibuprofen and NO-paracetamol (Burgaud et al.,
2002; Keeble & Moore, 2002). Unlike aspirin, however, these NSAIDS inhibit COX
reversibly and are therefore likely to be less selective antithrombotic agents.
1.5.4.1 NCX4016
Nicox Inc. produce the drug, NCX4016 (2 acetoxy-benzoate 2-(2-nitroxymethyl)-
phenyl ester; commonly called nitroaspirin. Fig. 1.5). It comprises an aspirin
molecule linked by an ester bond to a molecular 'spacer' molecule, which in turn is
linked to an organic nitrate group (Fiorucci & Del Soldato, 2003).
NCX4016 has been demonstrated not to be ulcerogenic at equivalent concentrations
as ulcerogenic aspirin. Furthermore, it causes a dose-dependent protection against
gastric lesions induced by IICI / ethanol mix in rats (Takeuchi et al., 1998a).
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Fig. 1.5. Structural formula of aspirin, the organic nitrate compound GTN and NO-aspirin,
NCX4016.
Mechanisms for the reduced gastric side-effects of NCX4016 may include reduced
leukocyte infiltration to the gastric mucosal vasculature (Fiorucci et a/., 1999). In
addition, it has been reported that NCX4016 spares the gastric mucosa in rats via
inhibition of caspase activity through cGMP-dependent and -independent pathways
(Fiorucci et al., 1999). Caspases are a family of proteases that are involved in
cytokine release and apoptosis (Creagh & Martin, 2001). Aspirin, but not NCX4016,
caused increased activity of caspases 1 and 3. It is suggested that NO-aspirins cause
a post-translational inactivation of caspases, possibly by S-nitrosation (Dimmeler et
al., 1997).
Inhibition of caspase 1 has also been proposed as a model of the anti-inflammatory
effects of NCX4016 (Fiorucci et al., 2000) that can be demonstrated using the
carrageenan-induced hind paw oedema model (an acute model of inflammation), in
which NCX4016 was demonstrated to cause similar effects to the parent compound
(al-Swayeh et al., 2000).
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NCX4016 is an organic nitrate that relies upon enzymatic breakdown to yield NO
(Wallace et al., 2002) and this fact may limit its antiplatelet effects. Platelets have a
poor capability of releasing NO from organic nitrates (Weber et al., 1996) and the
metabolism of both NCX4016, and the organic nitrate compound, GTN, has been
reported to occur through identical mechanisms (Grosser & Schroder, 2000). It is
therefore possible that compounds such as NCX4016 will fail to show additional,
NO-mediated effects in platelets, at least in vitro. Despite these limitations, however,
antiplatelet effects may still be retained in vivo, presumably through remote organic
nitrate activation in vascular cells other than platelets (e.g. smooth muscle cells); a
rather inefficient method of NO delivery specifically to platelets. Anti-platelet effects
of NCX4016 have been demonstrated ex vivo, in animals and humans (Fiorucci et
al., 2004; Fiorucci et al., 2003; Momi el al., 2005; Wainwright el al., 2002). In
addition, it has been demonstrated to have beneficial effects in vivo in vascular cell
types other than platelets, including protection of vascular endothelium in diabetic
rats (Pieper el al., 2002), reduction of blood pressure in hypertensive rats (Muscara et
al., 2001), prevention of restenosis in hypercholesterolemic mice (Napoli et al.,
2001) and reduction of infarct size in a model of cardiac ischaemia in pigs
(Wainwright et al., 2002).
1.5.4.2 Furoxans
A new range of drugs, in which a NO-donating moiety (furoxan group, fig. 1.6 and
1.7.) is linked by ester linkage to the aspirin molecule, appear to overcome the
problem of gastric lesions (Cena et al., 2003). However, the NO release mechanism
is unlikely to require the same cellular machinery as that for organic nitrates,
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suggesting that they might offer a degree of NO-mediated anti-platelet effects to
complement those of the aspirin moiety.
\
Aspirin moiety Furoxan moiety
Fig. 1.6. General structural formula of a furoxan-aspirin hybrid drug.
Furoxan compounds B13 and Bl2, their respective aspirin hybrids (3-cyanofuroxan-
4-yl)methyl 2-acetoxybenzoate (B8) and (3-carbamoylfuroxan-4-yl)methyl 2-
acetoxybenzoate (B7) and their respective NO-free counterparts (furazans), 4-
cyanofurazan-3-yl)methyl 2-acetoxybenzoate (B16) and (4-carbamoylfurazan-3-
yl)methyl 2-acetoxybenzoate (B15) are shown in figure 1.7.
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Figure 1.7. Structural formulae of furoxans (B8 and B7) and their NO-free equivalents, the
furazans (B16 and B15) and their aspirin-free counterparts (B13 and B12).
The furoxan-aspirin hybrids have previously been demonstrated to be anti¬
inflammatory in the carrageenan-induced paw oedema model in rats (at a dose
equimolar with 120 mg/kg aspirin); B8 was demonstrated to inhibit the paw volume
increase by ~ 60 %, B7 gave a 50 % inhibition and aspirin gave a 55 % (Cena el al.,
2003).
The mechanisms of NO-release, antiplatelet and anti-inflammatory actions of these
promising compounds have yet to be fully elucidated.
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The aims of this project are to characterise the nitric oxide (NO)-releasing and COX-
inhibiting effects of novel furoxan derivatives of aspirin in order to investigate the
possible antithrombotic and anti-inflammatory effects with a view to possible
protection against atherothrombosis.
The primary hypotheses that will be addressed are:
• That an aspirin-like action is retained by the hybrids and brings about COX
inhibition in vitro.
• That the hybrid compounds bring about vasorelaxation through an NO-
dependent mechanism.
• That NO-hybrids retain antiplatelet effects in vitro, relying on both the NO
and aspirin moieties.
• That NO-release by the hybrids occurs intracellularly and is dependent on the
presence of intracellular antioxidants.
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2. General Methods
2.1. Electron Paramagnetic Resonance (EPR)
EPR is a spectrometric technique that can be used to detect oxidising free radicals.
The technique utilises a chemical spin-trap, which reacts with free radical species
that would otherwise be too short-lived for detection (e.g. NO, O2", 'OH), to form a
stable radical adduct. The adduct is placed within a strong magnetic field and EPR
spectrometry measures its absorption of electromagnetic (microwave) radiation.
In these studies, the spin trap agent used was l-Hydroxy-3-carboxy-2,2,5,5-
tetramethylpyrrolidine .HC1 (CPH). The effectiveness of CPH as a spin trap in
biological systems has been investigated elsewhere (Dikalov et al., 1997).
The CPH spin adduct yield a typical 3-peak trace, centred around 3360 G (as shown
in Fig. 2.1) when recorded by EPR due to the spin of the 3 nitrogen isotopes
impacting upon the magnetic field.
1 1 —r~ i r~
3333 3343 3353 3363 3373
Gauss
Fig. 2.1. A typical trace from the CPH-centred adduct in EPR
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2.1.1 COX-1 Activity Assay
It has been previously demonstrated that the reduction of PGG2 by the peroxidase
element of COX to its corresponding alcohol concurrently causes an oxidation (Eling
el til., 1985). An assay was developed in which the spin-trapping agent CPU was
oxidised to the stable adduct 3-carboxy-proxy (CP) under the action of the
peroxidase. The adduct produced a characteristic signal, the intensity of which, could
be recorded by EPR.
The specific experimental protocol is detailed in chapter three (section 3.2.1), but
briefly, the COX assay was performed in l ml of sample mixture in Tyrode's buffer
(137 mM NaCl, 2.7 mM KCl, 1.05 111M MgS04, 0.4 mM NaH2P04, 12.5 mM
NaHC03, 5.6 mM Glucose, 10 mM HEPES and 0.8 mM CaCl in dH20 at pH 7.4).
Ovine seminal COX-1 (100 units/ml; purchased from Sigma, Poole, UK) was
incubated with an equimolar concentration of haematin for 5 min in an eppendorf
tube at 37 °C prior to the assay start point to replace the haem lost in the purification
process (Malkowski el ctl, 2000).
Test drug (e.g. aspirin) was then added and incubated at 37 °C for a further 10 min
before addition of the spin trapping agent, CPH. Immediately, a baseline reading was
performed by EPR by taking a 50 pi sample from the incubation vessels containing
the reaction mix into a glass micropipette tube (BLAUBRAND IntraMARK) which
was then suspended within the core of the magnet (at 37 °C) in the EPR instrument.
The intensity of the signal corresponding to formation of the radical adduct, 3-
carboxy-proxyl was recorded by EPR spectrometry. The substrate AA (as sodium
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salt; purchased from Sigma) was added after 2 min and three further EPR readings
were taken 1.5, 4 and 6 min after the addition of AA. The suicidal nature of COX
activation means that the period of activation is complete within approximately 1
min of AA addition.
The results were corrected for any auto-oxidation of spin-trap by subtraction of
values recorded from a duplicate sample run in the absence of AA. Auto-oxidation
was minimized by preparation of the spin trap, CPH, in ethylenediaminetetraacetic
acid (EDTA) solution, which protected the spin trap against metal ion-induced
oxidation.
The EPR signals were measured using a Miniscope (MS200) X-band spectrometer
(Magnettech, Germany) with the following instrument settings: BO-field, 3356
Gauss; sweep width; 50 Gauss, sweep time, 30 sec; modulation amplitude, 1500
mGauss; microwave power, 20 mW.
2.2 Vasodilator Effects
2.2.1 Animals
Male Wistar rats (250-300 g) were purchased from Charles River (UK). They were
allowed to settle for one week before being used for the experimental procedure.
Animals were housed in groups in a controlled environment and fed a standard
laboratory feed with water ad libitum.
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2.2.2 Myography
Experiments were performed on thoracic aortas from male Wistar rats (250-300g).
Rats were sacrificed by cervical dislocation and the aorta was then dissected free,
excised and placed in ice-cold Krebs buffer of the following composition (111M):
NaCl, 119; KC1, 4.7; CaCl2, 2.5; MgS04, 1.17; KH2S04, 1.18;NaHC03, 25; EDTA,
0.027 and glucose, 5.5.
Adherent connective and adipose tissue was removed and the aorta was dissected
into rings (approx 4 mm in length). Aortic rings were mounted onto fixed segment
support pins of a Multi myograph with basal tension set to 80 mN (Mulvaney-
Halpern, model 610M, Danish MyoTech, Aarhus, Denmark) connected to a MacLab
(v 4e. AD Instruments, Hastings, UK). Once mounted, the rings were incubated at 37
°C in Krebs buffer bubbled with 5 % C02 in 02 gas.
After rings were allowed to equilibrate for 20 min, 3 doses of KC1 (125 mM in Krebs
buffer) were introduced in order to test the contractile integrity of the rings. Vessels
were washed with Krebs until fully relaxed between KC1 additions and after the final
addition. The endothelial integrity of the vessels was tested by testing endothelium-
dependent relaxation in response to ACh (10 uM) before and after treatment with L-
NAME (200 p,M) to inhibit the activity of primarily eNOS. A relaxation after ACh of
<10% was the criterion for L-NAME-induced inhibition.
Following L-NAME-treatment, a concentration-response curve to a-1 adrenoceptor
agonist phenylephrine (0.001 - 1 pM) was constructed for each ring and a suitable
concentration selected to produce -80% contraction (ECbo)- This concentration was
subsequently used for prcconstricting the rings. The relaxation to increasing
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concentrations of test compounds was investigated on rings preconstricted with
phenylephrine as described in the individual experimental chapters.
2.3 Preparation of Platelets
Peripheral venous blood was drawn through a 19 gauge needle from the antecubital
fossa of human volunteers who were non-smokers and had not taken any platelet-
active agents during the previous 10 days. Blood was collected into 50 ml Falcon
tubes containing 3.8 % sodium citrate and centrifuged at 350 g for 20 min at room
temperature (RT) to obtain platelet rich plasma (PRP). This sample could be further
centrifuged at 1200 g for 10 min to obtain platelet poor plasma (PPP). Washed
platelet (WP) samples were obtained by adding 300 ng.mF1 prostacyclin to a 2 ml
PRP sample before centrifuging at 1200 g for 10 min. The supernatant was then
discarded and the pellet resuspended in Tyrode's buffer. Prostacyclin (300 ng.ml"1)
was again added before a second 10 min centrifugation (1200 g). Finally the pellet
was resuspended in 2 ml Tyrode's buffer. The preparation and use of platelet
products in this thesis (along with other blood products) is indicated in Fig. 2.2.
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2.4.1 Turbidometric Platelet Aggregometry
Inhibition of platelet aggregation was measured using optical platelet aggregometry
in a 4-channel aggregometer (CHRONO-LOG 470 VS, Labmedics) for the majority
of the experiments described. Data were captured via an analogue digital converter
(MacLab 4e, AD Instruments) and recorded using MacLab chart v3.3.7. Aggregation
was recorded as a change in turbidity (light transmission) in PRP or WP measured
against a PPP or Tyrode's buffer reference respectively.
Specific protocols are as described in the individual experimental chapters, but
briefly, inhibition of aggregation by the various drugs was tested by incubating 0.5
ml aliquots of PRP or WP at 37 °C, stirring continuously at 1000 rpm. The samples
were then treated with the test drug for 10 min before induction of aggregation with
supra-maximal concentrations of collagen (2.5 pg.mf'). Aggregation was expressed
as a percentage inhibition of control aggregation obtained with 2.5 pg.mf1 collagen
(type I). Experiments were also performed with the addition of 50 pM of the cGMP
inhibitor H-(l,2,4) oxadiazolo (4,3-a) quinoxallin-l-one (ODQ; Tocris Cookson,
Bristol, UK), 15 min before addition of the test drug in order to determine the
contribution of cGMP to any antiaggregatory effects.
2.4.2 Impedance Platelet Aggregometry
To measure the effects of the non-hybrid furoxan compound, B13, in whole blood,
impedance platelet aggregometry was used. Blood samples were drawn by
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venesection from the antecubital fossa of human volunteers. Collected blood was
diluted 50:50 in PBS and placed in tubes incubated at 37 °C and stirred at 10000 rpm
in a dual channel aggregometer (Chronolog Ca560, Labmedics), fitted with
impedance electrodes. Aggregation was induced using 2.5 pg.mf' collagen and
responses were recorded for electrical impedance. Platelet aggregates between the
two electrode probes impede the current between them and give a trace that is
captured via an analogue digital converter (MacLab 4e, AD Instruments). Results
were expressed as percentage inhibition of the response to a collagen only control.
The precise protocol is detailed in section 5.2.1.1.
2.5 NO Release
2 ml samples of PRP, PPP, WP or Tyrode's buffer were incubated in a 2-channel
aggregometer (Chronolog Ca560, Labmedics, Stockport, UK) at 37°C and stirred
continuously at 6000 rpm. An isolated NO electrode (ISO-NO MARKII, World
Precision Instruments, Stevenage, UK) was introduced into the cuvette and allowed
to stabilise for at least 10 min until a stable baseline was achieved. Data were
captured via an analogue digital converter (MacLab 4e, AD Instruments, Sussex,
UK) and recorded using MacLab chart v3.3.7.
The instrument was calibrated using 2-(N,N-diethylamino)-diazenolate-2-oxide
(DEA/NO; 0.1-1.6 pM; Fig. 2.3) in pH 4 buffer. DEA/NO is known to decompose
rapidly at pi I < 5 to release two molecules of NO per molecule DEA//NO (Davies &
Ren, 2001).
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(a) (b)
60s [NO] (nM)
Fig. 2.3. (a) Example calibration trace and (b) graph for the NO electrode. Additions of
DEA/NO (in nM) are indicated. Calibration assumes two molecules of NO are released per
molecule of DEA/NO.
The precise experimental protocols are given in the individual experimental chapters,
but briefly, the test drug was added to the cuvette and the release of NO was
recorded for ten min before addition of the NO scavenger haemoglobin (10 pM) to
confirm the contribution of NO to the signal.
In order to elucidate any involvement of endogenous reducing agents in the release
of NO from the NO-aspirins, experiments were also carried out in Tyrode's buffer,
reconstituted with approximate plasma and intracellular concentrations (as indicated
in Table 2.1) of albumin and glutathione (GSH) and ascorbate, both alone, and in
combination.
PLASMA INTRACELLULAR
4 % albumin Tyrode's buffer
3 liM GSH 3 mM GSH
50 pM ascorbate 1 mM ascorbate*
Table 2.1. Table to show the concentrations of
endogenous reducing agents (GSH and ascorbate), both
intracellular^ and in plasma. To investigate the release of
NO under plasma or intracellular conditions, 4% albumin
or Tyrode's buffer, respectively, was reconstituted with the
reducing agents at the concentrations indicated, both
alone and in combination. *Only in the presence of 20 mM
HEPES to buffer its acidic pH.
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A platelet extract was also prepared from samples of PRP. A platelet count was
determined using a Coulter AC.T 8 Hematology Analyzer (Coulter Electronics,
Luton, UK). The platelets were washed as above in the presence of prostacyclin (300
ng.mr1) to obtain a platelet pellet. The total platelet volume of the pellet was
calculated by multiplying the number of platelets by average platelet volume
(5.14xl0"15 L; obtained from the haematology analyzer). The pellet was resuspended
in 1 ml of 0.5 % Triton X in Tyrode's buffer for 1 h and the dilution of cell contents
estimated using the above calculation. This was then homogenized by hand for 15
min and centrifuged at 12000 g for 10 min to give a cell extract. NO-aspirin hybrids
were added to 1 ml of this supernatant in the assay as described above. Experiments
were also carried out in the presence of the thiol alkylator, 5,5'-dithiobis(2-
nitrobenzoic acid) (DTNB), to determine the necessity of thiols in the release of NO.
Owing to the different profile of NO release by the various drugs, it was established
that area under the curve (AUC) was more representative of NO release than peak
concentration in these experiments.
2.6 Peroxynitrite Release
Due to its free radical nature, NO can rapidly react with reactive oxygen species
(ROS). One particular example is the reaction with the ROS, superoxide (O2") to
form peroxynitrite (ONOO"; equation 1; Saran et al., 1990):
NO + Of ► ONOO" (1)
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The enzyme superoxide dismutase (SOD) will prevent formation of peroxynitrite by
removing superoxide through catalyzing its conversion to hydrogen peroxide (H2O2;
equation 2):
02" + 2H+ SOD 02 + H202 (2)
Two sets of experiments were undertaken to determine whether the compounds B8
and B7 generate any peroxynitrite in addition to NO.
It has been demonstrated that EPR, using the spin trap agent, CPU, is an effective
method of trapping peroxynitrite (Dikalov el al., 1997). Samples of PRP were
incubated with the test compound (e.g. B8, B7) and CPH ± SOD (500 U.mf1) at 37
°C. Control samples were performed without the test compound, and also, with the
known peroxynitrite generator GEA 3162 (Taylor el al., 2004). EPR readings (as
described in section 2.1.1) were taken at 1, 10, 20, 30, 60 and 120 min and formation
of the adduct 3-carboxy-proxyl recorded.
Experiments were also carried out using the NO electrode with PRP and PPP
samples treated with B8 or B7. SOD (500 U-mf1) was added in order that it would
unmask any further NO that might otherwise have formed peroxynitrite.
2.7 Preparation of Monocytes and Macrophages
Mononuclear cells were isolated from human blood using dextran sedimentation and
Percoll gradients as follows: peripheral venous blood was drawn from the antecubital
fossa of human volunteers (non-smokers; age 20-45. Fig. 2.2). Blood was collected
into 50 ml Falcon tubes containing 3.8 % sodium citrate and centrifuged at 350 g for
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20 min at RT. Following aspiration of the PRP, leukocytes were separated from the
erythrocyte pellet by dextran sedimentation. 2.5 ml dextran (6 % in 0.9 % NaCl;
Dextran 500 000, Pharmacia, Kent, UK) was added per 10 ml of pellet and the
volume made up to 50 ml with saline, pre-warmed to 37 °C. This was left to
sediment for not longer than 30 min at RT. The leukocyte rich upper layer was
removed and transferred to a 50 ml Falcon tube and made up to 50 ml with saline,
pre-warmed to 37 °C before centrifugation at 350 g for 6 min. The pelleted cells
were resuspended in 2.5 ml of 55 % Percoll (Pharmacia; in PBS without Ca2+).
Percoll gradients were prepared by overlaying 2.5 ml differing densities of Percoll at
RT. The bottom layer was 89 % Percoll made in PBS (without Ca2+). This was
overlaid with 2.5 ml 68 % Percoll, and the 55 % layer containing the leukocytes was
layered on top. The gradients were centrifuged at 700 g for 20 min. Mononuclear
cells were harvested from the 55/68 % interface, washed twice in PBS without Ca2H
and then resuspended at a concentration of 4x 106 cells/ml in ISCOVES DMEM
(Sigma).
Autologous recalcified plasma (serum) was prepared by addition of 220 pi 1 M
CaCh to 10 ml of PRP in a sterile glass tube. This was incubated for 1 h at 37 °C.
The serum was then separated from the platelet plug and refrigerated at 4 °C in a
plastic tube.
2.8 Inflammatory Marker Studies
Mononuclear cells were plated out in 48-well plates at a concentration of 2 x 106 per
well. After 1 h, non-adherent cells were removed by washing wells with Flank's
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buffered salt solution (HBSS). Macrophages were derived from monocytes by
culturing the monocytes in 1SCOVES DMEM (supplemented with 10 % autologous
serum) at 37 °C for a week, with the medium being changed after 3-4 days.
On day 7, the medium in each well was changed and fresh medium containing a test
drug or DMSO vehicle added to wells with or without the inflammatory stimulant,
LPS (1-100 ng.mf1 for pilot CBA studies. 10 ng.mf1 for all further studies). Cells
were then incubated at 37 °C for 4 h before removal of the cell supernatants, which
were subsequently frozen at -70 °C for future studies.
The same procedure was also carried out on mononuclear cells which had not been
matured into macrophages with drug treatments and 4 h incubations taking place
immediately after the final cell washing step of the blood preparation.
2.8.1 Cytometric Bead Array (CBA)
A human inflammation cytometric bead array kit that detects levels of IL-8, IL-l(3,
IL-6. IL-10, TNFa and IL-I2p70 was purchased from BD Biosciences (Oxford, UK;
cat no. 551811). The protocol was carried out as per kit instructions on supernatants
from macrophages treated as described in section 6.2.2. The technique is based on
using a series of spectrally discrete particles to capture and quantitate various soluble
inflammatory markers. A mixed population of six beads with distinct fluorescence
intensities, each coated with a specific antibody for either IL-8, IL-l(3, IL-6, IL-10,
TNFa and IL-12p70 were incubated with the test samples. The antibodies were
conjugated with the fluorochrome phycoerythrin (PE), the fluorescence of which is
detectable by flow cytometric analysis (FL3 channel of BD FACScan).
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2.8.2 Enzyme-Linked Immunosorbent Assays (ELISAs)
Human TNFa and IL-8 ELISA kits were purchased from BD Biosciences (cat no;
550610 and 550999 respectively) and performed as per kit instructions on the
supernatants removed from macrophage or monocyte plates. These TNFa and IL-8
ELISAs utilise a monoclonal antibody specific for TNFa (or IL-8) coated onto a 96-
well plate. Any TNFa (or IL-8) present in the test samples binds to the immobilized
antibody. The wells were then washed and a streptavidin-horseradish peroxidase
conjugate mixed with a biotinylated anti-human TNFa (or IL-8) antibody added,
giving an antibody-antigen-antibody "sandwich". A colour agent was incubated
which produces a blue colour in direct proportion to the amount of TNFa (or IL-8)
present in the initial sample. Finally, after a set time, a stop solution was used to stop
this reaction, changing the colour from blue to yellow. The absorbances of each well
were then read at 450 nm using a Thermo Labsystems Multiskan Ascent plate reader
running Ascent software Version 2.6.
2.8.3 Lactate Dehydrogenase (LDH) Assay
The cytotoxic impact of the compounds was assessed by measuring the quantity of
the enzyme LDH in the supernatant. This is a stable cytoplasmic enzyme present in
all cells, which is rapidly released following carnage to the plasma membrane. A kit
was purchased from Roche (cat no 1 644 793) to quantify cell death by LDH
quantification in the supernatants from treated cells (section 2.8). The kit works by a
two-step reaction in which LDH catalyses conversion of a tetrazolium salt to a
coloured formazan salt that absorbs light at 490 nm. The absorption recorded at 490
nm using a Thermo Labsystems Multiskan Ascent plate reader is proportional to the
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number of damaged cells. The exact experimental protocol was as described in
section 7.2.4.
2.8.4 Immunofluorescence for NF-kB p65 Subunit
NF-kB is a transcription factor responsible for the control of the gene expression of
proinflammatory cytokine, TNFa. Normally, NF-kB is kept in an inactive state in the
cytoplasm, bound to an inhibitory subunit named IkB. NF-kB exists as a dimer (can
be either a homodimer or heterodimer). The most common form is a heterodimer
composed of the p65/p50 subunits (Panwalkar el ai, 2004). The phosphorylation of
IkB and its subsequent degradation leads to the activation of NF-kB. The NF-kB
dimer containing the p65 subunit; the dominant factor in the induction of the TNFa
gene, then translocates from the cytoplasm to the nucleus where it activates
transcription of target genes such as TNFa (Baldwin, 1996; Kaltschmidt el al., 1999;
Liu et al., 2000; Totzke el al., 2006).
Immunofluorescence for the p65 subunit was used to visualise the translocation of
NF-kB. Mononuclear cells were isolated and resuspended as described in section 2.7.
4><106 (1ml) cells were placed on a glass coverslip within a 6-well plate and left in an
incubator (37 °C; 1 h) to adhere. Non-adherent cells were then removed by washing
wells with F1BSS. Cells were treated with the test compound and stimulated with
LPS as described in chapter seven (section 7.2.5). The cell-covered coverslips were
then washed 3 times with PBS and 1 ml of 3 % paraformaldehyde (in deionised
water; dFLO) was added and the cells left to fix (RT) for 20 min. Coverslips were
then washed again 3 times with PBS and then incubated for 10 min at RT with 1 ml
of 50 mM glycine to quench aldehyde groups. Following another 3 PBS washes, 1
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ml of blocking solution (10% sheep serum in 0.2 % fish skin gelatin (Sigma)) was
added to the coverslips and they were left overnight at 4 °C.
The following morning, after washing the cells, 100 pi of primary antibody (NF-kB
p65 mouse anti-human (BD Biosciences, cat no. 610868); 1:50 dilution in blocking
solution) was added to the cells. An hour later, following three PBS washes, 100 pi
of a 1:250 dilution (in blocking solution) of secondary antibody (Alexa Fluor® 488
goat anti-mouse IgG; Invitrogen, cat no. A-11001) was added and left to incubate for
1 hr at RT in the dark. The green fluorescent secondary antibody is FITC-labelled
and is excited at 488 nm and excited at 530 nm.
Finally, three PBS washes, followed by three dH20 washes were carried out to
prevent crystal formation. Coverslips were then mounted onto slides using Moviol
(Calbiochem, Merck, Nottingham, UK) and the slides were then stored in the dark at
4 °C.
2.8.4.1 Microscope Image Capturing
Images from the immunofluorescence slides were captured with a camera connected
to a Zeiss Axiovert S100 microscope using Improvision Openlab 3.1.5 software.
Images were captured at a magnification of x 100 using oil immersion.
2.9 Materials
General laboratory reagents (such as buffer salts) were supplied by Sigma and
Fisher. Other reagents were diluted in either Tyrode's buffer, PBS, DMSO, dff20,
0.01 M NaOFI or ISCOVES DNEM. Vehicles and suppliers are detailed in Table 2.2.
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Company locations are listed in Table 2.3. Furoxan-aspirins, furoxan compounds,
furazan-aspirins and NCX4016 were synthesized (Cena el al., 2003) and generously
supplied by Universita degli studi di Torino, Torino, Italy.
REAGENT VEHICLE
VIDvil'fG., Tb'.x ■. .::t:
SUPPLIER
AA DMSO Sigma
Albumin Tyrode's buffer Sigma
Ascorbate Tyrode's buffer Sigma
Aspirin PBS Sigma
Collagen (type I; fibrils;
equine)
Supplied as water soluble
solution (suspension)
Labmedics
COX-1; ovine Supplied as water soluble
solution
Sigma
CPU 10 mM EDTA in dH20** Axxora
cPTIO PBS Sigma
DEA/NO 0.01 M NaOH Axxora
DTNB DMSO Sigma
Furoxans/Furoxan aspirin 1% DMSO in PBS University of Turin
Glutathione Tyrode's buffer Sigma
Gliotoxin ISCOVES DNEM Sigma
Haemoglobin H20* Sigma
Hematin (bovine) DMSO Sigma
Human serum albumin Tyrode's buffer Sigma
Indomethacin 1% DMSO in PBS Sigma
L-NAME Krebs Sigma
LPS ISCOVES DNEM Sigma
NS-398 1% DMSO in PBS Sigma
ODQ DMSO Tocris Cookson
pgi2 PBS Sigma
Phenylephrine Krebs Sigma
Salicylic Acid PBS Sigma
SOD PBS Sigma
Triton-X-100 Tyrode's buffer Sigma
Table 2.2. Suppliers and vehicles for reagents.
* Met-haemoglobin was reduced to the ferro form by sodium dithionate (57.4 pM),
and excess dithionate was then removed by dialysis (Martin et al., 1985).
** Minimises metal ion-induced auto-oxidation of the spin trap.
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LOCATION
Axxora Nottingham, UK




Sigma Aidrich Poole, UK
Tocris Cookson Bristol, UK
World Precision Instruments Stevenage, UK
Table 2.3. Companies and locations.
2.10 Statistics
Statistical analyses are as stated in the individual experimental chapters. All
statistical tests were performed using GraphPad Prism version 4 (GraphPad
Software, San Diego, USA). * is used to represent a p value between 0.01 and 0.05,
** represents a p value of 0.001 to 0.01 and *** represents p values less than 0.001.
P values greater than 0.05 were deemed not significant. Where expressed, data are in
the form mean ± standard error of the mean (S.E.M.).
2.11 Figures
Graphs for this thesis were produced using GraphPad Prism version 4. Other
diagrams and figures were produced using OmniGraffle version 4 (The Omni Group,
Seattle, USA) and Illustrator CS2 (Adobe, Uxbridge, UK). Structural formulae were
drawn using ChemDraw version 10.0 (CambridgeSoft, Cambridge, MA, USA).
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3. Assessment of the COX-1 Activity of
Furoxan-Aspirin Hybrids by a Novel EPR-Based
Assay
3.1 Introduction
Prostaglandins are derived from arachidonic acid (AA) in a pathway dependent on
the Prostaglandin H2 synthase (PGHS; EC 1.14.99.1) family of enzymes. PGHS is
more commonly known as COX, referring to the first enzymatic activity of the
enzyme. COX converts AA to prostaglandin Ef, the precursor of all prostanoids. The
enzyme contains two active sites: a COX site, where AA is converted into the
hydroperoxy endoperoxide, prostaglandin G2 (PGG2), and a haem with peroxidase
activity that reduces PGG2 to PGH2 (Chandrasekharan & Simmons, 2004).
Two structurally similar COX isoforms exist (COX-1 and COX-2) which are
encoded by different genes and the expression of which varies between tissues
(Simmons el al., 2004). COX-1 is often referred to as the 'house-keeping' isoform
due to its regulatory functions in many tissues. COX-2 is virtually undetectable under
normal conditions in most tissues and is often referred to as the 'inducible' isoform
due to its tendency to be expressed in response to inflammatory stimuli. The
exception to this is in the brain and spinal cord, where COX-2 is constitutively
expressed and plays a role in nociception signalling (Hoffmann, 2000).
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The importance of COX as a therapeutic target has long been highlighted by the
actions of aspirin (Vane, 1971; Vane & Botting, 2003), the first drug of the family of
NSAIDs for use as analgesics, anti-inflammatory agents and antithrombotic agents.
In contrast to other NSAIDs, such as indomethacin, which reversibly bind at the
COX active site (Dannhardt & Kiefer, 2001), aspirin causes an irreversible inhibition
of COX by rapidly and selectively acetylating the hydroxyl group of a serine residue
(Ser 530) near the C-terminus of the enzyme, forming an impediment to the binding
of AA (DeWitt & Smith, 1988; Roth & Majerus, 1975; Roth et al., 1975). The
ensuing irreversible COX inhibition requires de novo synthesis of the enzyme for
subsequent production of prostaglandins.
The alteration of the chemical structure of aspirin, as has occurred in the generation
of the NO-aspirins, may impede its activity. It is therefore vital to ensure the activity
of the parent compound is not prevented, and thus, an assay to check that the NO-
aspirins retain a COX-inhibitory action was developed.
It is surprising that relatively few assays for the activity of the COX enzyme have
been developed. Amongst the most popular techniques is the measurement of
thromboxane B2 (TXB2). the stable metabolite of one of PGH2-derived TXA2, as a
marker of COX activity (Gierse el al., 2005). Alternatively, measurement of oxygen
consumption using an oxygen electrode (Gierse et al., 1999; Kulmacz & Wang,
1995), assays using radio-labelled substrate (Schneider et al., 2005) and
immunoassays for the prostaglandin products (Gierse et al., 1999) can also be
applied. More recently, a commercial chemiluminescent assay (Axxora, Nottingham,
UK) has been developed for use on purified enzyme. The assay involves the use of
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labelled substrate that generates a luminescent product under the action of the
hydroperoxidase element of COX, most likely via the generation of oxidising free
radicals.
EPR (methods chapter, section 2.1) has been previously utilised by others to measure
free radicals generated by COX as a measure of its activity (Schreiber et al., 1989;
Tsai et al., 1992). However these techniques can involve complex mechanisms to
trap the short-lived radical species. For instance, in an in vitro assay using purified
COX, liquid nitrogen was utilised to stop the reaction and was required to stabilise
the tyrosyl radical species generated, in order that it could be recorded by EPR (Tsai
et al., 1992). Another technique which recorded COX activity in mouse
keratinocytes relied on the use of the antioxidant glutathione to stabilize the
generated radical before trapping it with DMPO (Schreiber et al., 1989).
A convenient novel assay was therefore developed in order to assay the activity of
COX-1. The reduction of PGG2 by the peroxidase element generates the
corresponding alcohol. This reaction has previously been demonstrated to
concurrently oxidise aminopyrine molecules to aminopyrine free radicals (Eling et
al., 1985). Here, a spin-trapping agent, CPH, is oxidised to CP" under the action of
the peroxidase (Fig. 3.1), in a similar fashion to that previously seen with
aminopyrine. CP is a stable adduct which is detectable by EPR.
The studies in this chapter were carried out in order to validate this technique for
assaying COX-1 activity in vitro, in order that it could be further utilised to test the
hypothesis that the newly developed NO-aspirin compounds retain an anti-COX
activity.
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Fig. 3.1. Schematic diagram showing the peroxidase activity of COX. The process requires
prior formation of a tyrosine radical from a tyrosine residue in close proximity to the haem
group (Tyr 385). The tyrosyl radical is either recycled or participates in the suicide
inactivation of the enzyme (Smith et al., 2000). Following incorporation of oxygen and
formation of PGG2, the peroxidase reduces the peroxyl moiety to the equivalent alcohol.
The process allows for the concomitant oxidation of spin-trap CPH to CP; which is detected
by EPR.
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3.2 Methods
3.2.1 Measurement of COX-1 Activity
The activity of COX-1 was assessed using a novel EPR-based assay. The assay was
performed at 37°C in 1 ml of Tyrode's buffer (137 mM NaCl, 2.7 mM KC1, 1.05
mM MgS04, 0.4 mM NaH2P04, 12.5 mM NaHC03, 5.6 mM Glucose, 10 mM
HEPES and 0.8 mM CaCl2 in deionised water at pEI 7.4). 100 units/ml ovine seminal
COX-1 was incubated with 1.5 pM haematin (5 min, 37 °C) prior to the assay. Data
from the manufacturers of the COX-1 reveal that 1 unit of enzyme consumes 1
nanomole of oxygen at 37 °C in the presence of 1 pM haematin and 100 pM AA. 10
pi of the stock furoxan-aspirin, their furazan equivalent, NCX4016, indomethacin,
NS398 (Merck Biosciences, Nottingham, UK), aspirin or salicylic acid (SA) or a
vehicle control (DMSO, 1 %) was added and left to incubate for a further 10 min
prior to addition of the spin-trap, CPH (1 mM; as described in section 2.1). Final
drug concentration investigated in this study was 100 pM for all drugs. Further
concentrations (10 pM and 1 mM) of aspirin and salicylic acid were also
investigated. At this point (time = -2 min), a baseline EPR measurement was taken
(MS200, Magnettech, Germany. Instrument settings: BO-field, 3356 Gauss; sweep
width; 50 Gauss, sweep time, 30 sec; modulation amplitude, 1500 mGauss;
microwave power, 20 mW). After 2 min (time = 0), 100 pM AA (as sodium salt) was
added. Further EPR readings were taken at 1.5, 4 and 6 min. The suicidal nature of
COX-1 activation means that the period of activation is complete within ~1 min of
AA addition (Simmons el al., 2004).
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The results are corrected for any auto-oxidation of spin-trap by subtraction of values
recorded from a duplicate sample run in the absence of AA. The intensity scale on
the y-axis of all graphs is an arbitrary scale based upon the area under the curve of
the first derivative traces generated.
3.2.2 Statistics
Statistical analysis was by 2-way ANOVA or by 1-way ANOVA and Dunnetfis post-
test carried out using GraphPad Prism version 4. * is used to represent a p value
between 0.01 and 0.05, ** represents a p value of 0.001 to 0.01 and *** represents p
values less than 0.001. P values greater than 0.05 were deemed not significant.
Where expressed, data are in the form mean ± s.e.m.
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3.3 Results
3.3.1 Time-dependent Adduct Generation by COX-1
Addition of AA caused a time-dependent increase in the characteristic 3-line EPR
spectrum for a spin-adduct with the unpaired electron in the vicinity of a nitrogen
atom. Traces of the 3-line spectrum of the CP adduct obtained with a control sample
and samples containing COX-inhibitor aspirin can be viewed in Fig 3.2.
Control
100 |iM aspirin
1 mM aspirin i .yi^
I I I I I
3333 3343 3353 3363 3373
Gauss
Fig. 3.2. Sample EPR spectra obtained in the absence (control; COX +
AA) and presence of aspirin (100 mM or 1mM) after correction for
background autoxidation. EPR settings: BO-field, 3356 Gauss; sweep
width; 50 Gauss, sweep time, 30 sec; modulation amplitude, 1500
mGauss; microwave power, 20 mW.
The majority of the reaction was complete by the time the first reading was taken.
The signal developed rapidly before the first reading (244 intensity units.min"1), but
subsequently slowed to a relatively constant rate (65 intensity units.min"1) over the
following 4.5 min of the assay (Fig 3.3. n = 9-12); the equivalent experiment without
AA failed to show the initial rapid rise and was significantly lower than the AA-
treated sample throughout (p=0.02, 2-way ANOVA, repeated measures).
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-B- 100 iiM Aspirin
Fig. 3.3. Mean data for development of EPR signal intensity (AU) with time in the absence
(control; COX + AA) and presence of aspirin (100 mM). In both cases, substrate (AA) was
added at t=0 min. P=0.02, 2-way ANOVA, repeated measures: n=9-12. Values are mean ±
SEM.
From these data, it was determined that the point t=1.5 min was an appropriate point
at which to compare spin-adduct generation between control and NSAID-treated
COX-1, given that spin-adduct generation in response to AA had peaked -
subsequent adduct formation was at an equivalent rate in control and AA-treated
samples and was likely to be due to non-specific auto-oxidation of CPH.
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3.3.2 Inhibitory Effect ofAspirin and Salicylic Acid
The impact of pre-incubation of COX-1 with different concentrations of aspirin (10
pM - 1 mM) is shown in Fig 3.4. The lower end of this range was representative of
the known therapeutic range for human antiplatelet effects and the higher end for
aspirin-mediated anti-inflammatory effects (Mitchell et al., 1993; Osnes et al., 1996;
Sils et al., 1988). Results indicate that aspirin concentrations of 100 pM and 1 mM
caused significant inhibition of spin-adduct formation at the 1.5 min time-point (to
72 ± 11 and 100 ± 16 % of control respectively; P<0.05 for both compared to
control, 1-way ANOVA followed by Dunnetfis post-hoc analysis).
Parallel experiments with SA (10 pM - 1 mM; n = 6) showed that a 10 min pre¬
incubation with SA failed to significantly inhibit generation of the spin-adduct, even


















10 pM 100 pM 1 mM
Fig. 3.4. Effect of aspirin and salicylic acid (10 pM - 1 mM) on EPR signals generated
from COX-1 after treatment with substrate (AA). In each case, incubations with aspirin
or SA were for 10 min prior to the baseline EPR reading (t=-2 min, not shown). AA was
added at t=0 min and readings shown were taken at t= 1.5 min.*P<0.05, **P<0.01; 1-
way ANOVA with Dunnett's post-hoc test vs. control: n=8-10. Values are mean ± SEM.
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3.3.3 Comparative Pharmacology of COX-1 and COX-2
Inhibitors
The assay was further verified by the screening of a COX-2 selective inhibitor,
NS398 (Fig. 3.5). Equivalent concentrations (100 piM) of the recognized non¬
selective COX inhibitors, aspirin and indomethacin both significantly (P<0.05 and
P<0.01 respectively; l-way ANOVA with Dunnett's post-hoc test) inhibited
generation of the EPR-detectable spin adduct at 1.5 min (72 ± 11 and 114 ± 10 %
inhibition of control response respectively), but the COX-2-selective inhibitor,
NS398 had no effect (P>0.05) on this assay of COX-1, despite its use at a

















Fig. 3.5. Comparative effects of SA and recognized NSAIDs (all 100 pM) on EPR signal
intensity measured at t=1.5 min. *P<0.05, **P<0.01; 1-way ANOVA with Dunnett's post-
hoc test vs. control: n=6-10. Values are mean + SEM.
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3.3.4 Inhibitory Effect of NO-Aspirin Compounds
A significant inhibition of COX activity was observed with the furoxan-aspirins, B8
and B7 (100 pM; p<0.05 and p<0.01 respectively; 1-way ANOVA with Dunnett's
post-hoc test vs. control, n=6). Even greater inhibition was demonstrated with the
NO-free furazan equivalents, B16 and B15 (100 pM, p<0.01; 1-way ANOVA with
Dunnett's post-hoc test vs. control for both, n=6). The furazan compounds
demonstrated a significantly greater inhibition of COX than aspirin (p<0.01 for both
as assessed by Student's t-test). No significant difference was observed between
inhibition with the furoxan hybrids and their furazan equivalents (p>0.05 for both, as
assessed by Student's t-test). The nitrooxy-ester, NCX4016 (100 pM) also abolished
COX activity (p<0.01; 1-way ANOVA with Dunnett's post-hoc test vs. control,
n=6). The NO donor DEA/NO (100 pM) failed to significantly inhibit generation of
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ES3+ B15
Fig. 3.6. Effect of aspirin, furoxans, furazans and NCX4016 (all 100 pM) on EPR signals
generated from COX-1 after treatment with substrate (AA). In each case, drug incubations
were for 10 min prior to the baseline EPR reading. Readings shown were taken 1.5 min after
the addition of AA. *P<0.05, **P<0.01; 1-way ANOVA with Dunnett's post-hoc test vs.
control: n=6-10. Values are mean ± SEM.
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3.4 Discussion
In order to investigate the whether the hybrid drugs retained a COX-inhibitory action
in vitro, a simple, reliable assay was first developed and verified.
3.4.1 Assay Development and Verification
The principle of the assay was based on the concomitant oxidation (Fig. 3.1) which
occurs with the reduction of PGG2 to its corresponding alcohol by the peroxidase
element of COX (Eling et al., 1985). This oxidation can be exploited in the absence
of antioxidant GSH to oxidise spin-trapping agent CPH to the stable adduct, CP',
which generates a characteristic 3-line EPR spectrum. The amplitude of the EPR
signal is proportional to the amount of adduct generated.
Results indicated that isolated COX-1 enzyme generated sufficient adduct generation
upon addition of the enzyme substrate, AA, to be easily detectable by EPR. The
initial peak in the detected signal recorded at the first reading, had by the subsequent
time-points slowed to a rate that was equivalent to the signal generation from
substrate-free enzyme, most likely due to autoxidation of the spin trap. The loss of
specific enzyme-mediated adduct generation is unsurprising, given the well-
recognised suicidal nature of activated COX-1 (Simmons et al., 2004; Smith et al.,
2000). From these time-course experiments, a 1.5 min time-point was selected for
subsequent comparative studies, because by this time the AA-dependent adduct
generation was complete but the signal was not significantly enhanced by
autoxidation of the spin trap.
Aspirin pretreatment (10 min) was shown to have a concentration-dependent
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inhibitory effect in the published range (Mitchell et al., 1993), but the acetyl-free
counterpart, SA, failed to significantly inhibit enzyme activity. The lack of effect of
SA indicates that aspirin-mediated inhibition of the enzyme is dependent on the
acetyl group, the moiety involved in COX inhibition, and not due to a non-specific
antioxidant effect. SA was not expected to have any effect in this assay because it is
known not to affect COX-1 or 2 activity (Wu, 2000) except in intact cells (Mitchell
et al., 1993), possibly by suppressing COX-2 transcription in response to exogenous
stimuli (Xu et al, 1999). Furthermore, the reversible, non-specific COX inhibitor,
indomethacin (Kulmacz & Lands, 1985), was demonstrated to have a powerful
inhibitory effect. Addition of the COX-2 specific inhibitor, NS398, failed to cause
inhibition. NS398 specifically inhibits COX-2 by inducing a slow structural
transition of the enzyme upon binding that results in significant and irreversible
inhibition of COX-2 (Copeland et al., 1994). Unsurprisingly, it had no effect in this
assay of COX-1, despite being used at a concentration known to inhibit COX-2
(Futaki et al., 1994). Signal intensities shown in the figures are after subtraction of an
AA-free control from a parallel experiment to account for autooxidation of the spin
trap. A negative signal (as observed with indomethacin for example) therefore
indicates that the control value was greater than the AA-treated sample, which might
suggest that AA has a slight antioxidant effect on its own.
The assay was sensitive to the inhibitory effects of conventional NSAIDs (aspirin
and indomethacin) and not to SA or a COX-2 specific inhibitor. These results
confirmed the assay to be a relevant screen for NSAIDs with different modes of
inhibitory action and therefore it was used to screen the NO-aspirin compounds.
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3.4.2 COX-inhibitory Effect of NO-Aspirin Compounds
Both the nitrooxy-ester NCX4016, and the furoxan-aspirin hybrids were
demonstrated to significantly inhibit COX-1. The alterations to the chemical
structure by the hybrids perhaps play a role in bringing about the inhibition that was
observed to be greater than that by the unaltered aspirin compound. The powerful
inhibitory effect of the furoxan-aspirin hybrids in the purified COX-1 assay, together
with the equally powerful effects of the furazan equivalents and the lack of
significant inhibition observed with the NO donor DEA/NO, suggests that the COX-
1-inhibitory activity of B8 and B7 is more likely to be aspirin-mediated than NO-
mediated.
This assay demonstrates that the furoxan-aspirin hybrids retain an aspirin-like action
in vitro. At face value, these data would indicate that the compounds have potential
to be antithrombotic through inhibition of COX-1. However, it is important to
recognize that the COX-inhibitory effect might be lost in biological media or in vivo,
depending on how these compounds are hydrolysed under physiologically relevant
conditions. Previous studies (Cena et al., 2003) have demonstrated complete
hydrolysis of the furoxan-aspirin acetyl group in serum. This feature would suggest
that in plasma, there would be at least a partial loss of the acetyl group, resulting in
formation of the SA equivalent. As SA was demonstrated to have no effect in this
assay of COX activity, any loss of acetyl group may prove to limit the effectiveness
of the drug. Other groups have also demonstrated that COX inhibition by the hybrid
NCX4016 has a similar requirement for the acetyl-group but not the NO moiety
(Corazzi et al., 2005).
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3.4.2.1 NO Impact on COX-inhibitory Effect
Interestingly, it might be expected that the NO moiety of the hybrids could influence
the COX-inhibitory action of the aspirin moiety because NO has been previously
reported to both inhibit and stimulate activity of the COX enzyme. NO-mediated
inhibition of thromboxane generation has been reported to occur via a cGMP-
independent mechanism in platelets (Tsikas et al., 1999). NO-mediated inhibition of
COX-1 may be a possible mechanism for this effect (Kanner et al., 1992; Tsai et al.,
1994). In contrast, however, NO has also been reported to increase the production of
eicosanoids such as PGI2 through activation of COX in endothelial cells, again in a
cGMP-independent manner (Davidge et al., 1995). There is a greater amount of
evidence for an NO-mediated activation of COX (for review see Salvemini, 1997).
Activation of COX by NO has been observed in various in vitro (Hajjar et al., 1995;
Landino et al., 1996; Salvemini & Masferrer, 1996; Salvemini el al., 1993) as well as
in vivo systems (Salvemini & Masferrer, 1996). The contrast in the reported impact
of NO on COX may be due to the COX isotype present. It has further been shown
that the interaction between NO and COX is not a direct one (Tsai et al., 1994) and
thus the opposing effects could be a result of differing intermediary pathways. A
further possible explanation is that the NO-related species, peroxynitrite, is
responsible for the effect (Landino et al., 1996). In such case, the formation of
peroxynitrite would not occur in purified enzyme studies and so would not be
observed (Davidge et al., 1995). The results in this chapter reveal the inhibition of
COX-1 obtained with the furoxan hybrids not to be significantly different from that
obtained with their furazan equivalents. These data indicate that the NO moiety has
no impact in any manner on the COX-1-inhibition by the aspirin moiety in vitro.
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However, as discussed above, in an in vivo situation, this may alter due to indirect
effects of the NO on COX or as a consequence of the formation of NO-related
species such as peroxynitrite, which may act to increase COX activity (Landino et
al., 1996).
3.4.3 Summary, Future Directions and Therapeutic
Implications
The assay presented in this chapter was used as an initial screen to ensure that
modification of the aspirin molecule to include an NO-donating moiety had not
impaired its ability to inhibit COX. The data show that, at least in vitro, an aspirin¬
like inhibition of COX-1 does occur.
This gives the furoxan NO-aspirins potential to retain the beneficial cardiovascular
effects of aspirin. Aspirin irreversibly inhibits COX via an acetylation reaction (DeWitt
& Smith, 1988; Roth & Majerus, 1975; Roth et al., 1975). The aspirin-mediated
reduction in cardiovascular risk comes about through inhibition of platelet aggregation
by action on platelet COX-1. This results in reduced production of TXA2, a vital
element in the induction of irreversible platelet aggregation (FitzGerald, 1991; Hamberg
et al., 1975). Due to the anucleate nature of platelets, recovery of full platelet COX
activity only takes place after - 10 days following platelet turnover (Burch et al., 1978).
This chapter demonstrates that the furoxan NO-aspirin compounds, along with the
organic nitrate compound, NCX4016, retain the ability to inhibit COX in vitro and thus
have the potential to be antithrombotic through aspirin-mediated inhibition of platelet
COX-1. Further studies to ensure the effect is retained in vivo and to discover the
contribution of NO will help determine their effectiveness as antithrombotic drugs.
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Chapter Four: Vasodilator Effects ofFuroxans and Furoxan-Aspirin Hybrids
4. Vasodilator Effects of Furoxans and Furoxan-
Aspirin Hybrid Drugs
4.1 Introduction
In healthy blood vessels, eNOS-derived NO is generated by the endothelium in
response to shear stress, hypoxia and endogenous mediators (Arnet et al., 1996; Hori
et al., 1998; Rapoport et al., 1983) where it mediates vasodilatation in order to
increase local blood flow. NO released by the endothelium acts directly upon the
adjacent smooth muscle cells to bring about relaxation. The mechanism is virtually
exclusively cGMP-dependent; NO acts on cytosolic guanylate cyclase to increase
cGMP, which results in a reduction of intracellular calcium in smooth muscle cells
and thereby relaxation (Collins et al., 1986; Gruetter et al., 1981; Ignarro et al.,
r
1987; Liu et al., 1992; Miller et al., 2000; Rapoport et al., 1983).
Endothelial dysfunction, as typically occurs in atherosclerosis, is often defined as
decreased endothelial production of NO, causing the endothelium to become
proinflammatory and prothrombotic, with reduced capacity for vasodilatation. In
addition to its role in atherosclerosis (discussed in chapter one), endothelial
dysfunction in epicardial vessels and those of the coronary microcirculation is also
thought to play a role in effort-related angina (Egashira et al., 1993; Gordon et al.,
1989; Quyyumi et al., 1992; Zeiher et al., 1995). The vasodilatory role of NO is
exploited by the use of NO-donating organic nitrate compounds such as GTN and
ISDN, which are traditionally used to treat exercised-induced angina. The organic
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nitrates rapidly dilate veins and coronary arteries, thus reducing cardiac work and
improving the blood supply to the heart (Abrams, 1885).
The action of aspirin in the blood vessel is an interesting one due to the role of COX
in the production of the vasoconstricting substance TXA2 (Hamberg et al., 1975).
However, the vasodilatory substance PGI2, which plays a role in overcoming the
vasoconstrictive effects of TXA2 is also COX-derived (Bunting et al., 1976; Dusting
el al., 1977).
The ability of NO to cause vasodilatation was utilised in this chapter as a screening
tool to determine whether the furoxan compounds and their respective aspirin
hybrids were NO-active. The hypothesis that the furoxan compounds (B13 and B12)
and their NO-aspirin counterparts (B8 and B7), but not their NO-free furazan hybrids
(B16 and B15), cause vasorelaxation was investigated in isolated rat aortas using
myography. Temporal experiments were also conducted with the hybrid compounds
in order to establish the durability of the vasodilator effect and the ease with which
the drug can be washed out.
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4.2 Methods
4.2.1 Vasorelaxant Effects of Furoxan-Aspirins in Isolated
Aortae
Myography experiments were performed on isolated rings of thoracic aorta from
male Wistar rats, dissected and calibrated as detailed in section 2.2. Mounted rings
were bathed in Krebs buffer at 37 °C and bubbled with 5 % CO2 in O2 gas. The
contractile integrity of the rings was first investigated using KCl as described in the
methods chapter (section 2.2.2). The rings were treated with L-NAME (200 uM) to
prevent generation of any eNOS-derived NO. The ai adrenoceptor agonist,
phenylephrine, was used to achieve smooth muscle contraction. A concentration-
response curve to phenylephrine (0.001 - l pM) was constructed in order to
determine the concentration for each ring that gave ~ 80 % of the maximum
achievable contraction (ECso).
Relaxation to the furoxan compounds, Bl3 (1 pM - 30 nM), and B12 (0.1 - 300
pM). furoxan-aspirin hybrids. B8 (0.3 nM - 3 pM) and B7 (30 nM - 100 pM), and
their NO-free counterparts, B16 (0.3 nM - 3 pM) and B15 (30 nM - 100 pM), were
investigated by the cumulative addition of increasing concentrations (chosen
following pilot experiments) of the test drug on rings preconstricted with
phenylephrine (ECso concentration). Peak relaxations were recorded and results
expressed as a percentage relaxation of the contraction to the ECso concentration of
phenylephrine.
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4.2.2 Duration of Action of Furoxan-Aspirin, B7, in Isolated
Aortae
Experiments were also undertaken to determine the rate of NO release from the
compounds. This was as above but, following the addition of a single concentration
of B8 (30 nM) or B7 (3 pM), the vessels were left to incubate.
In order to determine whether compounds were trapped in tissue or formed durable
NO stores, the ease with which the drug was washed out was investigated with B7.
After administration of a single concentration (3 pM), the myography chamber was
emptied either every 10 or every 30 min and new Krebs, containing the ECgo dose of
phenylephrine added until the full contraction to phenylephrine was restored.
4.2.3 Statistics
Statistical analysis was by 2-way ANOVA carried out using GraphPad Prism version
4. * is used to represent a p value between 0.01 and 0.05, ** represents a p value of
0.001 to 0.01 and *** represents p values less than 0.001. P values greater than 0.05
were deemed not significant. Where expressed, data is in the form mean ± s.e.m.
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4.3 Results
4.3.1 Vasorelaxant Effects of Furoxan Compounds in Isolated
Aortae
The myography experiments revealed that Bl3 induced concentration-dependent
relaxation of phenylephrine-contracted rat aortic rings (log EC50 = -9.96 ± 0.09. Fig.
4.1). Preincubation with ODQ (50 uM) abolished the effect completely (p < 0.001; 2-
way ANOVA. B13 + ODQ vs. B13 alone). In the presence of 500 pM cPTIO (log
EC50 = -8.88 ± 0.08) there was a partial, but significant (p < 0.001; 2-way ANOVA,
B13 + cPTIO vs. B13 alone) inhibition.
Log [B13J (M)
Fig. 4.1. Vasodilator effect of furoxan compound B13. Isolated rat aortic rings were
preconstricted with an EC8o dose of phenylephrine and the peak relaxation to B13 (1
pM - 30 nM) ± ODQ (50 pM; 15 min pre-treatment) were recorded. n=6. Values are
mean ± s.e.m. *** = p < 0.001 2-way ANOVA with Bonferroni post-test, B13 + cPTIO
and B13 + ODQ vs. B13 alone.
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B12 caused concentration-dependent relaxation of phenylephrine-contracted rat
aortic rings (log EC50 = -5.31 ± 0.04. Fig. 4.2). Preincubation with ODQ (50 pM)
inhibited the effect fully (p < 0.001; 2-way ANOVA, B12 + ODQ vs. B12 alone),
whereas preincubation with 500 pM cPTIO (log EC50 = -4.4 ± 0.09) gave a partial,







Fig. 4.2. Vasodilator effect of furoxan compound B12. Isolated rat aortic rings were
preconstricted with an EC8o dose of phenylephrine and the peak relaxation to B132
(0.1 - 300 pM) ± ODQ (50 pM; 15 min pre-treatment) were recorded. n=6. Values are
mean ± s.e.m. . *** = p < 0.001 2-way ANOVA with Bonferroni post-test, B12 + cPTIO
and B12 + ODQ vs. B12 alone.
4.3.2 Vasorelaxant Effect of B8 in Isolated Aortae
B8 (0.3 nM - 3 pM) evoked concentration-dependent relaxation in isolated rat aortic
rings preconstricted with phenylephrine. Data revealed the log EC50 of B8 to be -8.11
± 0.15 (Fig. 4.3). Relaxation to B8 was completely abolished following
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the same concentrations, B16, the NO-free equivalent of B8, failed to cause
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Fig. 4.3. Vasodilator effect of furoxan-aspirin compound B8 and its NO-free
equivalent B16. Isolated rat aortic rings were preconstricted with an EC80 dose of
phenylephrine and the peak relaxation to B8 (0.3 nM - 3 pM) ± ODQ (50 pM; 15 min
pretreatment) or B16 (0.3 nM - 3 pM) were recorded. *** = p<0.0001. 2-way ANOVA
B8 vs. B16/B8+ODQ. n=6. Values are mean ± s.e.m.
4.3.3 Vasorelaxant Effect of B7 in Isolated Aortae
The furoxan-aspirin B7 (30 nM - 100 pM) also evoked concentration-dependent
relaxation of phenylephrine-contracted isolated rat aortic rings, with a log EC5o of -
6.09 ± 0.05 (Fig. 4.4). Preincubation with ODQ (50 pM) prevented this B7-induced
relaxation (p<0.0001. 2-way ANOVA B7 vs. B7 + ODQ). At the same
concentrations, B15, the NO-free equivalent of B7, failed to cause significant
relaxation (pO.OOOl. 2-way ANOVA B7 vs. B15. Fig 4.4).
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Fig. 4.4. Vasodilator effect of furoxan-aspirin compound B7 and its NO-free
equivalent B15. Isolated rat aortic rings were preconstricted with an EC80 dose of
phenylephrine and the peak relaxation to B7 (30 nM - 100 uM) ± ODQ (50 pM; 15
min pretreatment) or B15 (30 nM - 100 pM) were recorded. *** = p<0.0001. 2-way
ANOVA B7 vs. B15/B7+ODQ. n=6. Values are mean ± s.e.m.
4.3.4 Duration of Vasorelaxation Effect of B7 in Isolated
Preliminary data revealed that the effect of B8 (30 nM) was transient, and an
approximate 90 % recovery was observed within 10 min. By contrast, the effect of
B7 at (3, 1 and 0.3 pM) persisted beyond 3 h. A typical trace (from n = 6) of the
relaxation achieved with both drugs is shown in Fig. 4.5.
Aortae
91




following a single concentration (30 nM) of B8 (top) or a single concentration (3 [iM) of B7
(bottom). The response to B7 was typically sustained for longer than 3 h.
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The reversibility of the effect on washout was then tested using the longer acting of
the two hybrids, B7. Experiments were conducted in which every 10 or 30 min, the
B7 (3 |iM)-containing Krebs was replaced by fresh phenylephrine (ECgo)-containing
Krebs. Data revealed that the contraction was generally restored within 4 washes,
irrespective of the timeframe (Fig. 4.6).
Time (min) Time (min)
Fig. 4.6. Duration of action of a single (3 uM) dose of furoxan-aspirin compound B7.
(a) shows the effect of a single wash after every 10 min and (b) shows the effect of a
single wash after every 30 min. n=6 for each. Values are mean ± s.e.m.
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4.4 Discussion
4.4.1 Furoxan-lnduced Vasodilatation of Rat Aortic Rings
Both furoxan compounds (B13 and B12) induced concentration-dependent relaxation
of phenylephrine-contracted rat aortic rings with log EC50 of -9.96 ± 0.09 and -5.31 ±
0.04 respectively. In the case of both furoxans, the effect was demonstrated to be
entirely cGMP-dependent as indicated by the ability of the sGC inhibitor, ODQ, to
abolish the responses. These data imply a role for NO in the furoxan-mediated
vasodilatation. The use of L-NAME in the organ bath demonstrates that the activity
of B13 and B12 does not depend on NO release from vascular endothelial cells and
instead suggests a direct donation of NO from the compounds to overcome the lack
of endogenous NO.
Incubation with the NO scavenger, cPTIO, gave a significant partial inhibition of the
effect of both B13 and B12. The failure of cPTIO to fully abolish the effect of the
furoxan is likely due to the locality of action. The literature is unclear as to the
locality of action of cPTIO; it has been reported to act both intracellularly (Yi el al.,
2002) and extracellularly (Amano & Noda, 1995; Doran et al., 2003). The data
obtained here would imply that cPTIO acts in a compartment that is largely
inaccessible to the NO released by the furoxans and thus does not fully prevent the
action of the NO released. However, it may also be the case that the furoxans B13
and B12 release their NO in closer proximity to sGC, and thus that reaction occurs
too quickly for cPTIO to have an effect.
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The remarkable ability of B13 to cause vasorelaxation at concentrations in the
picomolar range is an exciting revelation. The existing NO donor drug. DEA/NO,
has been reported to have a EC5o of 35 nM in rat aortic rings preconstricted with
norepinephrine (Sausbier et al., 2000). The EC5o of 110 pM obtained in this study
reveals B13 to be ~300-fold more potent than DEA/NO. DEA/NO is considered a
primarily extracellular NO donor (Crane et al., 2005; Hirasaki et al., 1996). It has
previously been hypothesised that cGMP-dependent NO effects correspond with
intracellular release of NO (Crane et al., 2005; Miller et al., 2004). Following this
hypothesis, the cGMP nature of the effect by the furoxans would imply their NO is
released intracellularly. The release in closer proximity to the sGC could account for
the extremely high potency of B13 in particular.
4.4.2 NO-Aspirin-Induced Vasodilatation
The furoxan-aspirin compounds, B8 and B7 evoked concentration-dependent
relaxation in isolated rat aortic rings preconstricted with phenylephrine. As revealed
by the log EC50S, B8 was approximately 100 times more potent than B7. In the case
of both furoxan-aspirin compounds, preincubation with the guanylate cyclase
inhibitor, ODQ, completely abolished the relaxation, indicating a role for the
NO:sGC pathway in this response.
Further evidence for the involvement of NO in the furoxan-aspirin mediated
relaxation comes from the response to the furazan-aspirin equivalents. At the same
concentrations as their respective furoxan counterparts, NO-free B16 and B15 failed
to reverse the phenylephrine-induced contraction. These data suggest that the
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relaxation achieved by B8 and B7 is completely NO-mediated and unlikely to
involve aspirin-mediated COX inhibition under these conditions.
The use of L-NAME in the organ bath demonstrates that the activity of the
compounds B8 and B7 does not depend on NO release from vascular endothelial
cells and instead indicates a direct donation of NO from the compounds.
The vasorelaxant effects of the organic nitroaspirin, NCX4016, have been
investigated previously by others. NCX4016 caused vasodilatation in norepinephrine
-preconstricted rat tail arteries in a process that relies on cGMP and not the aspirin
moiety (Rossoni et al., 2002). These data fit with the findings for the furoxan NO-
aspirins in that the effect is all NO and specifically cGMP-mediated.
4.4.3 NO-Mediated Vasodilatation
NO causes vasodilatation by a cGMP-dependent mechanism, whereby the increase in
cGMP reduces intracellular calcium in smooth muscle cells causing them to relax
(Collins et al., 1986; Gruetter el al., 1981; Ignarro et al., 1987; Liu et al., 1992;
Rapoport et al., 1983). The lack of response observed in this study following
preincubation with ODQ, further confirms the role of cGMP in the NO-mediated
vasorelaxation to furoxans.
A further mechanism of NO-induced vasodilatation is via NO-mediated stimulation
of the potent vasorelaxant compound, PGI2. NO does this by a cGMP-independent
stimulation of the activity of the enzyme COX (Davidge et al., 1995). However, due
to the possible activity of the aspirin moiety (chapter three) of these compounds, this
mechanism is unlikely to play a role in this situation. Indeed, the cGMP-dependent
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nature of the response indicated by the ODQ data indicates that it does not play a
role.
4.4.4 Aspirin-Mediated Vasodilatation?
The dual inhibition by aspirin in the generation of vasoconstricting substance TXA2
(Hamberg et al., 1975) and the vasodilatory substance PGI2 (Bunting et al., 1976;
Dusting et al., 1977) gives uncertainty as to whether aspirin will give a vasodilatory
or constrictive response.
TXA2 acts through a specific G-protein coupled receptor known as the TP receptor.
Stimulation of the TP receptor leads to phospholipase C activation, release of inositol
triphosphate and an increase in the intracellular Ca2+ level, thus triggering smooth
muscle contraction (Habib et al., 1997; Narumiya et al., 1999). The source of the
vasoconstricting TXA2 is platelet COX-1 (Patrono et al., 2005) and due to their
anucleate nature, following aspirin inhibition, full TXA2 recovery will only take
place as a function of platelet turnover (Burch et al., 1978). However, it is important
to note that as this study uses isolated aortic rings, there is no source of platelet-
derived TXA2 in this model, and so no contractile response for the aspirin to inhibit.
In contrast, in the vasculature, PGI2 is predominantly COX-2-derived and the main
source is endothelial cells (Fitzgerald, 2004). PGI2 brings about endothelium-
dependent vasorelaxation by action on IP receptors (Coleman et al., 1994).
Stimulation of the IP receptors brings about vascular smooth muscle cell relaxation
in a process that relies upon cAMP (Coleman et al., 1994; Halushka et al., 1989).
Interestingly, studies with cultured vascular smooth muscle cells demonstrate that the
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vasorelaxant substance PGI2 is produced only on stimulation by thrombin (Weksler
el al., 1978; Whiting et al., 1980) or when in co-culture with platelets (Weksler et al.,
1977) and thus suggest that PGI2 is produced endogenously to overcome the
vasoconstrictive effects of TXA2. It was further shown that, following treatment with
aspirin, PGf> is restored within only a couple of hours (Whiting et al., 1980).
It is generally accepted that in in vivo situations, aspirin treatment will result in a
vasodilatory effect due to the predominant inhibition of platelet-derived TXA2 over
that of endothelium-derived PGI2. Due to platelets only possessing COX-1 (Patrono,
1994) and aspirin being nearly 170-fold more selective for COX-1 than COX-2
(Vane et al, 1998), low dose aspirin that is effective at inhibiting platelet COX-1-
derived TXA2 without affecting endothelial COX-2-derived PGI2 (FitzGerald, 2002;
Patrono et al., 2001) can be administered. These facts, combined with the ability of
the endothelial cells to restore PGI2 production quickly (Fuster et al., 1993; Weksler
et al., 1978), suggest that aspirin will bring about a vasodilatory action. Indeed, the
reason behind the recent withdrawal of COX-2-specific inhibitors is due to an
imbalance between vascular PGI2 and platelet TXA2, resulting in an increased risk of
stroke. The increased risk of thrombus is thought to be due to inhibition of COX-2 in
endothelial cells leading to reduced generation of the anti-thrombotic and vasodilator
agent, PGI2, in relation to the unaffected COX-1 derived, TXA2 (Fitzgerald, 2004).
It is proposed that the lack of platelets in the isolated preparation used here could be
the reason behind the lack of vasodilatory response to NO-free furazans B16 and B15
and that the situation may alter in in vivo situations.
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The data here show that whilst the addition of the aspirin group decreases the
potency of B13 (Table 4.1) by approximately 70-fold, the addition of aspirin to B12
to form B7 caused a slight increase in potency. It is likely that the release of NO and
hence the effect of the drug is related to its structure and thus NO release requires
investigating.
BBsIJSSM Hi:":
B13 -9.96 ± 0.09
B12 -5.31 ± 0.04
B8 -8.11 ± 0.15
B7 -6.09 ±0.05
Table. 4.1. Log EC50 s obtained in the rat aorta
myography experiments.
4.4.5 B7 - Duration and Reversibility of Action
The data here show that, in the case of B8, NO is released transiently, and that within
approximately 10 min 90 % of the contraction to phenylephrine is recovered. For B7
the onset of the relaxation is slower but the effect was sustained for longer and
exceeded the life of the tissue preparation.
The reversibility of the effect of the compounds was investigated with the wash-out
experiment. Data obtained in this study demonstrated that whilst a single
concentration of the furoxan-aspirin compound B7 would last in excess of three
hours, it was fairly easily washed out of the system. The wash-out experiments were
carried out at two different time frames (10 and 30 min) and revealed that rather than
persisting for a set period of time, the response to the drug persisted as a function of
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washes. If it is to be presumed from the previous data that the drug releases NO
intracellularly, due to the speed at which a response was seen with the myography
apparatus (within seconds), it appears that the drug enters the cell quickly. The
susceptibility of B7 to rapid washout implies it is not being trapped in the
intracellular compartment but, instead, is simply equilibrating across the membrane.
It is important to note that this study is likely a poor predictor of the duration of
action in vivo. The drug is likely to respond differently in different vessels and the
wash-out with phenylephrine-containing Krebs does not likely reflect that of blood
flowing through the vessel in vivo. Furthermore, factors such as metabolism by
cytochrome P450s and clearance will undoubtedly play a role in vivo. It may be that
alteration of the chemical structure could alter the equilibrium across the cell
membrane leading to less diffusion of unaltered drug out of the cell.
4.4.6 Summary and Future Directions
The data obtained here reveal the furoxan compounds, particularly B13, to be
promising and extremely potent vascular NO donor drugs. B13 caused relaxation of
vascular smooth muscle in vitro at concentrations in the picomolar range,
demonstrating it, to my knowledge, to be the most potent vasodilator NO-donor drug
yet discovered.
The data here clearly show a concentration-dependent vasodilatation by the furoxan
NO-aspirins in isolated rat aortae. The effect is NO-mediated, as demonstrated by
lack of response with the furazan equivalents, and the susceptibility to ODQ pre-
treatment is indicative of an exclusively cGMP-dependent effect. The inclusion of
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the aspirin moiety has a more dramatic impact on the potency of B13 than B12, most
likely due to the effect of the structural change on the NO release.
In addition to their aspirin-like action revealed in chapter three, the furoxan hybrids
have an NO mediated action and, therefore, both elements of the hybrid have the
potential to be active, at least in vitro. Their NO-mediated action appears to vary
with structure and thus the NO-release mechanism requires further exploration.
101
CHAPTER FIVE
Comparative Pharmacology of Novel
Furoxan and Furoxan-Aspirin Hybrid
Compounds in Platelets
Chapter Five: Comparative Pharmacology ofNovel Furoxan and Furoxan-Aspirin Hybrids in
Platelets
5. Comparative Pharmacology of Novel Furoxan
and Furoxan-Aspirin Hybrid Compounds in
Platelets
5.1 Introduction
The NSAID, aspirin, is the most commonly used prophylactic drug in the prevention of
coronary thrombotic events (ISIS-2, 1988; Manson et al., 1991; PHS-Committee,
1989). As previously discussed, aspirin reduces COX-1-generated TXA2, therefore
inhibiting platelet aggregation for the lifetime of the platelet (Burch et al., 1978; DeWitt
& Smith, 1988; FitzGerald, 1991; Hamberg et al., 1975; Roth & Majerus, 1975; Roth
et al., 1975). The unfortunate limitation of the long-term use of aspirin is that it can
cause gastrointestinal disorders, including ulceration (Cameron, 1975; Seager &
Hawkey, 2001; Tramer et al., 2000; Wallace, 1997), due mainly to the inhibition of
prostaglandins that normally protect the gastric mucosa (Robert et al., 1979; Schoen &
Vender, 1989; Wallace, 1997; Whittle, 1977).
NO-aspirins, or aspirin esters containing an NO-donor moiety, were developed in the
hope of overcoming the gastric side-effects of aspirin through various gastroprotective
effects of drug-derived NO.
Whilst NO hybrids of aspirin were primarily designed to protect against damage to the
gastric mucosa, there may be additional antiplatelet benefits of drug-derived NO. NO
displays antithrombotic actions through its ability to inhibit platelet adhesion
(Radomski et al., 1987b; Radomski et al., 1987d) and aggregation (Pasqui et al., 1991;
Radomski et al., 1990; Radomski et al., 1987c). Inhibition of platelet aggregation
occurs primarily via stimulation of cGMP; the platelet aggregation response to sodium
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nitroprusside has been shown to be entirely cGMP dependent (Sogo et al., 2000).
However, cGMP-independent signalling mechanisms have also been identified (Crane
et al., 2005; Gordge et al., 1998; Homer & Wanstall, 2002; Sogo et al., 2000;
Trepakova et al., 1999).
The release of NO from an existing nitroaspirin, NCX4016, and glyceryl trinitrate
has been reported to occur through identical mechanisms (Grosser & Schroder,
2000). Platelets have a poor capability of releasing NO from organic nitrates like
these (Weber et al., 1996) and thus it is possible that compounds such as NCX4016
will fail to show additional, NO-mediated effects in platelets, at least in vitro. A
further limitation of NCX4016 is the probability of tolerance with long-term or high
dose use; there is no evidence to suggest that NCX4016 will not be susceptible to the
tolerance problems associated with long-term or high dosage use of traditional
organic nitrates (Munzel et al., 2005).
However, the furoxan series of NO-aspirin hybrids do not possess an organic nitrate
group and might not be susceptible to the same failings. The NO moiety has already
been demonstrated to be active in vascular smooth muscle cells (chapter four), but in
this chapter the effects of the hybrid-derived NO will be examined in platelets, where
the aspirin moiety also has potential for action (chapter three). Here, the mechanism of
action of two furoxan-aspirin hybrid drugs, B8 and B7 (Fig. 1.7), with different NO-
releasing properties (Cena et al., 2003) are investigated in human platelets in vitro along
with their parent counterparts B13 and B12 (Fig. 1.7), which do not possess an aspirin
moiety in order to test the hypothesis that the hybrids have antiplatelet action
contributed to by both elements. The antiplatelet effects are compared with that of
existing nitroaspirin compound, NCX4016 (Fig. 1.5), which has an alternative NO-
releasing moiety.
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The effect of the furoxans on platelet aggregation was examined by two techniques.
Turbidometric platelet aggregometry allowed the evaluation of the impact of plasma
components on the efficacy of the drugs. Impedance aggregometry was utilised to
examine the effects in whole blood where the optical density of the samples
prevented the use of the turbidometric technique. Impedance aggregometry allowed
determination of whether the drug could withstand the NO scavenging effect of
haemoglobin in erythrocytes.
5.2.1.1 Impedance Platelet Aggregometry
Impedance aggregometry was used to investigate the ability of the furoxan
compound, Bl3, to withstand the NO-scavenging properties of endogenous
scavenger haemoglobin. Human blood was collected as described in chapter two
(section 2.2) and diluted 50:50 in PBS. I ml samples were placed in tubes incubated
at 37 °C and stirred at 1000 rpm in a dual channel aggregometer, fitted with
impedance electrodes. Following a 10 min preincubation with either DEA/NO or
B13 (100 and 300 pM), aggregation was induced using 2.5 pg.mf1 collagen and
electrical impedance recorded for the subsequent 5 min. Results are expressed as
percentage inhibition of the response to a collagen-only control.
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5.2.1.2 Turbidometric Platelet Aggregometry
The effect of the furoxans and furoxan-aspirin hybrids on platelet aggregation was
examined by optical (turbidometric) platelet aggregometry to allow the evaluation of
the impact of plasma components on the efficacy of the drugs.
Inhibition of platelet aggregation was measured in a 4-channel aggregometer as
described in section 2.4.1. Aliquots (0.5 ml) of either PRP or WP (prepared as in
section 2.3) were incubated at 37 °C and constantly stirred at 1000 rpm. Platelet
samples were treated with either B13 (1 nM - 10 pM), B12 (3 - 300 pM), B8 (10
nM - 3 pM), B7 (10 pM - 1 mM), the respective NO-free furazan equivalents of B8
and B7; B16 (10 nM - 3 pM) or B15 (10 pM - 1 mM), the organic nitrate,
NCX4016 (3 pM - 0.3 mM), aspirin or SA (3 pM - 1 mM) for 10 minutes before
induction of aggregation with supra-maximal concentrations of collagen (2.5 pg.mf
'). Aggregation was then recorded for 5 min following addition of the agonist.
Experiments were also performed with the addition of the cGMP inhibitor ODQ (50
pM) 15 min before addition of the test drug in order that the contribution of cGMP to
the antiaggregatory effects could be determined. Aggregation was expressed as a
percentage inhibition of control aggregation obtained in response to 2.5 pg.mf1
collagen.
5.2.2 Statistics
Statistical analysis was by either students' t-test or 2-way ANOVA carried out using
GraphPad Prism version 4. * is used to represent a p value between 0.01 and 0.05, **
represents a p value of 0.001 to 0.01 and *** represents p values less than 0.001. P
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values greater than 0.05 were deemed not significant. Where expressed, data are in
the form mean ± s.e.m.
5.3 Results
5.3.1 Impedance Platelet Aggregometry
Whole blood aggregometry was limited by failure of B13 to remain in solution at
concentrations above 300 pM. B12 also failed to stay in solution at concentrations
high enough (> 300 pM) to obtain an effect in this system.
The data obtained demonstrate that the furoxan B13 causes significantly greater
inhibition of collagen (2.5 pg.mf^-induced platelet aggregation than that obtained
with the NO donor compound, DEA/NO, in whole blood at both 100 pM and 300
pM (for both concentrations, p < 0.05 as analysed by Student's t-test; Fig. 5.1). 300
pM B13 gave a 37.7 ± 6.8 % inhibition, whereas an equimolar concentration of
DEA/NO gave 11.0 ± 7.0 %. At 100 pM, B13 gave 21.3 ± 6.7 % and DEA/NO 0.7 ±
6.3 %.
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300 [xM 100 jxM
Fig. 5.1 Inhibition of collagen (2.5 |xg mr1)-induced platelet aggregation in whole
blood by the furoxan compound, B13 (100 and 300 pM). n = 6 - 7. Values are
mean ± s.e.m. * = significant difference (p < 0.05) as analysed by students' t-test.
5.3.2 Turbidometric Platelet Aggregometry
5.3.2.1 Effect of Furoxan B13
The furoxan Bl3 caused concentration-dependent inhibition of collagen-induced
platelet aggregation in both PRP and WP (log IC50 = -6.4 ± 0.2 and -6.9 ± 0.2
respectively). No significant difference between effect in PRP and WP (p = 0.71) as
assessed by 2-way ANOVA; Fig. 5.2). The effect was significantly inhibited by
preincubation with the sGC inhibitor, ODQ, in both PRP and WP (p = 0.020 and
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5.3.2.2 Effect of Furoxan B12
B12 also caused concentration-dependent inhibition of collagen-induced platelet
aggregation in both PRP and WP but at approximately 300x higher dose than Bl3
-m-B13
"♦» B13 + ODQ
-a-Bl3
#"■' B13 + ODQ
log [B13] (M)
Fig. 5.2 Inhibition of collagen (2.5 ug ml"1)-induced platelet aggregation in (a) PRP and (b)
WP by the furoxan compound, B13 (1 nM - 10 fxM) and the impact of the guanylate cyclase
inhibitor, ODQ (50 (xM; 15 min preincubation) on this effect; n = 6. Values are mean ± s.e.m.
Statistical analysis by two-way ANOVA demonstrated that preincubation with ODQ




(log IC50S in PRP and WP are -3.8 ± 0.2 and -4.1 ± 0.2 respectively, p = 0.0172 as
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assessed by 2-way ANOVA; Fig. 5.3). Preincubation with the sGC inhibitor, ODQ
caused significant inhibition of the effect of B12, in WP (p <0.0001; 2-way








































Fig. 5.3. Inhibition of collagen (2.5 fig ml" )-induced platelet aggregation in (a) PRP and (b)
WP by the furoxan compound, B12 (3 - 300 pM) and the impact of the guanylate cyclase
inhibitor, ODQ (50 uM; 15 min preincubation) on this effect, n = 6. Values are mean ± s.e.m.
Statistical analysis by two-way ANOVA revealed preincubation with ODQ significantly
inhibited the effect of B12 in WP (***; p <0.0001).
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5.3.2.3 Effect of Aspirin, Salicylic Acid and NCX4016
Aspirin (3-300 pM) caused concentration-dependent inhibition of collagen-induced
platelet aggregation in PRP and the effect was enhanced in WP, but SA failed to
show an inhibitory effect, even at concentrations of 300 pM (Fig 5.4; n=6-8).
NCX4016 (3-300 pM) had no effect on collagen-induced platelet aggregation in PRP
(Fig. 5.4a; n=6), but did cause concentration-dependent inhibition of platelet
aggregation in WP that was significantly enhanced compared to aspirin (Fig 5.4b,
P=0.002; n=6). Responses to NCX4016 were insensitive to the soluble guanylate
cyclase inhibitor, ODQ (15 min preincubation; P=0.88, NCX4016 + ODQ vs.
NCX4016 alone in WP; Fig. 5.4b).
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Fig. 5.4. Collagen (2.5 |jg.mr1)-induced platelet aggregation in PRP and WP. a. Effect of
NCX4016, salicylic acid and aspirin on collagen-induced platelet aggregation in PRP. ***
P<0.0001, n = 6-7. b. The effect of the guanylate cyclase inhibitor, ODQ (50 pM; 15 min
preincubation), on responses to NCX4016 in WP. ** P = 0.002, n = 6. Values are mean ±
SEM. Statistical analysis by 2-way ANOVA.
112
Chapter Five: Comparative Pharmacology ofNovel Furoxan and Furoxan-Aspirin Hybrids in
Platelets
5.3.2.4 Effect of B8
B8 (10 nM-3 pM) caused concentration-dependent inhibition of collagen-induced
platelet aggregation in PRP at concentrations ~100-fold lower than for aspirin (B8
log IC50 in PRP = -6.21 ± 0.07; Fig. 5.5a. See Fig 5.4a for aspirin effect.). ODQ
significantly inhibited the responses to B8 in PRP (Fig. 5.5a; n = 6-8; PO.OOOl),
whilst the NO-free, structurally related furazan derivative of B8 (B16; 10 nM-1 mM)
was considerably less effective at inhibiting platelet aggregation than B8 in PRP
(Fig. 5.5a; PO.OOOl; n = 8).
The effects of B8 in PRP were largely mirrored in WP: B8 was found to be a
powerful inhibitor of collagen-induced aggregation (log IC50 = -6.23 ± 0.06) and its
actions were significantly inhibited by ODQ (Fig 5.5b; PO.OOOl; n = 6-8). B16 had
a significantly greater inhibitory effect on platelet aggregation in WP compared to
PRP (log IC50 = -4.27 ± 0.05; Fig 5.5b: PO.OOOl. PRP B16 vs. WP B16; n = 6-8).
113













Fig. 5.5. Collagen (2.5 [jg.mr )-induced platelet aggregation in PRP and WP. a. Effect of B8
(± ODQ; 50 pM, 15 min preincubation) and its NO-free equivalent, B16, on collagen-induced
platelet aggregation in PRP. P< 0.0001 (B8 + ODQ vs. B8 alone, n = 6 - 9). b. The effect of
ODQ (50 pM) on responses to B8 in WP. P< 0.0001 (+ ODQ vs. B8 alone), n = 6 - 9.
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5.3.2.5 Effect of B7
B7 (10 pM-1 mM) was less effective than B8 and aspirin at inhibiting collagen-
induced platelet aggregation in PRP (B7 log IC50 = -3.43 ± 0.7). ODQ significantly
inhibited the response of B7 in PRP (Fig. 5.6a; n = 6-7. PO.OOOl). B15 was
ineffective in PRP.
In order to make a direct comparison, concentrations studied with WP were dictated
by the PRP response curve. B7 (10 pM-1 mM) was considerably more effective in
WP (log IC50 = -4.6 ± 0.9; Fig 5.6 b) than PRP. The inhibitory effects of B7 in WP
were significantly attenuated by ODQ (P=0.002, 2 way ANOVA; n=6-7). In stark
contrast to the findings in PRP, B15 was found to be a powerful inhibitor of platelet
aggregation in WP (B15 log IC50 in WP = -4.22 ± 0.1); indeed, at concentrations of
100 pM or more, it was as effective as B7 under these conditions.
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Fig. 5.6. Collagen (2.5 |jg.mr1)-induced platelet aggregation in PRP and WP. a. Effect of B7
(± ODQ; 50 pM) and its NO free equivalent B15 on collagen-induced platelet aggregation in
PRP. *** P<0.0001, n = 6 - 7. b. The effect of ODQ (50 pM) on the B7 response in WP. ***
P< 0.0001, n = 6 - 7. Values are mean ± SEM. Statistical analysis by 2-way ANOVA.
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5.4 Discussion
These studies provide evidence that the both furoxans and furoxan-aspirin hybrid
drugs provide concentration-dependent inhibition of collagen-induced platelet
aggregation in vitro. The effect was determined to be sGC-dependent by use of
cGMP inhibitor, ODQ.
5.4.1 Furoxan-lnduced Inhibition of Platelet Aggregation
The endogenous metalloprotein, haemoglobin, is found in erythrocytes where it
functions to transport oxygen in the blood by use of its iron-containing core (For
review see Habler & Messmer, 1997). However, NO can also react with
haemoglobin and so, haemoglobin can act as an endogenous mechanism to limit NO
bioactivity (Gladwin el al., 2004; Kosaka et al., 1989). This feature can be exploited
experimentally and haemoglobin is often used as an NO scavenger. NO reacts with
haemoglobin in its oxygenated state to form methaemoglobin and nitrate but also
reacts with deoxy-haemoglobin to form iron-nitrosyl-haemoglobin. This reaction,
were it not for the containment of haemoglobin in the erythrocyte and the effect of
plasma streaming, would consume all available NO (Butler et al., 1998; Gladwin et
al., 2004; Lancaster, 1996; Vaughn el al., 2000).
Whole blood impedance aggregometry was therefore utilised to determine the impact
of cellular haemoglobin on the function of the furoxans. Collected data was limited
by the failure of B12 to stay in solution at concentrations high enough to obtain an
effect. For the same reason, B13 data above 300 pM were not collected.
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The data did, however, reveal some interesting information. At concentrations which
cause similar inhibition of platelet aggregation in PRP (data not shown), the effect of
B13 and DEA/NO are significantly different in whole blood. At both concentrations
studied, B13 caused significantly greater inhibition of collagen-induced platelet
aggregation than that of the NO donor compound DEA/NO in whole blood. These
data show that, despite requiring higher concentrations than necessary to have an
effect in PRP, B13 can overcome the NO-scavenging effects of haemoglobin. The
fact that in PRP these concentrations yield similar results with B13 and DEA/NO,
but in the presence of haemoglobin, the antiplatelet effect of B13 is greater, shows
B13 to be a more effective inhibitor of platelet aggregation than DEA/NO under
physiological conditions. Furthermore, the data shows potential for B13 to retain an
antiplatelet effect in vivo.
The in vitro study of the scavenging effect of haemoglobin on the antiplatelet activity
of NO donors is not commonplace. However, one study shows that the effect of NO-
donors, S-nitrosoglutathione and RIG 200 are subject to inhibition by haemoglobin
(Megson et al, 2000). The results of this study may indicate that the NO released by
B13 is released in a compartment less accessible to haemoglobin than to DEA/NO,
S-nitrosoglutathione and RIG 200. The obvious inference from such data is that NO
from B13 is released inside platelets, whilst that from other NO donors is released
predominantly extracellularly. Further support for the theory of intracellular release
of NO comes from the hypothesis that cGMP-dependent vasorelaxation (as
demonstrated in chapter four) is correlated with intracellular release of NO (Crane et
al., 2005; Miller et al., 2004).
118
Chapter Five: Comparative Pharmacology ofNovel Furoxan and Furoxan-Aspirin Hybrids in
Platelets
Turbidometric assessment revealed the furoxans B13 and B12 to both cause
concentration-dependent inhibition of collagen-induced platelet aggregation in both
PRP and WP, although B13 did so at approximately 1000-fold lower concentrations.
The effect of B13 in PRP and WP was determined to be cGMP-dependent as
demonstrated by significant attenuation of responses by the sGC inhibitor, ODQ.
There was no significant difference between the inhibition of aggregation by B13 in
PRP and in WP, suggesting that plasma has no impact on the process. The lack of
impact of plasma on the response could again be an indication that the NO is released
by these compounds in a compartment inaccessible to the plasma - such as inside the
cell. As with the data obtained in chapter four, the cGMP-dependent nature of the
response would indicate an intracellular release of NO (Crane el al., 2005).
There was a significant difference in the B12-induced inhibition of aggregation in
PRP compared to WP, with higher concentrations required in PRP to achieve the
same effect. The differential contribution of cGMP on the response in PRP and WP
may be dependent on their release location as hypothesised by Crane. (Crane et al.,
2005). The data reveal that B12-induced inhibition of aggregation in WP is cGMP-
dependent but that in PRP, ODQ data indicate that B12 acts via a cGMP-independent
mechanism - possibly implying a role for plasma in the extracellular release of NO
from B12.
5.4.2 NO-Aspirin-lnduced Inhibition of Platelet Aggregation
The results show that two novel furoxan-aspirin hybrids drugs effectively inhibit
collagen-induced platelet aggregation and that the relative contribution of NO to the
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inhibitory effect is dependent on the characteristics of the specific furoxan involved.
The potent effects of B8 were considered to be largely NO-dependent on account of
the fact that the closely related NO-free furazan, B16, had only a very weak
antiplatelet effect. B7 was a less potent inhibitor of aggregation than B8; but the
effects were also primarily NO-mediated in PRP, where the furazan counterpart was
largely ineffectual. However, in WP, it was apparent that the antiplatelet activity of
B7 comprised both NO-dependent and -independent components. The existing
nitrooxy-ester, nitroaspirin (NCX4016), was also an effective anti-platelet agent in
WP but the effects were entirely sGC-independent and were altogether lost in PRP.
The furoxan-aspirin hybrid drugs inhibited platelet aggregation in both WP and PRP,
although the effects of both compounds, and B7 in particular, were attenuated in
PRP. The comparatively weak inhibitory effects of the NO-free furazan counterparts
is indicative of a major role for NO in platelet inhibition, whilst the inhibitory effect
of ODQ confirmed that a major component of the effects were sGC-dependent,
especially in PRP. The impact of ODQ on responses was less pronounced in WP,
particularly in the case of B7, due in part to the greater influence of NO-independent
effects, as illustrated by increased sensitivity of WP to the furazan counterparts of B7
and B8. The effects of the furazan derivatives were weak compared to aspirin, but
were nevertheless more potent than SA under the conditions of these experiments.
The lower activity of these agents in PRP compared to WP is in keeping with the
complete hydrolysis of the furoxan-aspirin acetyl group in serum (Cena et al., 2003),
resulting in formation of relatively ineffectual SA. These hybrid molecules are likely
to undergo hydrolysis at two positions: firstly, at the acetyl group, converting aspirin
to SA and secondly at the other ester linkage to release the furoxan. The order and
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rates at which hydrolysis occurs will greatly influence the ability of these compounds
to retain aspirin activity.
The high levels of NO release by B8 and the loss of its aspirin effect in PRP imply
that its antiplatelet actions are mainly NO-mediated. However, B7, which has an IC50
closer to that of aspirin, does display a cGMP-independent antiplatelet effect in WP
implying a role for aspirin. This characteristic reveals it to be a more suitable hybrid
candidate, allowing a role for both NO and aspirin. This is in contrast to B8 where
NO dominates. However, the unfortunate loss of the aspirin effect in PRP is an issue
that needs to be addressed by appropriate modification of the chemical structure.
The finding that NCX4016 is an effective inhibitor of platelet aggregation in WP is
in keeping with previous in vitro studies using NCX4016 (Lechi et al., 1996) and the
related drug, NCX4125 (Minuz et al., 1995; Wallace et al., 1995). However, the
results here go on to show that the effect is lost in PRP, possibly due to sequestration
by a plasma constituent such as albumin or due to breakdown in the plasma to the
inactive SA. Interestingly, the inhibitory effect of NCX4016 was significantly
enhanced compared to aspirin but was not affected by the sGC inhibitor, ODQ.
Whilst a cGMP-independent effect of NCX4016-derived NO cannot be ruled out, the
known inability of platelets to effect NO release from organic nitrates (Weber et al.,
1996), and the COX assay data (chapter three) demonstrating powerful anti-COX
activity of NCX4016, suggests that the antiplatelet action of NCX4016 is most likely
NO-independent. Although this study shows NCX4016 to be a poor inhibitor of
platelet function, its effects in other cells types may still make it a useful
cardiovascular drug. Anti-platelet effects may still be retained in vivo through remote
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nitrooxy-ester activation in cells other than platelets (e.g. smooth muscle cells),
although this would appear to be a rather inefficient method of NO delivery
specifically to platelets. Nevertheless, antiplatelet effects of NCX4016 have been
demonstrated ex vivo, in animals and humans (Fiorucci el al., 1999; Fiorucci et al,
2004; Momi et al., 2005; Wainwright et al., 2002). Furthermore, NCX4016 has
beneficial effects in vivo, where it has been demonstrated to protect the vascular
endothelium in diabetic rats (Pieper et al., 2002), to reduce blood pressure in
hypertensive rats (Muscara et al., 2001), to prevent restenosis in
hypercholesterolemic mice (Napoli et al., 2001) and to reduce infarct size in a model
of cardiac ischemia in pigs (Wainwright et al., 2002).
An interesting observation with these data is that whilst the IC50 of B7 is
approximately 200-fold less than for its aspirin-free equivalent B12 in PRP and
around 500-fold less in WP, the addition of an aspirin group to B13 to form B8 does
not impact on its IC50. This implies an NO-independent role for B7 to complement
the NO effect. These data further confirm the dominance of the NO moiety of B8 and
once again show that B7 acts as a better hybrid by allowing action of both of its
components.
5.4.3 Summary, Future Directions and Therapeutic
Implications
The data show the furoxan compound B13 to be an effective inhibitor of platelet
aggregation and to be more resistant than the NO donor DEA/NO, to the scavenging
effects of haemoglobin probably on account of intraplatelet release of NO.
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The main drawback of the furoxan compounds B12 and B13 is their solubility.
Whilst it cannot be ruled out that the drugs would still retain an action in vivo at
concentrations that are soluble in biological media, alteration to the chemical
structure may be necessary to achieve beneficial effects.
Whilst addition of the aspirin molecule to B13 to form B8 did not impact on its
effects in WP or PRJP, addition of aspirin to B12 did yield a more potent drug. Both
the hybrids B7 and B8 did, however, cause concentration-dependent, NO-induced
antiplatelet effects, with B8 being approximately 1000-fold more potent.
Previous studies have shown that both furoxan-aspirins (Cena et al, 2003) and
NCX4016 (Fiorucci et al., 1999; Fiorucci & Del Soldato, 2003; Fiorucci et al., 2003)
achieve their original goal of a preferential gastrotoxicity profile over aspirin,
suggesting either a masking of the toxic aspirin effect or an active NO element in the
gastrointestinal tract. However, the activity of both the NO and aspirin elements of
the hybrids in platelets is questionable. NCX4016 has no antiplatelet action in PRP
and in WP it fails to demonstrate aspirin-independent effects, possibly due to
sequestration by a plasma constituent. Unlike NCX4016, the furoxans demonstrate
aspirin-independent effects on platelet aggregation in both PRP and WP in vitro, but
their ability to retain the action of aspirin is compromised, particularly in PRP. The
furoxans appear to display a more effective antiplatelet activity over NCX4016, but
further molecular modifications are necessary in an effort to retain the aspirin actions
in addition to achieving the added benefits ofNO.
In summary, whilst the furoxan hybrid examples tested in these experiments carry
some limitations, it is probable that with chemical modification to retain an aspirin-
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6. NO-Release Mechanism of Novel Furoxan
and Furoxan-Aspirin Hybrids in Platelets
6.1 Introduction
There are a variety of mechanisms by which NO donors release NO. Organic nitrate
compounds such as GTN, ISDN and the NO-aspirin hybrid, NCX4016, require
bioactivation by enzyme catalysis (Chen et al., 2002; Grosser & Schroder, 2000;
Sydow et al., 2004). The requirement for such bioactivation is thought to be at the root
of the phenomenon of nitrate tolerance that limits their use; vascular mitochondrial
aldehyde dehydrogenase, the enzyme that accomplishes bioactivation undergoes
nitrate-mediated inhibition (Chen et al., 2002; Hinz & Schroder, 1998; Sydow et al.,
2004).
The commonly-used experimental NO-donor, DEA/NO, does not require bioactivation
and will spontaneously release NO when in solution at a rate dependent on temperature,
pH and the nature of the nucleophile (Homer & Wanstall, 1998; Horstmann et al.,
2002; Keefer et al., 2001; Ramamurthi & Lewis, 1997). The rapid release of NO and
its very short half life of around 1 min at physiological temperature and pH (Homer &
Wanstall, 1998) limit its therapeutic potential.
It is important to characterise the NO release mechanism of the furoxan compounds in
order to fully understand their actions. Data from chapters four and five have led to the
hypothesis that the NO released by the furoxan hybrids is intracellular, but the
mechanism behind NO release remains to be elucidated.
There are numerous reports of paradoxical actions of NO in biological systems; it can
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be both cytotoxic and cytoprotective (Hattori et al., 2004; Keira et al., 2002; Polte et al.,
1997) and both pro- and antioxidant (Joshi et al., 1999; Rubbo et al., 1995; Struck et
al., 1995). It has been proposed that these paradoxical effects can be explained by the
precise NO-related species generated; peroxynitrite in particular is thought to be
responsible for many of the deleterious effects of 'NO' (Shaw, 2006). For this reason,
experiments were conducted in order to test the hypothesis that the hybrid compounds
release no peroxynitrite in platelet-containing samples.
In this chapter, the mechanisms of NO release from furoxans and furoxan-aspirin
hybrid drugs are investigated in human platelets in vitro. Furthermore, the possibility
of peroxynitrite release was studied in order to determine the specificity of the hybrids
as true NO donors.
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6.2 Methods
6.2.1 NO Electrode Measurements
The furoxan and furoxan-hybrid compounds were investigated in the same manner,
with the only exception being the use of Krebs as the buffer for the furoxan B13
experiments. The choice of buffer was decided to investigate the remarkable effects
observed with B13 in the myography experiments. However, it is important to note
that pilot experiments revealed no difference in release between samples in Tyrode's
compared to Krebs buffer.
NO release was detected using an NO electrode, as described in section 2.5. The
apparatus was set up and calibrated with DEA/NO (0.1-1.6 pM) as described in
section 2.5. 2 ml samples of PRP. PPP, WP (prepared as in section 2.3) or
Tyrode's/Krebs buffer were incubated in a 2-channel aggregometer (Chronolog
Ca560); 37 °C and stirred continuously (6000 rpm). An isolated NO electrode was
introduced into the cuvette and allowed to stabilise for at least 10 min until a steady
baseline was achieved. The test compound, either Bl3 (3 pM), B8 (100 pM) or B7
(500 pM) was added to the cuvette and the release of NO was recorded for 10 min
before addition of the NO scavenger, haemoglobin (10 pM) to scavenge the NO.
The involvement of endogenous reducing agents in the release of NO from the drug
was investigated in a further series of experiments. Experiments were carried out in
buffer reconstituted with approximate plasma and intracellular concentrations of
GSH and ascorbate (as indicated in table 2.1), both alone, and in combination.
Recordings were made from buffer ± 4% albumin, with the addition of varying
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concentrations of GSH (3 pM or 3 mM) ±50 pM ascorbate before the drug.
Ascorbate (1 mM) was also used, but only in the presence of 10 mM HEPES to
buffer its acidic pH.
To further investigate the possibility of intracellular release of NO from the furoxan-
aspirin hybrids suggested by the data from chapter five, a platelet cell extract was
prepared as described in section 2.5. 1 ml aliquots of the extract were incubated with
either B8 (100 pM) or B7 (500 pM) and the NO release was recorded as described
above. A further set of experiments were carried out following a 10 min
preincubation of the platelet extract with 500 pM 5,5'-dithiobis(2-nitrobenzoic acid)
(DTNB) before NO release from B8 (100 pM) or B7 (500 pM) being recorded.
Owing to the different profile of NO release by the different drugs, it was established
that AUC was more representative of NO release than peak concentration in these
experiments; results are quoted as AUC over the 10 min incubation (mmol.min).
6.2.2 Peroxynitrite Release
The possible release of peroxynitrite by the compounds was investigated by two
techniques making use of the enzyme SOD as outlined in section 2.6.
EPR was used to detect whether B8 and B7 released any peroxynitrite. Samples of
PRP were incubated with either 100 pM B8 or B7 along with the spin-trap, CPH (10
mM), ± SOD (500 U.mf1) at 37 °C. Control samples were performed without the
test compound and in addition, with the known peroxynitrite generator GEA 3162.
EPR readings (as described in section 2.1.1) were taken periodically for 120 min and
formation of the adduct 3-carboxy-proxyl (CP*) recorded.
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The NO electrode was also used to determine if any peroxynitrite was released. The
furoxans B8 (100 pM) and B7 (500 pM) were incubated in samples of PRP and PPP
as before, but with the addition of 500 U.mf1 SOD before recording with the NO
electrode for 10 min.
The enzyme superoxide dismutase (SOD) will prevent formation of peroxynitrite by
removing superoxide through catalyzing its conversion to hydrogen peroxide (below)





Statistical analysis was by 1 - or 2-way ANOVA or by students' Ptest. Bonferroni or
Dunnett's post-test were carried out as appropriate. Tests were performed using
GraphPad Prism version 4. * is used to represent a p value between 0.01 and 0.05, **
represents a p value of 0.001 to 0.01 and *** represents p values less than 0.001. P
values greater than 0.05 were deemed not significant. Where expressed, data are in
the form mean ± s.e.m.
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6.3 Results
6.3.1 NO Electrode Measurements; Effect of Endogenous
Antioxidants on NO Release from B13
Data for the compound B12 were not obtained due to its failure to stay in solution at
a concentration high enough to allow detection by the extracellular electrode. The
compound B13 (> 3pM) was found to release detectable NO in this system.
The electrode data revealed that the amount of NO released from Bl3 in Krebs
buffer was barely detectable (Fig. 6.1a). NO generation from platelet-containing
media (PRP and WP) was considerably enhanced (mean NO release = 10.45 ± 2.60
mmol.min and 10.67 ± 2.91 mmol.min respectively, Fig 6.1 b. P <0.01; PRP vs.
Krebs buffer alone, and P <0.05; WP vs. Krebs buffer alone. Both 1-way ANOVA
with Dunnett's post-test). In PPP the release was not significantly different from that
in Krebs buffer (2.49 ± 0.31 mmol.min. P > 0.05; PPP vs. Krebs alone, 1-way
ANOVA with Dunnett's post-test). Reconstitution of Krebs buffer with approximate
plasma concentrations of either albumin (4%), GSFI (3 pM) or ascorbate (50 pM)
singly (0.29 ± 0.19 mmol.min. 0.25 ± 0.10 mmol.min, 0.73 ± 0.39 mmol.min
respectively) or in combination (2.08 ± 0.72 mmol.min) failed to enhance the NO
generation from B13 (P > 0.05 vs. Krebs alone, 1-way ANOVA).
Following the reconstitution of Krebs buffer with approximately intracellular
concentration of GSH (3 mM), NO generation was enhanced (5.32 ± 1.29 mmol.min)
as with the addition of the intracellular concentration of ascorbate (1 mM; 4.08 ±
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1.97). A combination of GSH and ascorbate caused a considerable increase in NO
generation from B13 (16.02 ± 1.70 mmol.min, n=6, Fig 6.1b, PO.Ol vs. individual
components alone, 1-way ANOVA with Bonferroni post-test) to that beyond the
release with platelet-containing samples. No significant difference was observed
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Fig. 6.1. NO release recorded over 10 min from B13 (3 |uM) in various media, (a) NO release
from B13 in media related to plasma conditions: Krebs buffer was reconstituted with
approximate plasma concentrations of the plasma constituents, albumin (4%), GSH (3 mM)
and ascorbate (50 mM). 1-way ANOVA revealed no significant difference in NO release
between samples (b) Shows typical NO release from B8 in media related to platelet
conditions: Krebs buffer contained approximate intracellular concentrations of glutathione
and ascorbate (3 and 1 mM respectively). * = p < 0.05; combination of intracellular
components vs. individual components alone, 1-way ANOVA with Bonferroni post-test. GSH
= Glutathione. Ascorb = ascorbate. n = 6-7, values are mean ± s.e.m.
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6.3.2 NO Electrode Measurements; NO Release from NO-
Aspirin Hybrids
Experiments were performed in the presence of NCX4016 (100 pM) but NO release
was undetectable in samples of Tyrode's buffer, PRP and WP (n = 6-8 for each. Data
not shown). Sample recordings of NO generation from B8 and B7 in the presence
and absence of GSH and ascorbate are shown in Fig. 6.2.
Similar to NCX4016, NO release from the furoxans B8 and B7 was undetectable in
Tyrode's buffer alone (Fig. 6.2). However, it was detected in samples of PRP. WP,
PPP or Tyrode's buffer in the presence of approximate plasma concentrations of
albumin (4 %), GSH (3 pM) or ascorbate (50 pM; Fig. 6.3b, 6.4b).












Fig. 6.2. Shows typical 10 min traces of NO release recorded
using the NO electrode in Tyrode's buffer with or without ascorbate
(1 mM) and GSH (3 mM). (a) is following addition of B8 (100 piM)
and (b) is following addition of B7 (500 [iM).
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6.3.2.1 NO Release from B8; Effect of Endogenous
Antioxidants
NO was released from B8 in platelet-containing samples (PRP and WP; mean NO
release = 33.2 ± 2.9 mmol.min and 33.0 ± 2.5 mmol.min respectively; Fig 6.3b), and
in PPP (mean NO release for B8 = 21.0 ± 2.8 mmol.min; Fig 6.3a).
Reconstitution of Tyrode's buffer with approximate plasma concentrations of either
albumin (4%), GSH (3 pM) or ascorbate (50 pM) enhanced NO generation from B8.
A combination of these three constituents failed to enhance NO release from B8
beyond the effects seen with the individual components alone (2.7 ± 0.7 mmol.min;
Fig. 6.3a; P > 0.05 vs. GSF1 alone, P >0.05 vs. ascorbate alone, both 1-way ANOVA
with Bonferroni post-test).
Reconstitution of Tyrode's buffer with approximately intracellular concentrations of
GSH (3 mM) generated marginally less NO from B8 (14.4 ± 2.5 mmol.min; Fig
6.3b) compared with samples containing platelets. Ascorbate (1 mM) in Tyrode's
buffer caused minimal NO release from B8 (2.2 ± 0.9 mmol.min; Fig. 6.3b), but a
combination of GSH and ascorbate caused a considerable increase in NO generation
from B8 (247 ± 19 mmol.min, n = 6, fig 6.3b, P0.001 vs. individual components
alone, 1-way ANOVA with Bonferroni post-test). No significant difference was
observed between WP and PRP samples (p > 0.05, 1-way ANOVA).
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Fig. 6.3. NO release recorded over 10 min from B8 (100 (jM) in various media, a. NO
release from B8 in media related to plasma conditions: Tyrode's buffer was reconstituted
with approximate plasma concentrations of the plasma constituents, albumin (4%), GSH (3
pM) and ascorbate (50 pM). b. shows typical NO release from B8 in media related to platelet
conditions: Tyrode's buffer 3 mM and 1 mM are approximate intracellular concentrations of
glutathione and ascorbate respectively. *** = p < 0.001 as revealed by 1-way ANOVA with
Bonferroni post-test, n = 6 - 7. GSH = Glutathione. Ascorb = ascorbate. Values are mean ±
SEM.
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6.3.2.2 NO Release from B7; Effect of Endogenous
Antioxidants
Relatively low levels of NO were released from B7 in PRP and WP (1.6 ± 0.4
mmol.min and 3.8 ± 0.7 mmol.min respectively; n = 6, Fig 6.4b) despite the higher
drug concentration used. Reconstitution of the Tyrode's buffer with approximate
plasma concentrations of either albumin (4%), GSH (3 pM) or ascorbate (50 pM)
enhanced NO generation from B7 and a combination of these three constituents had
an additive effect on the release of NO from B7 (3.8 ± 0.8 mmol.min), where release
was equivalent to that seen in PPP (1-way ANOVA with Bonferroni post-test P <
0.05, Fig. 6.4a).
Reconstitution of Tyrode's buffer with approximately intracellular concentrations of
GSH (3 mM) increased NO release from B7 (8.5 ± 1.1 mmol.min). Ascorbate (1
mM) in Tyrode's buffer caused minimal NO release from B7 (3.1 ±1.6 mmol.min),
but a combination of GSH and ascorbate caused a considerable increase in NO
generation from B7 (47 ± 4 mmol.min n=6, Fig 6.4b).
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Fig. 6.4. NO release recorded over 10 min from B7 (500 pM) in various media, a. NO
release from B8 in media related to plasma conditions: Tyrode's buffer was reconstituted
with approximate plasma concentrations of the plasma constituents, albumin (4%), GSH (3
pM) and ascorbate (50 pM). b. shows typical NO release from B8 in media related to platelet
conditions: Tyrode's buffer 3 mM and 1 mM are approximate intracellular concentrations of
glutathione and ascorbate respectively. * = p < 0.05. *** = p < 0.001 as revealed by 1-way
ANOVA with Bonferroni post-test, n = 6 - 7. GSH = Glutathione. Ascorb = ascorbate. Values
are mean ± SEM.
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6.3.2.3 NO Release in a Platelet Cell Extract
The possibility of intracellular release of NO from the furoxan-aspirin hybrids was
further investigated using a platelet cell extract. The data showed a relationship
between the dilution factor of platelet extract and the amount of NO released from
both B8 and B7 (Fig. 6.5a and b respectively). NO generation by B8 (100 pM) failed
to increase at platelet extract dilutions below ~1 in 30, with a maximum NO
generation of -90 mmol.min. Pre-treatment of platelet extracts with the thiol
alkylator, DTNB (500 pM), all but abolished NO generation.
A similar pattern was observed with B7 (500 pM), but the amount of NO generated
in the presence of platelet extracts was >10-fold lower than from B8, despite the
higher drug concentration. In the case of B7. dilutions of platelet extract lower than
-1 in 75 failed to generate detectable NO. but there was a direct relationship between
NO generation and dilution factor at dilutions of 1 in 75 - 1 in 25 (Fig. 6.5b). DTNB
again showed a marked inhibitory effect on NO generation in the presence of platelet
extract. Colorimetric analysis of DTNB-treated samples yielded intracellular total
reduced thiol concentrations of 22 ± 4 mM (corrected for dilution; n = 5).
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Fig. 6.5. A sample of WP was suspended in 1 ml triton-X and then homogenized to release
platelet extract before centrifugation to remove membrane fraction. The dilution factor on x-
axis was calculated by volume of triton-X (1 ml) / (number of platelets x average platelet
volume), a. NO release from 16 platelet extracts treated with 100 pM B8. The grey line
shows samples treated in the same way but with a 10 min preincubation with 500 pM DTNB
before addition of B8. b. NO release from 13 platelet extracts treated with 500 pM B7. The
grey line shows samples treated in the same way but with a 10 min preincubation with 500
pM DTNB before addition of B7.
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6.3.3 Peroxynitrite Release
In the case of both B8 (100 pM) and B7 (500 pM), incubation with the enzyme SOD
(500 U.ml"1), had no effect on the amount of NO released as detected by the NO










fflPRP + 100 pM B8
EH]PRP + 100 pM B8
+ 500 U.mf1 SOD
(b)
2.On
jPRP + 500 uM B7
EHJPRP + 500 pM B7
+ 500 U.mf1 SOD
Fig. 6.6. NO release recorded over 10 min from (a) B8 (100 uM) and (b) B7 (500 pM) in
PRP. NO release from the furoxan-aspirin compounds was detected in the presence and
absence of the enzyme SOD to determine if there was any peroxynitrite release by the
compounds, n = 6. Values are mean ± SEM. Results were deemed not significant as
analysed by paired Students' t-test.
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EPR was also used to investigate any possible peroxynitrite release by the furoxan
NO-aspirins. The data showed no oxidation of the spin-trap by B7 in either PRP or
PPP; levels were very similar to an aspirin control (Fig. 6.7; p = 0.32 in PRP and
0.39 in PPP. 2-way ANOVA). There was an apparent effect of B8 in both PRP and





Fig. 6.7. Mean data for development of EPR signal intensity (AU) with time in (a) PRP and
(b) PPP in the presence of aspirin, B8 or B7 (all 100 piM) and spin trap CPH (1 mM). EPR
settings: BO-field, 3356 gauss; sweep width; 50 Gauss, sweep time, 30 sec; modulation
amplitude, 1500 mGauss; microwave power, 20 mW. n = 6.
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The known peroxynitrite generator, GEA 3162 (30 pM) caused an increase in EPR
signal (Fig. 6.8) that was significantly greater than that caused by B8 and was
sensitive to 500 U.mlSOD (PO.OOOl; 2-way ANOVA).
Time (min)
Fig. 6.8. Mean data for development of EPR signal intensity (AU) with time in PRP in the
presence of GEA 3162 (30 uM) and spin trap CPH (1 mM). EPR settings: BO-field, 3356
gauss; sweep width; 50 Gauss, sweep time, 30 sec; modulation amplitude, 1500 mGauss;
microwave power, 20 mW. n = 6.*** = P<0.0001; 2-way ANOVA.
142
Chapter Six: NO-Release Mechanism ofNovel Furoxan and Furoxan-Aspirin Hybrids in Platelets
6.4 Discussion
6.4.1 NO Release by B13
Significant release was achieved in platelet-containing samples (PRP and WP)
compared to buffer alone. The plasma components, albumin, GSH and ascorbate,
chosen for their reducing properties, were all found to have a limited capacity to
stimulate furoxan decomposition to release NO from B13. At extracellular
concentrations, these components individually stimulate small amounts of NO and in
combination the effects are additive but do not reach the amount released by PPP. At
intracellular concentrations, the antioxidant elements, GSH and ascorbate, play a role
in accelerating the release of NO compared to buffer alone; combination of these
elements accelerated release to beyond the levels recorded from platelet-containing
samples, suggesting that NO release by furoxan Bl3 is stimulated intracellularly by a
dual-effect of GSH and ascorbate. A minimal additional release of NO does occur in
the plasma; another element further to the antioxidants studied may contribute to this
release.
The significant stimulation of NO release in environments that mimic intracellular
conditions indicates very specific NO release and could explain the ability of Bl3 to
cause the vasorelaxation observed in chapter four at very low concentrations, as well
as and its resistance to the scavenging effects of cPTIO.
The NO release data also shed some light on the results from the platelet studies in
chapter five. The intracellular release indicated by the data in this chapter further
confirm that the cGMP-dependent antiplatelet effects are a consequence of
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intracellular release of NO (Crane el al., 2005). Intracellular release by B13 may also
explain the resistance of B13 to the scavenging effects of haemoglobin as
demonstrated by the whole blood aggregation study.
6.4.2 NO Release from NO-Aspirin Hybrid Drugs
The inability to detect NO from NCX4016 in this study is perhaps not surprising. The
release at NO from NCX4016 and GTN has been reported to occur through identical
mechanisms (Grosser & Schroder, 2000). Platelets have a poor capability to release
NO from organic nitrates (Weber et al., 1996) and thus, NCX4016 would not be
expected to release NO in the in vitro platelet samples investigated in this study.
The furoxan-aspirin hybrids B8 and B7, like the aspirin free equivalent, are very
stable compounds that appear to only decompose to release measurable NO when
they encounter appropriate media. There was no release of NO from the furoxans in
Tyrode's buffer, but NO generation was detected in PPP, WP and PRP. These
observations suggest that some elements of plasma can stimulate decomposition of
the furoxans and that the platelets themselves enhance the effect to a greater extent
for B8 than B7.
The plasma components, albumin, GSH and ascorbate were all found to have a
limited capacity to stimulate furoxan decomposition to release NO. In the case of B7,
these constituents could individually stimulate moderate NO release, and the additive
effect of all three could fully emulate NO release in PPP. The effect of these
constituents on B8 were similar, if less dramatic, for the individual reducing agents,
but here there was no additive effect when co-incubated, suggesting that an as yet
unidentified plasma constituent is responsible for a proportion of NO release from
B8.
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Reconstitution of Tyrode's buffer with intracellular levels of GSH and ascorbate
demonstrated that both of these reducing agents were mildly effective in stimulating
release of NO from the compounds. Interestingly, however, they acted synergistically
in co-incubation experiments to massively increase NO generation. The separate
experiments using platelet extracts established that there was a relationship between
the concentration of platelet extract and amount of NO generated from the furoxan-
aspirin hybrids. The ability of platelet extracts to generate NO from both furoxans
was found to be dependent on the presence of reduced thiol groups and, in keeping
with the other NO release data and the platelet aggregation experiments (chapter
five), B8 generated considerably more NO in the 10 min incubation period than B7.
Taken together, these results indicate that low-level decomposition of B7 in plasma
can be explained by the additive effects of albumin, GSH and ascorbate but that there
is also likely to be much greater NO release inside platelets mediated by the
synergistic action of ascorbate and reduced intracellular thiols. B8 is more sensitive
to the same agents, and its plasma decomposition is also affected by an as yet
unidentified plasma component, again similar to its aspirin-free equivalent, B13.
Given the reactive nature of NO. the apparent preferential release inside target cells
is a likely advantage for successful NO delivery over compounds that can only
generate NO remotely in cell types other than platelets.
The data here show that the compound B8 releases much more NO than B7 (~5-fold
more despite being used at a 5-fold less concentration). Such high levels of NO
explain the dominance of NO over aspirin in the antiplatelet studies (chapter five)
and further suggest that B7 is a more promising hybrid drug target where the NO
release is less dominant.
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6.4.3 Peroxynitrite Release
The two sets of studies used to investigate possible peroxynitrite release by the
hybrids revealed that neither B8 nor B7 releases significant amounts of peroxynitrite
in vitro. However, the results do not preclude generation of peroxynitrite in situations
where superoxide arises from a source other than the drugs themselves (e.g.
oxidative stress).
Peroxynitrite is formed on the reaction of NO with superoxide (Saran et al., 1990).
The enzyme SOD breaks down peroxynitrite by removing superoxide and catalyzing
its conversion to hydrogen peroxide. This yields the NO that the electrode detects
and thus is an indirect method of recording peroxynitrite release. The results of this
indirect recording revealed that in the case of both NO-aspirins, incubation with the
enzyme SOD had no effect on NO release therefore ruling out any masking of NO as
peroxynitrite.
Peroxynitrite releasewas also investigated using a direct method of detection. EPR
utilising a spin-trap agent has previously been demonstrated as an efficient method of
measuring peroxynitrite (Dikalov et al., 1997; Taylor et al., 2004). Whilst B7
generated no detectable signal in either PRP or PPP, was detected from B8 in both
PRP and PPP. It is most likely that this signal is not due to generation of
peroxynitrite but rather to a non-specific effect of NO in the system as indicated by
the failure of SOD to decrease the signal. In contrast, in the same system, a signal
corresponding to the formation of CP' from the reduced form of the spin-trap was
detected from the peroxynitrite generator, GEA 3162. In this case, incubation with
SOD caused a significant depletion of the signal.
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6.4.4 Summary and Future Directions
The results of this chapter reveal the furoxan and furoxan-aspirin compounds to
release their NO primarily in the intracellular environment when they encounter
antioxidants such as GSH and ascorbate. There is perhaps an as yet unidentified
component which contributes to the release of NO from B8 and B13 for which
cysteine is a possible candidate (Ferioli et al., 1995). The predominantly intracellular
release of NO by B13 is perhaps the reason behind its resistance to haemoglobin in
the whole blood aggregometry (chapter five) and its remarkable ability to cause
vasodilatation at picomolar concentrations (chapter four). The intracellular release by
the hybrids gives them an advantage as antithrombotics over the existing nitroaspirin,
NCX4016 which requires enzymatic breakdown not achievable by platelets (Grosser
& Schroder, 2000; Weber et al., 1996). Of the hybrids, B7 is the better drug
candidate due to its lower NO release, providing opportunity for a more balanced
action between the NO effect and thee COX inhibitory effect identified in chapter
three.
The major limitation of these experiments was the solubility of the furoxans and B12
in particular, which failed to stay in solution to allow in vitro exploration of NO
release. Chemical modification to the structure may improve the solubility of
compounds more soluble, however, it is likely that with development of a more
sensitive technique, data will be obtained for this compound.
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7. Anti-Inflammatory Effects of Furoxan-Aspirin
Hybrid Drugs in Human Monocytes and
Monocyte-Derived Macrophages
7.1 Introduction
In order to further determine cardiovascular benefits of the NO-aspirin compounds,
their anti-inflammatory actions in cell types relevant to atherosclerosis were
examined. Due to their ability to retain an aspirin-like inhibition of COX (chapter
three) and to release NO (chapter six), these drugs have the potential to be anti¬
inflammatory.
The anti-inflammatory effects of NO in the vasculature centre around its ability to
regulate endothelial cell-mediated leukocyte recruitment at a site of injury, which is
central to the atherogenesic process. NO reduces expression of P-selectin and thus
leukocyte recruitment in a cGMP-dependent process (Ahluwalia et al., 2004; Kubes
et al., 1991) and inhibits ICAM and VCAM expression (Berendji-Grun et al., 2001;
De Caterina et al., 1995; Spiecker et al., 1997). In addition, NO has anti¬
inflammatory effects in macrophages. Immunological or inflammatory stimuli, such
as activation by cytokines and bacterial products, stimulate macrophages to express
iNOS and generate large quantities of NO (Moncada & Higgs, 1995). NO inhibits
production of inflammatory cytokines IL-1 and IL-12 (Huang el al.. 1998; Obermeier
et al., 1999; Thomassen et al., 1997) and furthermore, in vitro and in vivo evidence
show that L-NMMA treatment increases TNFa production whereas L-arginine
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treatment reduces it (Iuvone el al., 1996). Interestingly, it has recently been shown
that a cGMP-mediated reaction is responsible for inhibition of peroxynitrite-induced
programmed cell death in human monocyte-derived macrophages, implying a further
role for NO during inflammation (Shaw, 2006).
COX inhibition is anti-inflammatory due to reduced production of prostaglandins
involved in the inflammatory response. The anti-inflammatory effects of aspirin are
more likely to be COX-2-mediated due to its tendency to be expressed in response to
inflammatory stimuli. Aspirin also plays a role in the production of endogenous anti¬
inflammatory agents known as aspirin triggered lipoxins (ATL). These are short¬
lived eicosanoids whose appearance in inflammation signals its resolution. ATL are
formed by aspirin by the 15-epi-LX pathway. In cytokine-rich environments, aspirin
acetylates COX-2, prompting it to act as a lipoxygenase rather than an endoperoxide
and thus, converting AA to 15-HETE which is subsequently transformed by 5-LO to
the ATLs, 15-epi-LXA4 or 15-epi-LXB4 (Claria & Serhan, 1995).
ATLs are thought to bring about beneficial effects, particularly in the resolution of
inflammation (McMahon et al., 2001). Recent evidence has shown that LXA4
downregulates the production of the inflammatory mediator, IL-12, (Machado et al.,
2006) which would otherwise persist, resulting in host damage. Furthermore, it has
been demonstrated that a defect in the signalling process of ATL results in
uncontrolled inflammation (Machado et al., 2006). The ability of aspirin to inhibit
cell accumulation during inflammation has also been attributed to the action of ATL.
It is thought that this process is due to the stimulation of eNOS and iNOS to produce
NO, which acts to provide anti-inflammatory effects such as inhibition of leukocyte-
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endothelial interactions (Paul-Clark et al., 2004; Taubert et al., 2004).
Cytokines are polypeptide or glycoprotein factors that act in an autocrine and/or
paracrine fashion to signal in a variety of biological processes. They are generally
classed as either pro-inflammatory (e.g. TNFa and IL-8) or anti-inflammatory (e.g.
TGF|3 and IL-10), although they can have paradoxical actions. Cytokines act in
various cell types and perform diverse functions. For example, the chemokine, IL-8,
which is produced by 1L-1- and TNFa-stimulated monocytes is involved in
chemotaxis for various immune cells, including neutrophils (Flarada et al., 1994). It
also plays a role in leukocyte adhesion to the endothelium (Graves & Jiang, 1995;
Rot et al., 1996). Other roles of IL-8 are in the inhibition of histamine release from
activated basophils (Kuna et al., 1991) and also in the mediation of pain (Cunha et
al., 1991). TNFa is secreted by monocytes, macrophages and neutrophils following
their stimulation by bacterial lipopolysaccharides. The various activities of TNFa
include mediation of CAM (Graves & Jiang, 1995), regulation of cell death in
tumour cells (Chang & Wisnieski, 1990), enhancement of neutrophil phagocytosis
(Klebanoff et al., 1986), control of neutrophil adherence to the endothelium (Graves
& Jiang, 1995) and synthesis of IL-1 production by macrophages (Dinarello et al.,
1986).
LPS is a bacterial endotoxin that stimulates the production of inflammatory
mediators such as the cytokines (i.e. TNFa and IL-8) via the activation of NF-kB
(Baldwin, 1996; Kubes & McCafferty, 2000; Totzke et al., 2006). The gene
expression of the pro-inflammatory cytokine, TNFa is controlled by the transcription
factor, NF-kB. Normally NF-kB is kept in an inactive state in the cytoplasm by being
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bound to a member of the IkB family. To date, seven such inhibitory subunits
comprise the IkB family (May & Ghosh, 1998). NF-kB exists as a dimer, most
commonly as a heterodimer composed of the p65/p50 subunits (Panwalkar et al.,
2004). The phosphorylation of IkB and its subsequent degradation leads to the
activation of the NF-kB. IkB is phosphorylated by kinases known as IKKs (IkB-
kinases) of which two subunits (a and (5) exist. The subunits form homo- or hetero-
dimers which, depending on their conformation, result in different patterns of NF-kB
activation (May & Ghosh, 1998). Following activation, the NF-kB dimer containing
the p65 subunit, the dominant factor in the induction of the TNFa gene then
translocates from the cytoplasm to the nucleus, where it activates transcription of
target genes, including TNFa. (Baldwin, 1996; Kaltschmidt et al., 1999; Liu et al.,
2000; Totzke et al., 2006). Glucocorticoids such as dexamethasone are commonly
used anti-inflammatory agents. Glucocorticoids have been shown to effectively
inhibit suppression of pro-inflammatory transcription factors such as NF-kB (Barnes,
2006). They act upon glucocorticoid receptors, which when stimulated, translocate to
the nucleus preventing histone acetylation, a vital step in the NF-kb-induced gene
transcription (Adcock et al., 2004; Barnes, 2006). Other mechanisms by which the
glucocorticoid receptor reduces TNFa expression include decreasing mRNA
stability, inducing expression of the inhibitor IkB, and altering co-factor (AP-1)
activity (Adcock et al., 2006).
This chapter shall investigate the anti-inflammatory properties of the hybrid drugs in
order to test the hypothesis that via their ability to inhibit inflammatory cytokine
release from LPS-stimulated human monocytes and monocyte-derived macrophages
the hybrids have an anti-inflammatory potential.
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7.2 Methods
7.2.1 Preparation of Monocytes and Macrophages
Peripheral venous blood was drawn from the antecubital fossa of human volunteers
(non-smokers; age 20-45). Mononuclear cells were isolated from human blood using
dextran sedimentation and Percoll gradients as described in section 2.7 and plated out
at a concentration of 2 x 106 per well (0.5 ml). Cells were grown for a week as
described in section 2.8 in order to differentiate into macrophages. On day 7 (or
immediately following their isolation for experiments on monocytes) the medium in
each well was changed to that containing 10 pM (selected based on results from
previous chapters) of either B8. B7, B16, B15, aspirin, NCX4016, DEA/NO or
dexamethasone (1 pM) with and without LPS (10 ng.mP1). Cells were then
incubated at 37 °C for 4 hours before removal of the cell supernatants, which were
frozen at - 70 °C and later used for biochemical analysis.
7.2.2 Cytometric Bead Array
The bead array was used in a pilot study to determine whether the NO-aspirin
compounds had any anti-inflammatory effects by inhibiting release of inflammatory
mediators released by macrophages following LPS stimulation. It was also used to
determine suitable drug and LPS concentrations for future studies. A commercial
human inflammation CBA kit that detects levels of IL-8. IL-1(3. IL-6, IL-10. TNFa
and IL-12p70 was used (BD Biosciences). The protocol was carried out as described
in chapter two (section 2.8.1) on supernatants from macrophages matured and treated
as in section 7.2.1 with the approximate antiplatelet EC50 concentration (chapter five;
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0.3 pM for B8/B16, 100 pM for B7/B15, 50 pM for aspirin and 10 pM for
NCX4016) of furoxan, NCX4016 or aspirin or a DMSO (0.1 %) control. The furazan
concentrations were determined by their furoxan-equivalent. Cells were stimulated
with 1-100 ng.mf1 LPS. Levels of the cytokines were recorded by detecting PE-
conjugated antibodies using flow cytometry. Results are expressed as a percentage of
level recorded from an LPS-only control.
7.2.3 Enzyme-Linked Immunosorbent Assays
Supernatants from the cell treatments described above were assayed for levels of
TNFa and IL-8 using commercially available ELISA kits (BD Biosciences).
Experimental protocols were carried out as per kit instructions, as described in the
methods chapter on monocytes and macrophages isolated and treated as in section
6.2.1. Levels of the cytokines were recorded by colourimetric analysis using a
platereader. Results are expressed as a percentage of level recorded from an LPS-
only control.
7.2.4 Lactate Dehydrogenase (LDH) Assay
LDH is a stable cytoplasmic enzyme present in all cells. As it is rapidly released
following damage to the plasma membrane its quantification can be used to measure
cell death. A commercially available kit (Roche) was utilised to quantify LDH and
thus cell death. 100 pi supernatant from the monocyte / macrophage studies
described above were mixed with 100 pi reaction mixture as per kit instructions and
left to incubate in the dark for 30 min before reading in the plate reader at 492 nm. A
calibration was performed by carrying out the assay on suspensions of varying cell
154
Chapter Seven: Anti-Inflammatory Effects ofFuroxan-Aspirin Hybrids in Monocytes and
Macrophages
concentrations (4, 3, 2, 1, and 0.5 x 106 cells/ml) which had been incubated with an
equal volume of 0.5 % Triton X for 1 hr at RT. homogenised for 15 min then
centrifuged at 250 g for 10 min. 100 pi supernatant was used in the assay giving a
final cell count of 2, 1.5, 1, 0.5 and 0.25 x lO5 cells in the assay. Levels of the cell
death were recorded by colourimetric analysis and results are expressed as
absorbance units.
7.2.5 Immunofluorescnce for NF-kB p65 Subunit
Monocytes (1 ml of 4><106 cells.ml"1) isolated as above were plated out onto glass
coverslips within wells of a 6-well plate and left to adhere. Following washing,
medium was then changed to ISCOVES DMEM (supplemented with 10 %
autologous serum) containing either gliotoxin (0.1 pg/ml), B8 or B16 (20 pM) or no
drug (DMSO 0.1 % control). Cells were left to incubate (37 °C) for 30 min. LPS (10
ng.ml"') or vehicle (ISCOVES DNEM supplemented with 10 % autologous serum)
was then added on top of the coverslip and left to incubate for a further 45 min.
The immunofluorescence protocol detailed in section 2.8.4, was then carried out on
the cell-covered coverslips before capturing the images using a camera connected to
a Zeiss Axiovert SI00 at a magnification of x 100 (using oil-immersion).
7.2.6 Statistics
Statistical analysis was by 1-way ANOVA followed by Dunnetf s post-test and was
carried out using GraphPad Prism version 4. * is used to represent a p value between
0.01 and 0.05. P values greater than 0.05 were deemed to be not significant. Where
expressed, data are in the form mean ± s.e.m.
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7.3 Results
From the CBA pilot study data, the cytokines TNFa and IL-8 were selected for
further exploration of any possible anti-inflammatory action of the compounds. 10
uM was identified as a suitable concentration at which to observe an effect of the
drugs.
7.3.1 Enzyme-Linked Immunosorbent Assay
None of the treatments had a significant effect on IL-8 release in either monocytes or
macrophages (Fig. 7.1./? > 0.05; 1-Way ANOVA; n =8 -10). Basal IL-8 levels were
21.3 ± 7 ng.mr1 for monocytes and 685 ± 67 pg.mf1 for macrophages. After LPS-
treatment these rose to 127 ± 11 and 34 ± 5 ng.mr1 respectively.
(a) (b)
IDMSO + LPS
EZ3 DEA/NO + LPS
E33B8 + LPS
EES B16 + LPS
CZ2B7 + LPS
E33B15 + LPS
E23 NCX4016 + LPS
ffffl ASA + LPS


















Fig. 7.1. Effect of potential anti-inflammatory agents on LPS (10 ng.mf ) -induced IL-8
release in human (a) monocytes and (b) monocyte-derived macrophages after 4 h treatment
with 10 [iM of either DEA/NO, B8, B16, B7, B15, NCX4016 or aspirin or 1 |.iM
dexamethasone (Dex). n = 8-10.* indicates P < 0.05 as assessed by 1-way ANOVA.
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B8 had a significant inhibitory effect on TNF-a release in human monocyte-derived
macrophages treated with LPS (Fig 7.2; p <0.05, 1-Way ANOVA followed by
Dunnetf s test; n = 8-10, 36 ± 10 % of LPS control) but not in macrophages without
LPS. The effect was equivalent in magnitude to that of dexamethasone, but was not
shared by DEA/NO, B7, the furazans, aspirin or NCX4016. In monocytes, B8, and to
a lesser extent, its NO-free equivalent, B16, significantly inhibited TNF-a release (to
28 ± 5, and 49 ± 9 % of control respectively). Basal TNF-a levels were 1.6 ± 0.4
ng.mf1 for monocytes and 0.9 ± 0.2 pg.mf1 for macrophages. After LPS-treatment
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Fig. 7.2. Effect of potential anti-inflammatory agents on LPS (10 ng.ml" )-induced TNF-a
release in human (a) monocytes and (b) monocyte-derived macrophages after 4 h treatment
with 10 [.iM of either DEA/NO, B8, B16, B7, B15, NCX4016 or aspirin or 1 |tM of
dexamethasone (Dex). n = 8-10. * = p < 0.05 1-Way ANOVA followed by Dunnett's test;
n=8-10.
7.3.2 Lactate Dehydrogenase (LDH) Assay
None of the treatments studied caused significant cell death (Fig. 7.3) compared to
untreated monocytes and macrophages. Levels of LDH released following the
treatments were comparable with that from ~ 0.5 x 103 cells, indicating an
approximate 13 % cell death in untreated cells.
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Fig. 7.3. (a) Calibration curve for the LDH assay. Bar graphs show LDH measurement in (b)
monocyte and (c) monocyte-derived macrophage supernatants after treatment with 10 uM of
either DEA/NO, B8, B16, B7, B15, NCX4016 or aspirin or 1 liM of dexamethasone (Dex) and
stimulated with LPS (10 ng.ml"1). n = 8-10. 1-way ANOVA revealed that there were no
significant differences between groups in either cell type.
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7.3.3 Immunofluorescence for NF-kB p65 Subunit
NF-kB p65 immunofluorescence revealed that the subunit location varied with the
drug treatment. Control cells displayed even staining throughout the cytoplasm, but
following stimulus with LPS, strong staining was observed in the nucleus and much
less in the cytoplasm (Fig. 7.4).
(a) (b)
Fig. 7.4. Representative immunofluorescent images from an n=3 (each of 4><106 cells), (a)
shows a control treated monocyte and (b) a monocyte following a 45 min LPS stimulus. C =
cytoplasm. N = nucleus. Scale bar represents 100 pm.
Incubation with gliotoxin before the LPS stimulus inhibited the nuclear translocation
of p65 as demonstrated by the presence of cytoplasmic staining (Fig. 7.5).
Fig. 7.5. Representative
immunofluorescent image from
an n=3 (each of 4*10 cells).
Image shows a monocyte treated
with gliotoxin (0.1 pg/ml, 30 min)
and stimulated with LPS (10
ng/ml, 45 min). C = cytoplasm. N
= nucleus. Scale bar represents
100 pm.
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Preincubation with the NO-aspirin B8 gave a dramatic shift in the staining compared




an n=3 (each of 4x10 cells).
Image shows a monocyte treated
with B8 (20 pM, 30 min) and
stimulated with LPS (10 ng/ml,
45 min). C = cytoplasm. N =
nucleus. Scale bar represents
100 pm.
Cells treated with the NO-free compound, B16, displayed cytoplasmic staining but
with a greater amount of nuclear staining than B8 treated cells (Fig. 7.7).
Fig. 7.7. Representative
immunofluorescent image from
an n=3 (each of 4x10 cells).
Image shows a monocyte treated
with B16 (20 pm, 30 min) and
stimulated with LPS (10 ng/ml,
45 min). C = cytoplasm. N =
nucleus. Scale bar represents
100 pm.
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7.4 Discussion
Taken together, these studies provide evidence that whilst no treatment significantly
altered IL-8 release, treatment with NO-aspirin B8, significantly reduced TNFa
release from both monocytes and monocyte-derived macrophages. A possible
mechanism for this anti-inflammatory action is through the inhibition of its
transcription factor, NF-kB.
The CBA pilot studies revealed that treatment by the furoxan and furazan aspirin
compounds had some impact on the release of various cytokines, in particular IL-8
and TNFa, from LPS-stimulated monocyte-derived macrophages in vitro. For this
reason the effect on these two cytokines were selected for further study.
7.4.1 Impact on TNFa-Release by Monocytes and
Macrophages
In monocyte-derived macrophages, the lack of effects of Bl6 and aspirin suggest that
the inhibitory effect of B8 on TNFa release is NO-mediated. Flowever, as this effect
is not mimicked by the NO donor, DEA/NO, it is apparently a specific property of
B8 that is possibly related to amount, duration or site of NO release. The possibility
of the diminished release of TNFa by B8-treated cells was simply due to a cytotoxic
effect of the compound was ruled not supported by results from the LDH assay.
None of the treatments caused a significantly different amount of cell death when
compared to untreated cells.
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In monocytes, TNFa release was inhibited by the NO-aspirin, B8, but also by its
NO-free furazan counterpart, B16. Aspirin showed no significant difference from the
LPS control. Similar to the macrophage results, DEA/NO did not cause significant
inhibition. Again, B8 could be acting via an NO-mediated mechanism specific to the
to amount, duration or site of NO release. However, the interesting observation that
NO-free, B16 also causes a significant inhibition suggests a possible further
mechanism. As discussed in previous chapters, the acetyl group of these compounds
is lost in plasma (Cena et al., 2003), leaving SA, through which, inhibition of
cytokine release has been previously reported (Feng et al., 2005; Mitchell et al.,
1997; Osnes et al., 1996). It may therefore be possible that under these experimental
conditions, a SA-mediated mechanism is responsible for the inhibition of TNFa
release observed with B8 and B16 treated cells.
In this study aspirin did not significantly reduce TNFa release from LPS-stimulated
monocytes or macrophages. This is consistent with a similar study in which aspirin
failed to have an effect even at a 30 x higher dose than was used in the present study
(Minuz et al., 2001). A further study did report an inhibitory effect of aspirin on
TNFa release from LPS-stimulated monocytes but this was at doses of 5-10 mM
(Osnes et al., 1996).
This study showed that NCX4016 did not significantly reduce the release of TNFa.
In a study carried out by others, NCX4016 did not inhibit TNFa release at the same
concentration used here (10 pM), but was shown to inhibit the release of TNFa and
IL-6 from LPS-stimulated macrophages at higher (100 and 300 pM) concentrations
and following a 6 h incubation (Minuz et al., 2001). Despite not being affected by
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ODQ, the authors suggest that the inhibitory effect of NCX4016 is NO-mediated due
to the failure of aspirin to inhibit cytokine release. A further study also showed that
NCX4016 (again at concentrations 10-fold higher than used in this thesis), inhibited
the release of IL-1|3 and IL-18 from LPS-stimulated monocytes, via NO-mediated
inhibition of the enzyme required for intracellular processing and maturation of IL-1
and IL-18 (caspase-1) activity (Fiorucci et al, 2000).
It is likely that the differing outcomes observed between this thesis and previous
studies are purely due to drug incubation time or concentrations. As the
concentrations studied in this thesis are more physiologically relevant, they are more
demonstrative of the true therapeutic potential of the drug. The results here show that
at a concentration at which the furoxan compound. B8, causes a significant 72%
reduction in TNFa release from monocytes and a 64% reduction from macrophages,
its organic nitrate counterpart does not. Such results indicate that further to its lack of
NO-mediated effects in the platelet studies (chapter five), NCX4016 also has no
impact on IL-8 or TNFa release from either monocytes or macrophages.
The differential effects of the same treatments observed between monocytes and
macrophages may indicate the necessity for different drug concentrations and
incubation times for the individual cell types. Possible explanations for this effect
may be the differential expression and activity of receptors and signalling pathways
between the two cell types. It has previously been reported that the anti¬
inflammatory effect of IL-4 on the release of TNFa and other cytokines, varies
between LPS-stimulated monocytes and macrophages (Hart et al., 1999). This effect
is due to loss of a receptor for IL-4 during monocyte differentiation (Hart et al.,
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1999). Other differences reported between monocytes and macrophages include
those showing that LPS activates cytosolic PLA2 in monocytes but not in
macrophages. A similar activation in monocytes, but not macrophages, is seen after
LPS-stimulation in the following signalling pathways: the MAP kinase, ERK,
phosphatidylinositol-3 kinase and p70S6 kinase (Barbour el al., 1998; Rao, 2001).
Further variations include increased expression of Ca2+-dependent protein kinase C
isoforms in monocytes when compared to macrophages (Monick et al., 1998) and
also that maturation into macrophages results in slower production of the cytokine,
IL-1 (3 (Herzyk et al., 1992). It is, therefore, possible that changes such as these to
receptor expression, signalling pathways and to the biosynthesis of cytokines, which
normally occur during the maturation of monocytes to macrophages, may impact on
the ability of the studied compounds to have a significant effect.
7.4.2 Impact on IL-8-Release by Monocytes and Macrophages
The IL-8 data revealed the hybrid compounds caused no significant enhancement or
reduction of IL-8 release from LPS-stimulated monocytes or macrophages at the
same drug concentrations and incubation times as for the TNFa experiments, despite
a significant reduction being induced by the anti-inflammatory glucocorticoid,
dexamethasone. The lack of effect of aspirin on IL-8-release is consistent with
previous studies where aspirin, even at ten-fold higher concentrations failed to affect
IL-8 release from LPS-stimulated monocytes (Fiorucci et al., 2000). Although the
possibility for an inhibitory effect of aspirin occurs in a cytokine-rich milieu through
the action of ATL to inhibit IL-8 mRNA expression by leukocytes (Jozsef et al.,
2002), failure of the NO-aspirins to have an effect is possibly due to the
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activation/release processes for IL-8 differing from that of TNFa. Whilst it is
generally accepted that IL-8, like TNFa, is stimulated by the transcription factor NF-
kB (Liu & Malik, 2006), it has been demonstrated that IL-8 gene transcription also
requires cooperative activity of an additional transcription factor, AP-1 (McKay &
Cidlowski, 1999; Mukaida & Murayama, 1998). Such complexities in the pathways
for the transcription of the gene give multiple points at which B8 could act to inhibit
TNFa release and not IL-8. Indeed, the action of B8 could even be further
downstream in the release of IL-8 protein or the lack of observed effect on IL-8
might possibly be due to insufficient drug being used. NCX4016 has previously been
demonstrated to inhibit IL-8 release from LPS-stimulated monocytes (Fiorucci et al.,
2000). However, they did use an unrealistically high concentration, whereas the one
used in this thesis was more physiologically relevant.
7.4.3 Impact of B8 on NF-kB Translocation in Monocytes
The immunofluorescence experiments further suggested a possible mechanism for
the B8-mediated inhibition of TNFa release. The stimulant used in these
experiments, LPS, is known to activate TNFa via the activation of the transcription
factor NF-kB (Baldwin, 1996; Kubes & McCafferty, 2000; Totzke el al., 2006).
Following stimulation with LPS, the p65-subunit containing NF-kB normally
translocates from the cytoplasm to the nucleus where it induces transcription of the
TNFa gene (Baldwin, 1996; Kaltschmidt et al., 1999; Liu et al., 2000; Totzke et al.,
2006). Control experiments involving a pre-treatment with the
epipolythiodioxoperazine, gliotoxin, demonstrated clear cytoplasmic staining and
reduced nuclear staining. Gliotoxin is known to exhibit immune suppressive activity
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in vitro and to selectively inhibit NF-kB activation (Pahl et al., 1996). The
immunofluoresence staining showed that pre-treatment with the NO-aspirin B8
inhibited the translocation of NF-kB, providing a similar level of cytoplasmic
staining as the gliotoxin control. The inhibition ofNF-kB translocation to the nucleus
provides a plausible explanation for the B8-induced reduction in TNFa release as
observed in the ELISA studies. It has previously been shown that NO inhibits LPS-
induced ikb-phosphorylation. thus inhibiting the activation of NF-kB (Hattori et al.,
2004).
B16-treated monocytes also displayed some evidence of cytoplasmic staining, but
with more nuclear staining than its NO counterpart. This result is consistent with the
ELISA data, where significant inhibition of TNFa release, albeit lesser than B8-
treated cells, was observed following B16 treatment.
7.4.4 Future Directions
The ELISA studies were carried out with equal concentrations of each of the drugs
studied (with the exception of dexamethasone). It is therefore possible that the
optimum concentration to observe any anti-inflammatory effects was not utilised.
Time-permitting, full concentration-response curves to each drug would have been
carried out to establish such information.
Whilst these studies reveal that the effect of B8 on the release of TNFa by
monocytes is due to an inhibitory effect on NF-kB translocation, the mechanism for
this effect is as yet unknown. Normally, NF-kB is kept in an inactive state in the
cytoplasm, bound to an inhibitory subunit named IkB (Ghosh et al., 1998). The
phosphorylation of IkB by IKK and the subsequent degradation of IkB leads to the
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activation of the NF-kB (Yamamoto & Gaynor, 2004). The degradation of IkB can
be studied by Western blotting using antibodies for IkB (Fujihara et al., 2002). A
possible future study could investigate the impact of the NO-aspirin compounds on
IkB to determine whether they activate NF-kB by causing IkB degradation.
7.4.5 Summary and Therapeutic Implications
The data here show that the furoxan-aspirin compound B8 has anti-inflammatory
effects in LPS-stimulated monocytes and macrophages through its reduction in NF-
kb-mediated TNFa release.
This action by B8 may provide clinical benefit in inflammatory diseases where anti-
TNFa therapy has been shown to be of therapeutic benefit such as arthritis, Crohn's
disease and asthma (Carroccio el al., 2006; Christodoulou & Choy, 2006; Russo &
Polosa, 2005; Siddiqui & Scott, 2006). The dual action of the COX-mediated aspirin
action of B8 (chapter three) and the anti-TNFa demonstrated here along with its
resistance to gastrotoxic effects (Cena et al., 2003), could indicate B8 to be a
promising antiarthritic drug.
It is now widely accepted that inflammation is a key element in atherogenesis and
atherosclerotic plaque rupture which leads to acute cardiovascular events such as
myocardial infarction or stroke (Ross, 1999). The release of TNFa by monocytes and
macrophages causes various effects involved in destabilising the atherosclerotic
plaque. TNFa plays a role in inflammatory cell recruitment to the plaque (Pober &
Cotran, 1990). It can also regulate the production of monocyte chemoattractant
protein-1, which is a potential signal for directed migration of monocytes into the
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intima (Libby et al., 1995). TNFa can regulate genes that encode other growth
factors and cytokines themselves (Libby et al1995). Furthermore, TNFa has been
demonstrated to promote adverse remodelling of vascular smooth muscle cells (Galis
et al., 1994; Geng et al., 1996; Jovinge et al., 1997) and to play a pro-inflammatory
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8. General Discussion
8.1 Introduction
Aspirin is one of the most commonly used drugs; over 40 billion aspirin are taken
every year in the United States (Schiffmann et al., 2005). Its use ranges from an anti¬
inflammatory and analgesic for arthritis sufferers to a prophylactic against
thrombosis in those at risk of a coronary event. Aspirin has been used for over 100
years and its mechanism of action has been understood for over 35 years. Despite
this, however, its use is still severely limited by its toxic effects in the gastro¬
intestinal tract.
Studies have revealed that gastrointestinal incidences associated with aspirin use
cause 16,000 deaths each year in the USA (Keeble & Moore, 2002). In the UK
12,000 hospital admissions and 2,230 deaths are attributable to NSAID use (Blower
et al., 1997). Furthermore, a recent study indicated that over 12% of all
gastrointestinal incidences and deaths could be attributed to low-dose aspirin use
(Lanas et al., 2005). It is therefore apparent that there is an urgent clinical need to
resolve the issue of gastrotoxicity related to aspirin use.
There have been several approaches to overcome the gastric side-effects of aspirin,
with mixed success. The recently developed selective COX-2 inhibitors, hailed to be
the new "wonder aspirins", have unfortunately now been withdrawn due to mounting
evidence of an increased risk of stroke. However, the newest candidate in the search
for a gastric-friendly aspirin, the NO-aspirin, appears to be more promising. The
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well-documented cytoprotective effects of NO led to the development of the NO-
releasing aspirin esters in the hope of overcoming the gastrotoxicity of aspirin.
However, the multifunction nature of NO has given these esters a broad range of
beneficial effects beyond their intended purpose.
8.2 Summary
The experiments in this thesis have explored a range of effects relevant to the
cardiovascular system of a novel series of furoxan derivatives of aspirin.
The experiments in chapter three were carried out in order to ensure that the
hybridisation process had not impacted on the activity of the aspirin moiety. If the
drugs are to be a suitable successor for aspirin, then it is imperative that they retain
its ability to inhibit COX-1 and thus have potential for an aspirin-mediated
antithrombotic (Patrignani et al., 1982; Roth et al., 1975), anti-inflammatory (Amann
& Peskar, 2002; Vane & Botting, 1998) and analgesic (Ferreira, 1980) effect. In the
absence of a simple and reliable commercially available COX assay, a novel assay
was first developed and verified in order to allow effective screening of the ability of
the NO-aspirins to inhibit COX-1.
The assay results were demonstrated to be comparable to those of other assay
techniques (Corazzi et al., 2005; Noreen et al., 1998; Young et al., 1996). All NO-
aspirins along with their NO-free counterparts were able to inhibit COX-1 to a
similar, if not greater extent than aspirin. The furoxan compounds were also
demonstrated to have a similar capability to the existing nitroaspirin, NCX4016, at
inhibiting COX (Corazzi et al., 2005). However, as plasma-mediated decomposition
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is not tested by this assay, it is important to recognise that the effect might be lost in
vivo depending on how these compounds are hydrolysed. As the furoxan-aspirin
acetyl group has been previously demonstrated to undergo complete hydrolysis in
serum (Cena et al., 2003), a partial loss of the acetyl group in plasma was only to be
expected. How active the compound remains in biological media could be further
elucidated by in vivo studies.
The studies in chapter four explored the activity of the NO element of NO-aspirin in
vascular tissue. The native furoxan compounds were found to have remarkable
potency; the reversible vasodilatory effects of B13 in the picomolar range revealed it
to be approximately 300-fold more potent than DEA/NO (Sausbier et al., 2000).
Such data show potential for the furoxan compound as a possible stand-alone donor.
The effect of the hybridisation of the furoxans to their aspirin derivatives on their
ability to cause vasodilatation appeared to vary with the chemical structure, but both
hybrids were revealed to cause concentration-dependent vasodilatation of
phenylephrine-constricted rat aortic rings. The vasodilatation caused by the hybrids
was determined to be NO:sGC-dependent as revealed by the cGMP-dependent nature
of the response and the lack of effect displayed by their NO-free equivalents, making
them comparable with the existing nitroaspirin, NCX4016 (Rossoni el al., 2002).
The combined data from chapters three and four indicated that both elements of the
furoxan hybrids were active, as would be a pre-requisite for an effective hybrid drug.
The remainder of the studies investigated properties of the drugs in cell types
relevant to atherothrombotic disease.
As NO-hybrids were originally developed in order to overcome the gastric side-
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effects of aspirin associated with its long-term use or high dose, the potential for
these hybrids to succeed aspirin as prophylactics against thrombotic coronary events
was investigated in chapter five. Firstly, it was demonstrated with the furoxan
compound. B13, that furoxans are capable of overcoming the NO-scavenging effect
of endogenous haemoglobin (Gladwin et al, 2004; Kosaka et al, 1989). The hybrids
were demonstrated to be potent antiplatelet agents, causing inhibition of collagen-
induced aggregation at doses up to 100-fold lower than aspirin. This suggests that the
NO element is active and contributing to the antiplatelet action (Pasqui et al, 1991;
Radomski et al., 1990; Radomski et al, 1987c). Studies with ODQ revealed that the
effect of inhibition of platelet aggregation was mainly cGMP-dependent in PRP,
indicating dominance of the NO moiety in the antiplatelet effect. In WP, the aspirin
moiety was more active, especially in the case of B7, confirming that the COX-
inhibitory action revealed in chapter three could be retained in biological media, but
suggesting that plasma impacted on the acetyl stability (Cena et al., 2003). The
studies in chapter five perhaps reveal the furoxan hybrids to be a better option than
the nitrooxy ester, NCX4016, which was shown to have no antiplatelet action in PRP
and, in WP, it failed to demonstrate aspirin-independent effects. These studies
extended work carried out by others with NCX4016 (Lechi et al, 1996) in WP. The
data in chapter five show the WP antiplatelet effect is lost in PRP, possibly due to
sequestration by a plasma constituent such as albumin or due to breakdown in the
plasma to the inactive salicylic acid. Unlike NCX4016, the furoxans demonstrated
aspirin-independent effects on platelet aggregation in both PRP and WP in vitro. The
advantage the furoxans have over NCX40116 is likely due to their lack of reliance on
enzymatic cleavage to release their NO (Grosser & Schroder, 2000).
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The experiments in chapter six were carried out to explore the NO-release
mechanism for the furoxans and their hybrids. Results from previous chapters
suggested that release was likely to occur in very close proximity to sGC in order to
explain the effects seen at very low doses. The lack of effect of the NO scavenger,
cPTIO in chapter four also indicated release in a compartment inaccessible to the
scavenger. Furthermore, the hypothesis by Crane et al that cGMP-dependent NO
effects correspond with intracellular release of NO (Crane et al., 2005) prompted
investigation into the effects of intracellular antioxidant species on the release of NO
from the furoxan compounds. Studies revealed that the furoxan-aspirin hybrids, B8
and B7, like their aspirin-free equivalents, are very stable compounds that appear
only to decompose to release significant NO when they encounter appropriate media.
There was no release of NO from the furoxans in Tyrode's buffer, but NO generation
was detected in PPP, WP and PRP. The observations indicated that some elements of
plasma can stimulate decomposition of the furoxans, but that a major release of NO
from furoxans and furoxan-aspirin hybrids occurs on encountering intracellular
concentrations of antioxidants, such as GSH and ascorbate. As the decomposition is
catalysed by endogenous agents, it may instil a potential for primarily intracellular
delivery of NO, on account of the differential distribution of such agents;
concentrations of glutathione and ascorbate are approximately 100- 1000-fold higher
within cells compared to plasma and extracellular fluid. This may be of clinical
benefit in ensuring that following administration, the drug is not sequestered by cell
free haemoglobin. Experiments within chapter six further revealed that under in vitro
conditions, neither B8 nor B7 release significant amounts of peroxynitrite in addition
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to NO, indicating they can be classified as pure NO-donors and are likely to avoid
the deleterious effects associated with peroxynitrite (Shaw, 2006).
The final chapter investigated the anti-inflammatory effects in monocytes and
macrophages. Data in chapter seven indicated that, whilst the furoxan-hybrids had no
significant impact on the release of IL-8, an anti-inflammatory action was
demonstrated via inhibition of TNFa release from LPS-stimulated human monocytes
and monocyte-derived macrophages by B8. Further investigation using by
immunofluorescence suggested a possible mechanism for this action to be through
impedance of the nuclear translocation of the TNFa transcription factor, NF-kB,
which NO has been previously shown to impact upon (Hattori et al., 2004).
8.3 Clinical Applications
Further to their intended use as a gastric-safe aspirin, the furoxan-aspirins have been
demonstrated throughout this thesis to have further beneficial effect due to the
actions of the drug-derived NO and this gives potential for various clinical
applications.
8.3.1 Cardiovascular Drugs
The multiple actions of the furoxan-hybrids instil the potential for them to be
beneficial in different aspects of cardiovascular disease.
8.3.1.1 Antithrombotic Effects
The most likely application for these drugs is in the replacements of low-dose aspirin
for the prevention of coronary events in patients prone to gastric events. The drugs
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have demonstrated both aspirin and NO-mediated inhibition of platelet aggregation
in vitro. The furoxan NO-aspirins are predicted to have a better antithrombotic
profile than NCX4016 due to the stability of the compounds, their targeted
intracellular release, but most importantly their lack of requirement for enzymatic
degradation, which platelets cannot perform.
The COX-2-specific inhibitors were recently withdrawn due to their actions causing
an imbalance between vascular PGR and platelet TXA2, resulting in an increased risk
of stroke. The increased risk of thrombus is thought to be due to inhibition of COX-2
in endothelial cells, leading to reduced generation of the antithrombotic and
vasodilator agent, PGI2, in relation to the unaffected COX-1 derived, TXA2
(Fitzgerald, 2004). It is predicted that, since aspirin is approximately 170-fold more
selective for inhibiting COX-1 than COX-2 (Vane et al., 1998), low-dose furoxan-
aspirins can be administered to achieve inhibition of platelet TXA2 without affecting
vascular PGI2, mirroring prophylactic aspirin therapy (Forster & Parratt, 1997; Vane
etal., 1998).
8.3.1.2 Anti-Inflammatory Effects
As it is now generally accepted that atherosclerosis is an inflammatory disease (Ross,
1999), the ability of B8 to inhibit the release of inflammatory cytokine, TNFa, as
presented in chapter seven, may reveal a further cardiovascular target for the furoxan
NO-aspirins. As discussed in chapter seven, the release of TNFa by monocytes and
macrophages during atherosclerosis causes various effects involved in both
formation and destabilisation of the plaque.
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With regard to utilising the drugs to treat atherosclerosis, caution must be applied.
Whilst they have an anti-inflammatory action which may decrease the inflammatory
load in a plaque, the role of NO-related species in necrosis of vascular smooth
muscle cells (Shaw, 2006) may result in destabilisation of the plaque cap, promoting
plaque rupture.
As the atherosclerotic lesion increases in size it can impact on blood flow through the
lumen resulting in ischaemia or angina, and this is where the furoxans may have
benefit through their vasodilatory action (discussed below).
8.3.1.3 Vasodilators?
Despite showing great potency in the myography experiments, the application of
these drugs as vasodilators is likely to be unsuccessful in the setting of angina. The
nitrate compounds, GTN and ISDN are effective at providing symptomatic therapy
for angina. They bring about their effect by rapidly dilating veins and coronary
arteries, thus reducing pre-load and cardiac work and improving blood supply to the
heart (Abrams, 1885). GTN predominantly dilates the larger coronary arteries while
having a minimal effect on small coronary resistance vessels as they lack the
metabolic pathway needed to convert them to their active form (Harrison & Bates,
1993). It is possible that the furoxans may not be as selective and also produce
vasodilation of the coronary resistance vessels, thus resulting in the phenomenon of
coronary steal.
NO-mediated vasodilators such as nitroprusside are not commonly used as
antihypertensive agents except in medical emergencies (Williams el al., 2004). As
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the selectivity of furoxan NO-aspirin drugs has not been studied, the remarkable
potency of the drugs indicates that, unless the release can be specifically targeted to
capacitance vessels, in order to prevent dilation of both arterial and venous smooth
muscle, it may be necessary administer it intravenously as occurs for nitroprusside
(Mann et al., 1978).
8.3.2 Anti-Arthritic Agents
The most likely application for these drugs apart from antithrombotic therapy is in
the treatment or relief from arthritic symptoms. NO-aspirins have the potential to be
anti-inflammatory through the actions of both the NO-moiety and the parent
compound. The ability to inhibit COX-1, as demonstrated in chapter three highlights
the potential that the NO-aspirins could retain the anti-inflammatory, as well as
analgesic actions of the parent compound, aspirin, providing benefit in arthritis.
The analgesic effect of aspirin is brought about through inhibition of COX-mediated
prostaglandin E2 and T production. These prostaglandins, whether synthesized
during inflammation or in the spinal cord, play a role in firing of nociceptors
(Ferreira, 1980). NO-aspirins have the potential to be analgesic through COX-
mediated inhibition of prostaglandin production, but the impact of their NO moiety is
harder to predict due to the role of NO apparently varying with the type, location and
cause of pain (Hoheisel et al., 2005; Luo & Cizkova, 2000; Semos & Headley,
1994).
178
Chapter Eight: General Discussion
The carrageenan-induced hind paw oedema model is used experimentally as an acute
model of inflammation. This model has demonstrated the furoxan derivatives to
cause at least similar anti-inflammatory effects to the aspirin (Cena et al., 2003).
The data in chapter seven show the furoxan NO-aspirin, B8, to inhibit the release of
inflammatory cytokine, TNFa but not IL-8. This anti-TNFa action by NO-aspirins
may provide clinical benefit in inflammatory diseases such as arthritis
(Christodoulou & Choy, 2006; Siddiqui & Scott, 2006). Rheumatoid arthritis is a
chronic inflammatory autoimmune disorder characterised by inflammation of the
lining, or synovium, of the joints. The joint destruction and pain associated with the
synovial inflammation can lead to substantial loss of mobility. Pro-inflammatory
cytokines are abundant in the joints of sufferers (Christodoulou & Choy, 2006). Anti-
TNFa drugs have been recently licensed for use in arthritis to limit the contribution
of the cytokine to inflammation (Siddiqui & Scott, 2006).
Treatment of arthritis with conventional NSAIDs is severely limited due to their
gastric side-effects. However, the furoxan NO-aspirins could offer a preferable
alternative to NSAID therapy. The dual action of the COX-mediated aspirin action
and the anti-TNFa response along with their resistance to gastrotoxic effects (Cena
el al., 2003) show a promising antiarthritic profile of the furoxan NO-aspirins.
In contrast, the nitroaspirin, NCX4016, despite having an equivalent anti¬
inflammatory potential to the furoxans, is unlikely to be a successful antiarthritic
drug due to problems of tolerance. As the NO-donating group of NCX4016 is an
organic nitrate it will be just as susceptible to the tolerance problems associated with
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long-term or high dosage use as nitrates such as GTN (Artz et al., 2002; Chen et al.,
2002; Munzel et al., 2005; Munzel et al., 1995; Stewart, 1888; Sydow et al., 2004).
8.3.3 Cancer Therapy
Another possible clinical application for the NO-aspirins is in cancer therapy. The
use of aspirin has been reported to reduce the risk of several cancers particularly
colorectal, but also oesophageal, breast, lung, and bladder (Baron, 1995; DuBois &
Smalley, 1996; Marnett, 1995; Wang & Dubois, 2006).
Colon cancers have been demonstrated to produce high levels of COX-derived
prostaglandins, particularly PGE2 (Karim & Rao, 1976). Such prostaglandins act to
enhance tumour growth (Lupulescu, 1996). Aspirin has a beneficial effect in
preventing tumour growth due to its ability to inhibit synthesis of prostaglandins
(Rosenberg et al., 1991; Sano et al., 1995). The involvement of PGEi in tumour
growth is attributed to stimulation of its EP4 receptor, leading to phosphorylation of
extracellular signal-regulated kinases (ERKs). Such activation of ERK signalling by
the EP4 receptors induces the functional expression of early growth response factor-1
which promotes tumour growth (Fujino et al., 2003; Pozzi et al., 2004). Studies have
shown the prostaglandins involved in cancer growth to be derived from COX-2 (Lim
et al., 2001; Sano et al., 1995) and thus the COX-2 inhibitors were proposed to have
a potential use in cancer prevention (Lim et al., 2001; Sinicrope, 2006; Yona &
Arber, 2006). Elowever, with the discovery of the cardiovascular risk related to use
of the specific COX-2 inhibitors (Fitzgerald, 2004; Yona & Arber, 2006), there
appears to be a further clinical opportunity for the NO-aspirins.
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It is hoped that the furoxan NO-aspirins could ideally inhibit the cancer-promoting
prostaglandins to the same extent as aspirin, but would avoid the gastrotoxicity of
aspirin and the cardiovascular risk of the specific COX-2 inhibitors. The nitrooxy-
ester has already been shown to be beneficial in an in vitro model using colon cancer
cell lines, where it was up to 250-fold more potent than aspirin at inhibiting the
growth of cancer cells (Kashfi & Rigas, 2005). The NO-aspirin was also determined
to be more potent than the parent compound in pancreatic, prostate, lung, skin,
leukaemia and breast cancer cell lines, in some cases up to 6000-fold more potent
(Kashfi & Rigas, 2005). Studies have also demonstrated beneficial effects of
NCX4016 in vivo, where it reduced cancer growth in a rat model of colonic
adenocarcinoma to a greater extent than aspirin in an NO-dependent manner (Bak et
al., 1998). It is therefore hoped that drugs of the furoxan-aspirin class could mirror
the positive effects ofNCX4016 in cancer.
8.4 Limitation of Compounds & Future Directions
Future studies with this drug class must include screening of a wide range of furoxan
NO-aspirins (Cena et al., 2003) in order to eliminate the limitations highlighted in
this thesis. Such limitations include instability of the acetyl group in plasma resulting
in diminished aspirin-mediated actions in the antiplatelet studies. As more promising
results were achieved with B7 over B8 it is likely that the acetyl stability is related to
the structure and thus screening may reveal a more favourable candidate.
Further issues exist related to structure and these may be resolved by screening of
other furoxan NO-aspirins (Cena et al., 2003). As demonstrated by the furoxans B12
and B13 in chapters five and six, the effects of these compounds are hindered by
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their solubility in aqueous media. However, as an effect was observed in the ex vivo
studies in chapter four, the solubility may not impact upon their therapeutic potential.
Chemical modification is also required to rectify the balance issue of B8 in order that
in can act equally through both moieties as should be expected of a true "hybrid". B7
is the better prototype hybrid due to its lower NO release but it still requires chemical
modification in order to retain its aspirin-like action in PRP.
8.4.1 In Vivo Effects
The aim of the experiments performed within this thesis was to characterise the NO-
release and COX-inhibitory actions of a novel class of NO-aspirins and to determine
their actions in cell types relevant to atherosclerosis. While these experiments have
provided valuable information on the actions of the furoxan aspirin compounds
within in vitro situations, the next logical step is to study their potential effects in an
in vivo setting.
As discussed, the most likely clinical application for these drugs is as antithrombotic
or anti-arthritic therapies and future in vivo studies would further elucidate their
suitability for such applications.
8.4.1.1 Ex Vivo Studies - Antithrombotic Effect
Ex vivo studies can be utilised to study the antithrombotic effect of drugs
administered in vivo. Such studies have been carried out with the existing NO-
aspirin, NCX4016, following oral administration in both pigs (Wainwright et al.,
2002) and humans (Fiorucci et al., 2004). Commonly, following administration of
the test drug, blood is drawn and whole blood aggregation is carried out as in chapter
182
Chapter Eight: General Discussion
five. Such protocol allows any impact of the in vivo metabolism of the drug on its
antiplatelet activity to be determined. These studies would be of particular
importance in investigating how stable the acetyl group is in vivo and if an aspirin-
mediated effect is observed as a consequence.
Another ex vivo technique commonly used to study platelets is the Badimon
perfusion chamber (Badimon et al., 1999; Badimon et al., 1987; Fernandez-Ortiz et
al., 1994). It can be utilised to simulate blood flow through tissue segments in order
to study platelet deposition and thrombus formation.
8.4.1.2 In Vivo Studies - Anti-Arthritic Effect
As the original purpose of the drugs was to avoid the gastrotoxicity associated with
long-term NSAID use for conditions such as arthritis, investigations into the
application of the drugs as anti-arthritic compounds should be tested in a chronic
model of arthritis. The adjuvant-induced model of arthritis in either mice or rats
(Donaldson et al., 1993; Gauldie et al., 2004) would enable study of the long-term
effects of the compounds could be investigated. Such studies would also be useful in
revealing the furoxans to be devoid of the tolerance problems expected to limit the
application of NCX4016.
8.4.1.3 In Vivo Studies - Anti-Atherosclerotic Effect
The complexity of the disease makes atherosclerosis difficult to treat. Flowever,
through their antiplatelet and anti-inflammatory actions, the furoxans may provide
some clinical benefit. In order to investigate such a possibility the Apo-E model
could be used for in vivo studies.
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The Apo-E deficient mouse is often used as a model of atherosclerosis (Nakashima
et al., 1994; Piedrahita et al., 1992; Reddick et al., 1994; Zhang el al., 1994). Mice
deficient in the amphipathic protein, Apo-E, suffer from a lack of receptor-mediated
clearance of chylomicrons, very low- and high-density lipoproteins, resulting in
plasma cholesterol levels 4-5 times higher than normal (Ishibashi et al., 1994). These
mice develop complex atherosclerotic lesions before they are 20 weeks old.
The Apo-E model could be a means of further investigating the anti-inflammatory
properties of the furoxan NO-aspirins in cardiovascular tissue. As previously
suggested, without knowing whether the NO-aspirins contribute to smooth muscle
cell necrosis (Shaw, 2006), it is difficult to predict their actions in an established
plaque. However, the effects on smooth muscle cell necrosis could be established
first using an in vitro assay that monitors uptake of bromodeoxyuridine into
proliferating cultured smooth muscle cells (such as bovine aortic smooth muscle
cells). Bromodeoxyuridine is a thymidine analogue which becomes incorporated into
the newly synthesised DNA of actively proliferating cells. Anti-bromodeoxyuridine
antibodies are commercially available (Calbiochem) which allow detection and
quantification of incorporation of bromodeoxyuridine and thus cell proliferation.
Such techniques would allow the impact of the furoxan NO-aspirins on the
proliferation of smooth muscle cells to be determined in vitro and may act as an
indicator of their affect on the stability of the atherosclerotic plaque cap. Cell
viability of the cultured smooth muscle cells could be assessed by LDH assay as in
chapter seven.
The Apo-E knockout model could be utilised to investigate the possible beneficial
effects of the furoxan NO-aspirins in vivo during atherosclerosis by experiments
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involving chronic subcutaneous implantation of NO-aspirin-eluting osmotic pumps
and post-mortem analysis of atheroma using conventional histological and
biochemical techniques at specific animal ages.
The Apo-E model may also be utilised to further explore anti-inflammatory effects of
the furoxan NO-aspirins. The induction of iNOS is common under inflammatory
conditions such as atherosclerosis, where inflammatory cytokines are associated with
its stimulus (Behr-Roussel et al., 2000; Buttery et al., 1996; MacNaul & Hutchinson,
1993). Experiments could be undertaken to determine whether the anti-inflammatory
nature of the furoxan NO-aspirin drugs have any effect on iNOS function through the
anti-cytokine effect revealed in chapter seven, in aortic rings from Apo-E knockout
mice.
A further use of the Apo-E model could be in a study to determine the effects that the
furoxan NO-aspirins have on blood pressure in both the atherosclerotic-prone and
normal mouse. Such a study would determine if the vasodilator action is retained in
vivo and would also clarify if the drugs are likely to suffer from the coronary steal
phenomenon.
However, if as predicted, the beneficial effect of these compounds is due to their
antithrombotic effect demonstrated in chapter five, it is imperative to study a murine
colony in which plaque rupture occurs (Johnson & Jackson, 2001) in order to
observe any beneficial effect in reducing the incidence of clinical manifestations of
thrombus formation such as MI or stroke.
It is to be expected that the in vivo application of these drugs will raise further issues
which commonly limit the use of NO-donor drugs. Such limitations include
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unwanted vasodilatation in patients prescribed the drugs for their antithrombotic
actions. However, as the COX-mediated inhibition gives an antiplatelet action for the
lifetime of the platelet, any problems related to hypotension evoked by these drugs
are likely to be shorter acting than the antiplatelet effect and although still potentially
problematic, it may be resolved by altering the dosing regime.
8.5 Conclusions
Data presented within this thesis have provided insight into the in vitro vascular
actions of a novel series of furoxan derivatives of aspirin. The drugs have been
demonstrated to have potent antiplatelet, vasodilatory and anti-inflammatory actions
contributed to by both moieties of the hybrid. It is hoped that such actions, along
with their favourable gastric profile, will enable them to replace aspirin as a
prophylactic against thrombotic events or perhaps even as an anti-inflammatory
agent in patients with arthritis, with further more speculative applications as anti¬
cancer or anti-atherosclerotic drugs.
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Mechanism of action of novel NO-releasing furoxan derivatives
of aspirin in human platelets
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1 Incorporation of a nitric oxide (NO)-releasing moiety in aspirin can overcome its gastric side
effects.
2 We investigated the NO-release patterns and antiplatelet effects of novel furoxan derivatives of
aspirin (B8 and B7) in comparison to existing antiplatelet agents.
3 Cyclooxygenase (COX) activity was investigated in purified enzyme using an electron
paramagnetic resonance-based technique. Concentration-response curves for antiplatelet agents + the
soluble guanylate cyclase inhibitor, ODQ (50/rM) were generated in platelet-rich plasma (PRP) and
washed platelets (WP) activated with collagen using turbidometric aggregometry. NO was detected
using an isolated NO electrode.
4 The furoxan derivatives of aspirin (B8. B7) and their NO-free furazan equivalents (B16, B15; all
100 jum) significantly inhibited COX activity (P<0.01; n = 6) in vitro and caused aspirin-independent,
cGMP-dependent inhibition of collagen-induced platelet aggregation in WP. B8 was more potent than
B7 (PRP IC50 = 0.62 + 0.1 fiM for B8; 400±89/rM for B7; P<0.0001. WP IC5Os = 0.6 + 0.1 and
62+10/rM, respectively). The NO-free furazan counterparts were less potent antiplatelet agents (WP
IC50s = 54 + 3^M and 62+lO^M, respectively; P<0.0001, B8 vs B16). Of the hybrids investigated,
only B8 retained antiplatelet activity in PRP.
5 NO release from furoxan-aspirin hybrids was undetectable in buffer alone, but was accelerated in
the presence of either plasma or plasma components, albumin (4%), glutathione (GSH; 3 /rM) and
ascorbate (50 /zM), the effects of which were additive for B7 but not B8. NO generation from furoxans
was greatly enhanced by platelet extract, an effect that could largely be explained by the synergistic
effect of intracellular concentrations of GSH (3 mM) and ascorbate (1 mM).
6 We conclude that the decomposition of furoxan-aspirin hybrids to generate biologically active NO
is catalysed by endogenous agents which may instil a potential for primarily intracellular delivery of
NO. The blunting of the aspirin effects of furoxan hybrids is likely to be due to loss of the acetyl
moiety in plasma; the observed antiplatelet effects are thereby primarily mediated via NO release.
Compounds of this class might represent a novel means of inhibiting platelet aggregation by a
combination of NO generation and COX inhibition.
British Journal ofPharmacology advance online publication, 15 May 2006; doi: 10.1038/sj.bjp. 0706743
Keywords: Nitric oxide; platelets; furoxan; nitroaspirin; thrombosis; antithrombotic
Abbreviations: AA. arachidonic acid; AUC, area under the curve; cGMP. cyclic 5'-guanosine monophosphate; COX-1,
cyclooxygenase-1; CPH, l-hydroxy-3-carboxy-2,2,5,5-tetramethylpyrrolidine.HCl; DEA/NO, 2-(A',Ar-diethyami-
no)-diazenolate-2-oxide; DMSO, dimethylsulphoxide; DTNB. 5,5'-dithio-bis(2-nitrobenzoic acid); EPR, electron
paramagnetic resonance; GSH, glutathione; NO, nitric oxide; ODQ, l//-[l,2,4]oxadiazolo[4,3-ce]quinoxalin-l-one;
PPP, platelet poor plasma; PRP, platelet-rich plasma; sGC, soluble guanylate cyclase; TFA, trifluoroacetic acid;
WP, washed platelets
Introduction
Aspirin is a nonsteroidal anti-inflammatory drug that has long
been used as a prophylactic against thrombotic coronary
events (ISIS-2, 1988; PHS-Committee, 1989; Manson et al.,
1991). It reduces cardiovascular risk, primarily through
irreversible inhibition of prostaglandin H synthase-1 (also
termed cyclooxygenase-1, COX-1 (-mediated platelet aggrega¬
tion (for review see, Patrono, 1994). Aspirin selectively and
*Author for correspondence; E-mail: ian.megson@ed.ac.uk
irreversibly acetylates a serine residue (Ser 530) of COX-1
(Roth & Majerus, 1975; Roth et al., 1975; DeWitt & Smith.
1988). COX-1 inhibition results in reduced production of
thromboxane A2, a vital element in the induction of
irreversible platelet aggregation in response to stimuli such
as collagen (FitzGerald, 1991: Hamberg et al., 1975). The
anucleate nature of platelets makes them unable to synthesize
new proteins and replace inhibited enzyme; recovery of full
platelet activity only takes place as a function of platelet
turnover (Burch et al., 1978). Aspirin also acts to inhibit the
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formation of thrombin (Kessels et al., 1994; Szczeklik el al.,
1992), a unique action that also prevents platelet aggregation
and impacts on the coagulation pathway. Taken together,
these properties offer a degree of platelet selectivity in the
action of aspirin.
Unfortunately, gastrointestinal disorders, including ulcera¬
tion, are a common side effect of aspirin, limiting its use
(Cameron, 1975; Wallace, 1997; Tramer et al., 2000; Seager &
Hawkey, 2001). The effect is due to inhibition of prostaglan¬
dins that normally protect the gastric mucosa (Whittle, 1977;
Robert et al., 1979; Schoen & Vender, 1989; Wallace, 1997).
Aspirin esters containing a nitric oxide (NO)-donor nitrooxy
function (e.g. NCX4016) are thought to overcome the gastric
side effects through the protective actions of drug-derived NO.
NO increases blood flow in the gastric mucosa, promoting
repair and removal of toxins (Wallace & Miller, 2000). NO
also increases secretion of protective gastric mucus (Brown
et al., 1993) and is thought to promote healing of gastric
ulcers by promoting angiogenesis (Ma & Wallace, 2000).
Alternatively, the protective effects of NO aspirin could be
due to masking of the aspirin carboxylic acid moiety by the
ester function (Rainsford & Whitehouse, 1976; Cena et al.,
2003).
While NO hybrids of aspirin were primarily designed to
protect against damage to the gastric mucosa, there may be
additional benefits of drug-derived NO through its many
protective effects in the vascular system. NO is a powerful
endogenous vasodilator (Palmer et al., 1987) which acts to
keep the vasculature in an active state of dilatation by
stimulating cGMP-mediated relaxation of vascular smooth
muscle cells. NO also opposes the adherence of monocytes to
the vessel wall (Tsao et al., 1997) and displays antithrombotic
actions through its ability to inhibit platelet adhesion
(Radomski et al., 1987b,c) and aggregation (Radomski
et al., 1987a; 1990; Pasqui et al., 1991). Inhibition of platelet
aggregation occurs primarily via stimulation of cGMP; the
platelet aggregation response to sodium nitroprusside has been
shown to be entirely cGMP dependent (Sogo et al., 2000).
However, cGMP-independent signalling mechanisms have also
been identified (Gordge et al., 1998; Trepakova et al., 1999;
Sogo et al., 2000; Homer & Wanstall, 2002; Crane et al., 2005).
Reduced NO synthesis or availability is heavily implicated as a
key factor in the initiation and progression of atherogenesis
(Anderson et al., 1995; Maxwell, 2002; Shaul, 2003).
The release at NO from NCX4016 and glyceryl trinitrate has
been reported to occur through identical mechanisms (Grosser
& Schroder, 2000). Platelets have a poor capability to release
NO from organic nitrates (Weber et al., 1996) and it is possible
that compounds such as NCX4016 will fail to show additional,
NO-mediated effects in platelets, at least in vitro. A new range
of drugs, in which a NO-donating moiety (furoxan group) is
joined by an ester linkage to the aspirin molecule (B8, B7;
Figure 1) appear to overcome the problem of gastric lesions
(Cena et al., 2003). However, the NO-release mechanism is
unlikely to require the same cellular machinery as that for
organic nitrates, suggesting that they might offer a degree of
NO-mediated antiplatelet effects to complement those of the
aspirin moiety.
In the present study, we investigated the mechanism of
action of two examples (3-cyanofuroxan-4-yl)methyl 2-acet-
oxybenzoate (B8) and (3-carbamoylfuroxan-4-yl)methyl 2-
acetoxybenzoate (B7); Figure 1), with different NO-releasing
properties (Cena et al., 2003) in human platelets in vitro. Here,
we characterize the NO-releasing and COX-inhibiting effects
of these novel furoxan derivatives of aspirin and compare their









Figure 1 Structural formulae of furoxan hybrids (B8 and B7), furazan hybrids (B16 and B15) and the nitrooxy-ester NCX4016.
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Nottingham, U.K.) was dissolved in 0.01 M NaOH. 1H-
[l,2,4]oxadiazolo[4,3-a]quinoxalin-l-one (ODQ; Cookson,
Langford, Bristol, U.K.) was dissolved in dimethylsulphoxide
(DMSO) and stored at —20°C. Collagen was purchased from
Labmedics (Stockport, U.K.). l-Hydroxy-3-carboxy-2,2,5,5-
tetramethylpyrrolidine. HC1 (CPH) was purchased from
Axxora. All other chemicals were purchased from Sigma
(Poole, Dorset, U.K.). All nitro-aspirins were synthesized at
the Universita degli Studi di Torino, as described (Cena et al.,
2003). Compound purity was assessed by high-performance
liquid chromatography before biological assays (over 98% for
all compounds; Merck Purosphere RP-18 column (Merck,
Darmstadt, Germany; 250 x 4 mm2, 5 /.im particle size) eluting
with flow rate of 1 mlmin~'. Mobile phase consisted of 0.1%
aqueous trifluoroacetic acid (TFA) and acetonitrile containing
0.1% TFA in different ratios according with compounds
properties. The column effluent was monitored at 224/254 nm).
Compound identity was chemically confirmed by nuclear
magnetic resonance.
The nitro-aspirins were dissolved in DMSO, then diluted in
PBS to give a final concentration of 0.1% DMSO, which pilot
studies had determined not to affect platelet aggregation. No
precipitation of any drug was observed following dilution.
COX activity assay
The ability of novel and established compounds to inhibit
COX-1 was measured using an adaptation of a published
method (Schreiber et al., 1989). The assay relies on detection
of oxidizing free radicals produced as a by-product by the
peroxidase element of the COX enzyme. A spin-trapping
agent, CPH, was utilized to trap the short-lived radicals,
forming a stable adduct, 3-carboxy-proxyl. The assay makes
use of commercially available purified COX-1 from ovine
seminal vesicles (Sigma), pretreated with haematin for 5min.
The COX activity assay was performed at 37°C in 1 ml of
Tyrode's buffer. In all, lOOUmD1 purified COX-1 was
incubated with 3 nM haematin (5 min, 37°C) prior to the assay.
Aspirin, salicylic acid, a furoxan, a furazan, NCX4016
(IOO/tm) or a vehicle control (DMSO, 1%) was added and
left to incubate for a further 10 min prior to addition of the
spin-trap, CPH (ImM). At this point (time zero), a baseline
EPR measurement was taken (MS200, Magnettech, Germany.
Instrument settings: BO-field, 3356 G; sweep width; 50 G,
sweep time, 30 s; modulation amplitude, 1500mG; microwave
power, 20 mW; microwave frequency, 9.3 GHz). After 2 min,
0.5 rnM AA (sodium salt) was added; EPR measurements were
made (50 p\ samples in micropipette tubes) after a further
1.5 min incubation. The suicidal nature of COX-1 activation
means that the period of activation is complete within ~ 1 min
of AA addition (as confirmed by pilot experiments).
The EPR results were corrected for any auto-oxidation of
spin-trap by subtraction of values recorded from a duplicate
sample run in the absence of AA. The intensity scale on the
y-axis of all graphs is an arbitrary scale based upon the area
under the curve (AUC) of the first derivative traces generated.
Results graphs show the timepoint 1.5 min after the addition of
AA, as this was determined in pilot experiments to be the most
appropriate point at which to compare free radical generation
between control and furoxan-treated COX-1, given that spin-
adduct generation in response to AA had peaked - subsequent
adduct formation was at an equivalent rate in control and
AA-treated samples and was likely to be due to nonspecific
auto-oxidation of CPH.
Blood preparation
Peripheral venous blood was drawn from the antecubital fossa
of human volunteers aged 20-45 years who were non-smokers
and had not taken any platelet-active agents during the
previous 10 days. Blood was collected into tubes containing
3.8% sodium citrate and centrifuged at 200 xg for lOmin at
room temperature to obtain platelet-rich plasma (PRP). An
aliquot of PRP was further centrifuged at 1200 x g for 10 min
to obtain platelet-poor plasma (PPP). Washed platelets (WP)
samples were obtained by adding 300 ngml"1 prostacyclin to a
2ml PRP sample before centrifuging at 1200 xg for lOmin.
Prostacyclin is commonly used at this concentration in this
type of study (Giuliano & Warner, 1999; Kobzar et al., 2001;
Crane et al., 2002). The effect of the prostacyclin is only
temporary due to its short half-life. The supernatant was then
discarded and the pellet resuspended in Tyrode's buffer
(137mM NaCl, 2.7 mM KC1, 1.05 mM MgS04, 0.4 mM
NaH2P04, 12.5mM NaHCO,, 5.6mM Glucose, 10mM HEPES
and 0.8 mM CaCl in dH20 at pH 7.4). Prostacyclin
(300ngmL') was again added before a second lOmin
centrifugation (1200 xg). Finally, the pellet was resuspended
in 2 ml Tyrode's buffer. For aggregation, platelet counts were
determined using a Coulter Ac.T 8 Hematology Analyzer
(Coulter Electronics, Luton, U.K.) and standardized to
250 x 109U' via dilution with PPP (PRP) or Tyrode's buffer
(WP).
Aggregation
inhibition of platelet aggregation was measured using optical
platelet aggregometry in a 4-channel aggregometer (Chrono-
Log, Labmedics, Stockport, U.K.) and data captured via
an analogue-digital converter (Maclab 4e, AD Instruments,
Sussex, U.K.). The instrument was calibrated such that the
difference in light transmission between test (PRP or WP) and
reference (PPP or Tyrode's buffer, respectively) samples was
set to generate an 80 mV signal. Typically, maximal aggrega¬
tion caused ~60mV change in signal. Briefly, PRP or WP
samples were equilibrated at 37°C and stirred continuously at
1000 r.p.m. The samples were then treated with either B8
(10nM-3/iM), B7 (10/rM-lmM), their respective NO-free
structurally related furazan derivatives, (4-cyanofurazan-3-
yl)methyl 2-acetoxybenzoate (B16; 10nM-3/rM) or (4-carba-
moylfurazan-3-yl)methyl 2-acetoxybenzoate (B15; 10^M-
1 mM), NCX4016 (3;iM-0.3mM) or aspirin (acetylsalicylic
acid; 3/rM-l mM) for 10 min before induction of aggregation
with supramaximal concentrations of collagen (2.5yigml_1).
The aggregation was then recorded turbidometrically over
5 min against a reference PPP sample. Experiments were also
performed with the addition of 50 pM (supramaximal concen¬
tration (Crane et al.. 2005)) of the cGMP inhibitor ODQ
15 min before addition of the drug. Aggregation was expressed
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as a percentage inhibition of control aggregation obtained with
2.5 jugml-1 collagen.
NO release
Samples of PRP. PPP or Tyrode's buffer (2 ml) were incubated
in the aggregometer at 37°C and stirred continuously at
1000 r.p.m. An isolated NO electrode (ISO-NO MARKII.
World Precision Instruments, Stevenage, U.K.), calibrated
using DEA/NO (0.1-1.6 jUM), was introduced into the cuvette
and allowed to stabilize for lOmin. B8 (100/rM) or B7 (500/rM)
was then added to the cuvette and the release of NO recorded
for 10 min before addition of haemoglobin (10 pu) to scavenge
any generated NO. Experiments were also carried out in
Tyrode's buffer+ 4% albumin, with the addition of glu¬
tathione (3 pM or 3mM), ±50yiM ascorbate before B8 or B7.
Ascorbate (1 mM) was also used, but only in the presence of
lOmM HEPES to buffer its acidic pH. The concentrations of
albumin, ascorbate and glutathione studied are all physiolo¬
gically relevant. The detection limit for the electrode under the
conditions of the experiment was found to be ~ 10 nM NO.
A platelet extract was also prepared from samples of PRP
and platelet count was determined using the Coulter Ac.T 8
Hematology Analyzer. The platelets were washed as above in
the presence of prostacyclin to obtain a platelet pellet. The
total platelet volume of the pellet was calculated by multi¬
plying the number of platelets by the average platelet volume
(5.14 x 10~I51; obtained from the hematology analyzer). The
pellet was resuspended in 1 ml of 0.5% Triton X in Tyrode's
buffer for 1 h and the dilution of cell contents estimated using
the total platelet volume from the above calculation. This was
then homogenized by hand for 15 min and centrifuged at
12,000 x g for 10 min to give a cell extract. B8 (100/iM) or B7
(500 pM) was added to 1 ml of this supernatant in the assay
as described above.
A further set of experiments was carried out following
a 10 min preincubation of the platelet extract with the thiol
alkylator, 5,5'-dithio-bis(2-nitrobenzoic acid) (DTNB;
500 /;M). The NO release from B8 (100/rM) or B7 (500 pM)
was then recorded as above. The samples were collected and
frozen (—20°C) and later used for thiol determination by
colorimetric analysis at 405 nm. Thiol levels of the extract
samples were determined from a standard curve created using

























Figure 2 EPR-based COX-activity assay, (a) Typical 3-peak EPR
spectra obtained in the absence (control; COX + AA) and presence
of aspirin or hybrid compound (all 100/jM) after correction for
background autoxidation. EPR settings: BO-field, 3356 G; sweep
width; 50 G, microwave frequency, 9.3 GHz; sweep time, 30 s;
modulation amplitude. 1500mG: microwave power, 20 mW. (b)
Effect of aspirin, salicylic acid, furoxans, furazans and NCX4016 (all
100 fiM) on EPR signals generated from COX-1 after treatment with
substrate (AA). In each case, drug incubations were for 10 min prior
to the baseline EPR reading. Readings shown were taken 1.5 min
after the addition of AA. *P<0.05, **P<0.01; one-way ANOVA
with Dunnet's post hoc test vs control: /7 = 6— 10. Values are
mean + s.e.m.
compared to a vehicle control (Figure 2; P<0.01; n = 8). A
significant inhibition of COX activity was also observed with
the furoxan-aspirins. B8 and B7 (100 pM: P<0.05 and P<0.01
respectively, n — 6). Even greater inhibition was demonstrated
with the NO-free furazan equivalents, B16 and B15 (100/iM.
Z3<0.01 for both, n = 6). The furazan compounds demon¬
strated a significantly greater inhibition of COX than aspirin
(PcO.Ol). The nitrooxy-ester, NCX4016 (100pwi) also abol¬
ished COX activity (PcO.Ol, n = 6). Salicylic acid (100/tM,
n = 6) failed to significantly inhibit generation of the spin-
adduct, as did the NO donor DEA/NO (100/iM, n = 6;
Figure 2b).
All results are expressed as the mean + s.e.m. Concentration-
response curves were analysed by two-way analysis of variance
(two-way ANOVA). EPR data were analysed by 1-way
ANOVA and NO electrode data by two-tailed paired Student's
/-test. Dunnett's or Bonferroni post-tests were carried out




Aspirin (100/jM) significantly reduced the EPR signal gener¬
ated by AA-stimulated purified COX-1 in Tyrode's buffer
Effect of aspirin, salicylic acid and NCX4016 on platelet
aggregation
Aspirin (3-300 pM) caused concentration-dependent inhibition
of collagen-induced platelet aggregation in PRP and the effect
was enhanced in WP, but salicylic acid failed to show an
inhibitory effect, even at concentrations of 300 pM (Figure 3;
« = 6-8). NCX4016 (3-300/iM) had no effect on collagen-
induced platelet aggregation in PRP (Figure 3a; /; = 6), but did
cause concentration-dependent inhibition of platelet aggrega¬
tion in WP that was significantly more potent than aspirin
(Figure 3b; P = 0.002; n = 6). Responses to NCX4016 were
insensitive to the soluble guanylate cyclase inhibitor. ODQ
(15min preincubation; Z3 = 0.88, NCX4016 + ODQ vs
NCX4016 alone in WP: Figure 3b).
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Figure 3 Collagen (2.5/tgmF')-induced platelet aggregation in
PRP and WP. (a) Effect ofNCX4016, salicylic acid and aspirin on
collagen-induced platelet aggregation in PRP. ***P<0.0001, n = 6-
7. (b) The effect of the guanylate cyclase inhibitor ODQ (50 /iM;
15min preincubation) on responses to NCX4016 in WP.
**p = 0.002, n = 6. Values are mean + s.e.m. Statistical analysis by
two-way ANOVA.
Effect of B8 and B7 on platelet aggregation
B8 (lOnM-3/tM) caused concentration-dependent inhibition
of collagen-induced platelet aggregation in PRP at concentra¬
tions ~ 100-fold lower than for aspirin (B8 IC50 in
PRP = 0.62 + 0.1/tM; Figure 4a, (see Figure 3a for aspirin
effect)). ODQ significantly inhibited the responses to B8 in
PRP (Figure 4a; n = 6-8; P< 0.0001), while the NO-free,
structurally related furazan derivative of B8 (B16; 10 nM-
1 mM) was considerably less effective at inhibiting platelet
aggregation than B8 in PRP (Figure 4a; P<0.0001; n = 8).
The effects of B8 in PRP were largely mirrored in WP: B8
was found to be a powerful inhibitor of collagen-induced
aggregation (IC50 = 0.6 + 0.1/im) and its actions were signifi¬
cantly inhibited by ODQ (Figure 4b; PcO.0001; n = 6-8). B16
had a significantly greater inhibitory effect on platelet
aggregation in WP compared to PRP (IC50 = 54±3/tM;
Figure 4b; P< 0.0001; PRP B16 vs WP B16; n = 6-8).
B7 (10/tM-lmM) was less effective than B8 and aspirin
at inhibiting collagen-induced platelet aggregation in PRP (B7
IC5O = 0.36±0.1 mM). ODQ significantly inhibited the re¬
sponse of B7 in PRP (Figure 4c; n = 6-7; P< 0.0001). B15
was ineffective in PRP.
In order to make a direct comparison, concentrations
studied with WP were dictated by the PRP response curve.
B7 (10/iM-lmM) was considerably more effective in WP
(IC50 = 24±8/(M) than PRP. The inhibitory effects of B7 in
WP were significantly attenuated by ODQ (P = 0.002, two-way
ANOVA; n = 6-l). In stark contrast to the findings in PRP,
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Figure 4 Collagen (2.5/igml"'pinduced platelet aggregation in
PRP and WP. (a) Effect of B8 ( + ODQ; 50/iM, 15min preincuba¬
tion) and its NO-free equivalent, B16, on collagen-induced platelet
aggregation in PRP. P<0.0001 (B8 + ODQ vs B8 alone, « = 6-9).
(b) The effect of ODQ (50 /iM) on responses to B8 in WP. P<0.0001
(+ ODQ vs B8 alone), n = 6-9. (c) Effect of B7 ( + ODQ; 50 /iM) and
its NO-free equivalent B15 on collagen-induced platelet aggregation
in PRP. ***P<0.0001, n = 6-l. (d) The effect of OD(J (50/jm)
on the B7 response in WP. ***P<0.0001, ;? = 6-7. Values are
mean + s.e.m. Statistical analysis by two-way ANOVA.
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aggregation in WP (B15 IC50 in WP = 62±10^m); indeed, at
concentrations of 100 pM or more, it was as effective as B7
under these conditions.
NO release from furoxan-aspirin hybrids:
effect of endogenous antioxidants
Sample recordings of NO generation from B7 and B8 in the
presence and absence of GSH and ascorbate are shown in the
inserts to Figure 5a and c. Owing to the different profile of NO
release by the different drugs, it was established that AUC was
more representative of NO release than peak concentration in
these experiments; subsequent values quoted are all AUC over
the lOmin incubation (mmolmin), but sample peak values are
also given for information.
NO release from NCX4016 (100/im) was undetectable in
Tyrode's buffer. PRP or WP (n = 6-8 for each). Likewise, NO
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Figure 5 NO release recorded over lOmin from B8 (100/jM) or B7 (500pM) in various media, (a) NO release from B8 in media
related to plasma conditions: Tyrode's buffer was reconstituted with approximate plasma concentrations of the plasma constituents,
albumin (4%). GSH (3/rM) and ascorbate (50 pM). Inset shows typical lOmin traces of NO release recorded via the NO electrode in
Tyrode's buffer with or without ascorbate (1 mM) and GSH (3mM). (b) Shows typical NO release from B8 in media related to
platelet conditions: Tyrode's buffer 3 and 1 mM are approximate intracellular concentrations of glutathione and ascorbate,
respectively; n = 6-7. GSH = Glutathione. Ascorb = ascorbate. Values are mean±s.e.m. (c) Shows NO release from B7 in media
related to plasma conditions. Inset shows typical lOmin traces of NO release from B7 recorded via the NO electrode in Tyrode's
buffer with or without ascorbate (1 mM) and GSH (3 mM) (d) shows NO release from B7 in media related to platelet conditions.
British Journal of Pharmacology
C.M. Turnbull et al Mechanism of action of NO-releasing furoxan 7
Tyrode's buffer alone (Figure 5a and c). However, it was
detected in samples of PRP, WP, PPP or Tyrode's buffer in the
presence of approximate plasma concentrations of albumin
(4%), GSH (3/zM) or ascorbate (50/zm; Figure 5b and d).
NO was released from B8 in platelet-containing samples
(PRP and WP; mean NO release = 33.2+ 2.9 and
33.0 + 2.5 mmol min, respectively, with both peaking at
— 1.25 /(M NO; Figure 5b), and in PPP (mean NO release for
B8 = 21.0±2.8mmolmin, peak at — 0.6/zm NO; Figure 5a).
Reconstitution of Tyrode's buffer with approximate plasma
concentrations of either albumin (4%), glutathione (3/zm) or
ascorbate (50/zm) enhanced NO generation from B8. A
combination of these three constituents failed to enhance
NO release from B8 beyond the effects seen with the individual
components alone (2.7 + 0.7 mmol min, peak at ~ 0.040 /zM for
GSH alone and — 0.038 //M NO in the presence of plasma
concentrations of albumin, GSH and ascorbate; Figure 5a;
P = 0.78 vs GSH alone, P = 0.13 vs ascorbate alone, both
unpaired Student's /-test).
Reconstitution of Tyrode's buffer with approximately
intracellular concentrations of GSH (3 mM) generated margin¬
ally less NO from B8 (14.4 + 2.5 mmol min; Figure 5b; peak at
— 0.124/zm NO) compared with samples containing platelets.
Ascorbate (1 mM) in Tyrode's buffer caused minimal NO
release from B8 ( = 2.2+0.9 mmol min; Figure 5b; peak at
~ 0.004 /zM NO), but a combination of GSH and ascorbate
caused a considerable increase in NO generation from B8
(247+ 19 mmol min, n = 6, Figure 5b. P< 0.0001 vs individual
components alone, unpaired Student's /-test; peak at
-2.31 /zM NO).
Relatively low levels of NO were released from B7 in PRP
and WP (1.6±0.4 and 3.8+0.7 mmol min, respectively; n = 6,
Figure 5d. Peaks at —0.085 and — 0.120/zM NO, respectively)
despite the higher drug concentration used. Reconstitution of
the Tyrode's buffer with approximate plasma concentrations
of either albumin (4%), glutathione (3 /zm) or ascorbate
(50 /zM) enhanced NO generation from B7 and a combination
of these three constituents had an additive effect on the release
of NO front B7 (3.8 +0.8 mmol min: peak at — 0.295/zm NO),
where release was equivalent to that seen in PPP (unpaired
Student's /-test P = 0.628; Figure 5c).
Reconstitution of Tyrode's buffer with approximately
intracellular concentrations of GSH (3mM) increased NO
release from B7 (8.5+1.1 mmol min; peak at — 0.504/zm NO).
Ascorbate (lniM) in Tyrode's buffer caused minimal NO
release front B7 (3.1 + 1.6 mmol min; peak at — 0.004/zm NO),
but a combination of GSH and ascorbate caused a consider¬
able increase in NO generation from B7 (47+ 4 mmol min
n = 6, Figure 5d; peak at — 0.642/zM NO).
Effect ofplatelet extract on NO generation from B8
and B7
There was a relationship between the dilution factor of platelet
extract and the amount of NO released from both B8 and B7
(Figure 6a and b). NO generation by B8 (100/zm) failed to
increase at platelet extract dilutions below — 1 in 30. with
a maximum NO generation of —90 mmol min. Prelreatment
of platelet extracts with the thiol alkylator, DTNB (500 /zM),
all but abolished NO generation.
A similar pattern was observed with B7 (500/zm), but the












Figure 6 A sample of WP was suspended in 1 ml 0.5% Triton X
and then homogenized to release platelet extract before centrifuga-
tion to remove membrane fraction. The dilution factor on A'-axis was
calculated by volume Triton X (1 ml)/(number of platelets x average
platelet volume), (a) NO release from 16 platelet extracts treated
with 100 /zM B8. The triangles show samples treated in the same way
but with a 10 min preincubation with 500/zM DTNB before addition
of B8. (b) NO release from 13 platelet extracts treated with 500/iM
B7. The triangles show samples treated in the same way but with a
10min preincubation with 500/zm DTNB before addition of B7.
was > 10-fold lower than from B8, despite the higher drug
concentration. In the case of B7, dilutions of platelet extract
lower than — 1 in 75 failed to generate detectable NO, but
there was a direct relationship between NO generation and
dilution factor at dilutions of 1 in 75 to 1 in 25 (Figure 6b).
DTNB again showed a marked inhibitory effect on NO
generation in the presence of platelet extract. Colorimetric
analysis of DTNB-treated samples yielded intracellular total
reduced thiol concentrations of 22 + 4mM (corrected for
dilution; n = 5).
Discussion
Our results show that two novel furoxan-aspirin hybrids drugs
effectively inhibit collagen-induced platelet aggregation and
the relative contribution of NO to the inhibitory effect was
dependent on the characteristics of the specific furoxan
involved. The potent effects of B8 were considered to be
largely NO dependent on account of the fact that the closely
related NO-free furazan, B16, had only a very weak antiplate¬
let effect. B7 was a less potent inhibitor of aggregation than B8
but the effects were also primarily NO mediated in PRP, where
the furazan counterpart was largely ineffectual. However, in
WP, it was apparent that the antiplatelet activity of B7
comprised both NO-dependent and -independent components.
The existing nitrooxy ester, nitro-aspirin (NCX4016). was also
an effective antiplatelet agent in WP but the effects were
fold dilution
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entirely sGC independent and were altogether lost in PRP. The
release of NO from the furoxans was found to be critically
dependent on the presence of endogenous reducing agents. NO
generation was most striking in the presence of intracellular
levels of ascorbate + GSH, which acted synergistically to
release NO. By contrast, the nitrooxy ester, NCX4016. failed
to generate detectable NO in samples containing either
platelets or plasma.
Both the nitrooxy ester, NCX4016, and the furoxan-aspirin
hybrids were demonstrated to significantly inhibit COX-1. The
alterations to the chemical structure in the hybrids perhaps
play a role in bringing about the enhanced inhibition that was
observed compared to the unaltered aspirin compound. The
powerful inhibitory effect of the furoxan-aspirin hybrids in
the purified COX-1 assay, together with the equally powerful
effects of the furazan equivalents and the lack of significant
inhibition observed with the NO donor DEA/NO, suggests
that the COX-1-inhibitory activity of B8 and B7 is more likely
to be aspirin-mediated than NO-mediated. This assay demon¬
strates that, in addition to their ability to inhibit platelet
aggregation via NO, the furoxan-aspirin hybrids retain an
aspirin-like action in vitro. At face value, these data would
indicate that any antiplatelet effects of the furoxan-aspirin
hybrids should be at least partially mediated by aspirin-
mediated inhibition of COX-1. However, it is important to
recognize that this effect might be lost in biological media or
in vivo, depending on how these compounds are hydrolysed
under physiologically relevant conditions. Previous studies
(Cena et al., 2003) have demonstrated complete hydrolysis of
the furoxan-aspirin acetyl group in serum. This feature would
suggest that in plasma, there is at least a partial loss of the
acetyl group, resulting in formation of the salicylic acid
equivalent. As salicylic acid was demonstrated to have no
effect in this assay of COX activity and failed to affect platelet
aggregation, modifications to the chemical structure to
improve retention of the acetyl group in plasma is likely to
be necessary to avoid loss of the COX-inhibiting effects of the
compounds. Other groups have also demonstrated that COX
inhibition by the hybrid NCX4016 has a similar requirement
for the acetyl group but not the NO moiety (Corazzi et al.,
2005).
The present study extends findings from preliminary
aggregation studies which have been published previously
(Cena et al., 2003). Here, we further investigated the relative
contribution of the NO- and aspirin moieties to the antiplatelet
effect. The furoxan-aspirin hybrid drugs inhibited platelet
aggregation in both WP and PRP, although the effects of both
compounds, and B7 in particular, were attenuated in PRP. The
comparatively weak inhibitory effects of the NO-free furazan
counterparts is indicative of a major role for NO in platelet
inhibition, while the inhibitory effect of ODQ confirmed that a
major component of the effects is sGC dependent, especially in
PRP. The impact of ODQ on responses was less pronounced in
WP, particularly in the case of B7. due in part to the greater
influence of NO-independent effects, as illustrated by in¬
creased sensitivity of WP to the furazan counterparts of B7
and B8. The effects of the furazan derivatives were weak
compared to aspirin, but were nevertheless more potent than
salicylic acid under the conditions of these experiments. The
lower activity of these agents in PRP compared to WP is in
keeping with the complete hydrolysis of the furoxan-aspirin
acetyl group in serum (Cena et al., 2003), resulting in
formation of relatively ineffectual salicylic acid. These hybrid
molecules are likely to undergo hydrolysis at two positions:
firstly, at the acetyl group, converting aspirin to salicylic acid
and secondly at the other ester linkage to release the furoxan.
The order and rates at which hydrolysis occurs will greatly
influence the ability of these compounds to retain aspirin
activity.
The high levels of NO release by B8 and the loss of its
aspirin effect in PRP imply that its antiplatelet actions are
mainly NO mediated. By comparison, B7, which releases NO
more slowly, has an 1C50 closer to that of aspirin. These
characteristics are more suitable for a NO-aspirin hybrid drug
because they provide potential for a more balanced action
between NO and aspirin antiplatelet effects. The unfortunate
loss of the aspirin effect in PRP, however, is an issue that needs
to be addressed by appropriate modification of the chemical
structure.
The finding that NCX4016 is an effective inhibitor of
platelet aggregation in WP is in keeping with previous in vitro
studies using NCX4016 (Lechi et al., 1996) and the related
drug, NCX4125 (Minuz et al., 1995; Wallace et al., 1995).
However, our results go on to show that the effect is lost in
PRP, possibly due to sequestration by a plasma constituent
such as albumin or due to breakdown in the plasma to the
inactive salicylic acid. Interestingly, the inhibitory effect of
NCX4016 was significantly enhanced compared to aspirin but
was not affected by the sGC inhibitor, ODQ. While a cGMP-
independenl effect of NCX4016-derived NO cannot be ruled
out, our inability to detect NO generation from this
compound, coupled with the known inability of platelets to
effect NO release from organic nitrates (Weber et al., 1996),
and the COX assay data demonstrating powerful anti-COX
activity of NCX4016. suggests that the antiplatelet action of
NCX4016 is most likely NO independent. Although our study
shows NCX4016 to be a poor inhibitor of platelet function,
its effects in other cell types may still make it a useful
cardiovascular drug. Antiplatelet effects may still be retained
in vivo through remote nitrooxy-ester activation in cells other
than platelets (e.g. smooth muscle cells), although this would
appear to be a rather inefficient method of NO delivery
specifically to platelets. Nevertheless, antiplatelet effects of
NCX4016 have been demonstrated ex vivo, in animals and
humans (Wainwright et al., 2002; Fiorucci et al., 2003; 2004;
Momi et al., 2005). Furthermore, NCX4016 has beneficial
effects in vivo, where it has been demonstrated to protect the
vascular endothelium in diabetic rats (Pieper et al., 2002), to
reduce blood pressure in hypertensive rats (Muscara et a!.,
2001), to prevent restenosis in hypercholesterolemic mice
(Napoli et al., 2001) and to reduce infarct size in a model of
cardiac ischaemia in pigs (Wainwright et al., 2002).
The furoxan drugs are very stable compounds that appear
only to decompose to release significant NO when they
encounter appropriate media. There was no release of NO
from the furoxans in Tyrode's buffer, but NO generation was
detected in PPP. WP and PRP. These observations suggest
that some elements of plasma can stimulate decomposition of
the furoxans and that the platelets themselves enhance the
effect to a greater extent for B8 than B7.
The plasma components, albumin, glutathione and ascor¬
bate, chosen for their reducing properties, were all found to
have a limited capacity to stimulate furoxan decomposition
to release NO. In the case of B7, these constituents could
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individually stimulate moderate NO release, and the additive
effect of all three could fully emulate NO release in PPP. The
effect of these constituents on B8 were similar, if less dramatic,
for the individual reducing agents, but here there was no
additive effect when coincubated, suggesting that an as yet
unidentified plasma constituent is responsible for a proportion
of NO release from B8.
Reconstitution of Tyrode's buffer with intracellular levels of
GSH and ascorbate demonstrated that both these reducing
agents were mildly effective in stimulating release of NO from
the compounds. Interestingly, however, they acted synergisti-
cally in coincubation experiments to massively increase NO
generation. The separate experiments using platelet extracts
established that there was a relationship between the concentra¬
tion of platelet extract and amount of NO generated from the
furoxans. The ability of platelet extracts to generate NO from
both furoxans was found to be dependent on the presence of
reduced thiol groups and, in keeping with our other NO release
data and the platelet aggregation experiments, B8 generated
considerably more NO in the lOmin incubation period than B7.
Taken together, these results indicate that low-level decomposi¬
tion of B7 in plasma can be explained by the additive effects
of albumin, GSH and ascorbate but that there is also likely to
be much greater NO release inside platelets mediated by the
synergistic action of ascorbate and reduced intracellular thiols.
B8 is more sensitive to the same agents, and its plasma
decomposition is also affected by an as yet unidentified plasma
component. Given the reactive nature of NO, the apparent
preferential release inside target cells is a likely advantage for
successful NO delivery over compounds that can only generate
NO remotely in cell types other than platelets.
Previous studies have shown that both furoxan-aspirins
(Cena et al., 2003) and NCX4016 (Fiorucci et al., 1999; 2003;
Fiorucci & Del Soldato, 2003) have a preferential gastro-
toxicity profile over aspirin, suggesting either a masking of the
toxic aspirin effect or an active NO element in the gastro¬
intestinal tract. However, the activity of both the NO and
aspirin elements of the hybrids in platelets is questionable.
NCX4016 has no antiplatelet action in PRP, and in WP it fails
to demonstrate aspirin-independent effects, possibly due to
sequestration by a plasma constituent. Unlike NCX4016, the
furoxans demonstrate aspirin-independent effects on platelet
aggregation in both PRP and WP in vitro, but their ability
to retain the action of aspirin is compromised, particularly
in PRP. The furoxans appear to display a more effective
antiplatelet activity over NCX4016, but further molecular
modifications are necessary in an effort to retain the aspirin
actions, in addition to achieving the added benefits of NO.
In summary, furoxan-aspirin hybrids are stable antiplatelet
compounds, the decomposition of which is catalysed by
endogenous agents which may instil a potential for primarily
intracellular delivery of NO, on account of the differential
distribution of glutathione and ascorbate within cells com¬
pared to plasma and extracellular fluid. While the furoxan
hybrid examples tested in these experiments carry a number of
limitations, they also highlight the therapeutic potential of
future exponents of this class of drugs.
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Abstract
Background: Prostaglandin H2 synthase (PGHS) is the enzyme that catalyses the two-stage
conversion of arachidonic acid to prostaglandin H2 (PGH2) prior to formation of prostanoids that
are important in inflammation. PGHS isozymes (-1 and -2) are the target for nonsteroidal anti¬
inflammatory drugs (NSAIDs).
Given the rekindled interest in specific anti-inflammatory PGHS inhibitors with reduced unwanted
side effects, it is of paramount importance that there are reliable and efficient techniques to test
new inhibitors. Here, we describe a novel in vitro electron paramagnetic resonance (EPR)-based
assay for measuring the activity of PGHS-1.
Methods: We validated a novel in vitro PGHS-i activity assay based on the oxidation of spin-trap
agent, I-hydroxy-3-carboxy-pyrroiidine (CPH) to 3-carboxy-proxy (CP) under the action of the
peroxidase element of PGHS-I. This quantifiable spin-adduct, CP, yields a characteristic 3-line
electron paramagnetic (EPR) spectrum.
Results: The assay is simple, reproducible and facilitates rapid screening of inhibitors of PGHS-I.
Aspirin (100 pM, I mM) caused significant inhibition of spin-adduct formation (72 ± I I and 100 ±
16% inhibition of control respectively; P < 0.05). Indomethacin (100 pM) also abolished the signal
(I 14 ± 10% inhibition of control; P < 0.01). SA and the PGHS-2-selective inhibitor, NS398, failed
to significantly inhibit spin-adduct generation (P > 0.05).
Conclusion: We have demonstrated and validated a simple, reproducible, quick and specific assay
for detecting PGHS-I activity and inhibition. The EPR-based assay described represents a novel
approach to measuring PGHS activity and provides a viable and competitive alternative to existing
assays.
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Background
Prostaglandins are derived from arachidonic acid (AA) in
a pathway dependent on the PGHS (EC 1.14.99.1) family
of enzymes, which are commonly known as cyclooxygen-
ase (COX), referring to the first step of enzymatic activity.
PGHS converts AA to prostaglandin H2 (PGH2), the pre¬
cursor of all prostanoids. The enzyme contains two active
sites: a COX site, where AA is converted into the hydroper-
oxy endoperoxide, prostaglandin G2 (PGG2), and a haem
with peroxidase activity that reduces PGG2 to PGH2 (For
review see [1]). The reduction of PGG2 by the peroxidase
element generates the corresponding alcohol. This reac¬
tion has previously been demonstrated to concurrently
oxidise aminopyrine molecules to aminopyrine free radi¬
cals [2). Here, a spin-trapping agent, l-hydroxy-3-car-
boxy-pyrrolidine (CPH) is oxidised to 3-carboxy-proxy
(CP), probably under the action of the peroxidase, in a
similar fashion to that previously seen with aminopyrine
(Fig- !)■
and is often referred to as the 'inducible' isoform due to its
tendency to be expressed in response to inflammatory
stimuli. The exception to this is in the brain and spinal
cord, where PGHS-2 is constitutively expressed and plays
a role in nociception signaling [4],
The importance of PGHS as a therapeutic target has long
been highlighted by the actions of aspirin, [5,6] the first
drug of the family of nonsteroidal anti-inflammatory
drugs (NSAIDs) for use as analgesics, anti-inflammatory
agents and antithrombotic agents. In contrast to other
NSAIDs, such as indomethacin, which reversibly bind at
the COX active site [7], aspirin causes an irreversible inhi¬
bition of PGHS by rapidly and selectively acetylating the
hydroxyl group of a serine residue (Ser 530) near the C-
terminus of the enzyme, forming an impediment to the
binding of AA [8-10]. The ensuing irreversible PGHS inhi¬
bition requires de novo synthesis of the enzyme for subse¬
quent production of prostaglandins.
Two structurally similar PGHS isoforms exist (PGHS-1
and PGHS-2) which are encoded by different genes and
the expression of which varies between tissues [3], PGHS-
1 is often referred to as the 'house-keeping' isoform due to
its regulatory functions in many tissues. PGHS-2 is virtu¬
ally undetectable under normal conditions in most tissues
385Tyr + Tyr""
Figure I
Schematic diagram showing the peroxidase activity of PGHS.
The process requires prior formation of a tyrosine radical
from a tyrosine residue in close proximity to the haem group
(Tyr 385). The tyrosyl radical is either recycled or partici¬
pates in the suicide inactivation of the enzyme (for review of
this process see [39], Following incorporation of oxygen and
formation of PGG2, the peroxidase reduces the peroxyl moi¬
ety to the equivalent alcohol. The process allows for the con¬
comitant oxidation of spin-trap CPH to CP which is detected
by EPR.
Interest in PGHS has been re-ignited recently on account
of two advances in the development of novel NSAIDs.
Firstly, nitroaspirins [11-14] are being developed in an
effort to overcome the gastrotoxic side-effects of aspirin
that represent the major limitation to its therapeutic use
[15-17]. Nitroaspirins make use of the protective effects of
nitric oxide (NO) to compensate for the potentially dam¬
aging impact of aspirin-mediated depletion of protective
prostaglandins in the gastric mucosa. Secondly, the sug¬
gestion that the gastrotoxic side effects of aspirin are due
to the inhibition of housekeeping PGHS-1, whereas its
anti-inflammatory effects are due to inhibition of PGHS-
2, led to the development of selective inhibitors of the
COX-2 activity of PGHS-2, in the hope that the beneficial
effects could be retained without injury to the gastric
mucosa [18], However, recently, several of these new
selective PGHS-2 inhibitors have been withdrawn due to
mounting evidence of an increased risk of stroke. The
increased risk of thrombus is thought to be due to inhibi¬
tion of PGHS-2 in endothelial cells leading to down regu¬
lation of anti-thrombotic prostaglandins (such as
prostacyclin) in relation to the unaffected PGHS-1 derived
thromboxanes [19-21].
Given the intense interest in PGHS activity and inhibition,
it is perhaps surprising that relatively few assays for the
activity of this enzyme have been developed. Amongst the
most popular techniques is the measurement of throm¬
boxane B2 (TXB2), the stable metabolite of PGH2-derived
TXA2, as a marker of PGHS activity [22]. Alternatively,
measurement of oxygen consumption using an oxygen
electrode [23,24], assays using radio-labelled substrate
[25] and immunoassays for the prostaglandin products
[23] can also be applied. More recently, a commercial
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been developed for use on purified enzyme. The assay
involves the use of labelled substrate that generates a
luminescent product under the action of the hydroperox-
idase element of PGHS, most likely via the generation of
oxidising free radicals.
Electron paramagnetic resonance (EPR) has been previ¬
ously utilized to measure free radicals generated by PGHS
as a measure of its activity [26,27]. However these tech¬
niques can involve complex mechanisms to trap the short¬
lived radical species. For instance in an in vitro assay using
purified PGHS, liquid nitrogen was utilised to stop the
reaction and was required to stabilise the tyrosyl radical
species generated, in order that it could be recorded by
EPR [26], Another technique which recorded PGHS activ¬
ity in mouse keratinocytes relied on the use of the antioxi¬
dant glutathione to stabilize the generated radical before
trapping it with DMPO [27].
Here, we present a novel method for assaying the activity
of PGHS-1 in which EPR is used to detect the stable adduct
CP, formed from oxidation of commonly available spin-
trap, CPH [28], under the action of the peroxidase ele¬
ment of PGHS-1. The aim of the studies described was to
validate this technique for assaying PGHS-1 activity in
vitro, to determine its effectiveness at establishing the
inhibitory effects of conventional NSAIDs and to confirm
that a COX-2-selective inhibitor was ineffective in this
assay.
Methods
Unless otherwise stated, all drugs and chemicals were pur¬
chased from Sigma, Dorset, UK. The assay was performed
at 37°C in 1 ml ofTyrode's buffer (137 mM NaCl, 2.7 mM
KC1, 1.05 mM MgS04, 0.4 mM NaH2P04, 12.5 mM
NaHC03, 5.6 mM Glucose, 10 mM HEPES and 0.8 mM
CaCl2 in deionised water at pH 7.4. 100 units/ml ovine
seminal PGHS-1 was incubated with 1.5 pM haematin (5
min, 37 °C) prior to the assay. Data from the manufactur¬
ers of the PGHS-1 reveals that 1 unit of enzyme consumes
1 nanomole of oxygen at 37 °C in the presence of 1 pM
haematin and 100 pM AA. Aspirin, salicylic acid,
indomethacin, NS398 (Merck Biosciences, Nottingham,
UK) or vehicle control (DMSO, 1%) was added and left to
incubate for a further 10 min prior to addition of the spin-
trap, CPH (1 mM; Axxora). At this point (t = -2 min), a
baseline EPR measurement was taken (MS200, Magnet-
tech, Germany. Instrument settings: BO-field, 3356 gauss;
sweep width; 50 Gauss, sweep time, 30 sec; modulation
amplitude, 1500 mGauss; microwave power, 20 mW). 2
min later,.100 pM AA (as sodium salt) was added (t = 0).
Further EPR readings were taken at t = 1.5 (the earliest
timepoint at which readings could consistently be taken
after addition of AA), 4 and 6 min. The suicidal nature of
PGHS-1 activation means that the period of activation is
anticipated to be complete within ~1 min of AA addition
[3]-
The results are corrected for any auto-oxidation of spin-
trap by subtraction of values recorded from a duplicate
sample run in the absence ofAA. The intensity scale on the
y-axis of all graphs is an arbitrary scale based upon the
area under the curve of the first derivative traces generated.
Statistical analyses
All statistical tests were performed using GraphPad Prism
version 4. P < 0.05 was considered to be statistically signif¬
icant. Tests performed were either 1-way ANOVA with
Dunnett's post-test or 2-way ANOVA, as indicated in the
text.
Results
Time-dependent adduct generation by PGHS-1
Addition of AA caused a time-dependent increase in the
characteristic 3-line EPR spectrum for a spin-adduct with
the unpaired electron in the vicinity of a nitrogen atom
(Fig 2a). The majority of the reaction was complete by the
time the first reading was taken (t = 1.5 min). The signal
developed rapidly before the first reading (244 intensity
units.min1), but subsequently slowed to a relatively con¬
stant rate (65 intensity units.min ') over the following 4.5
min of the assay (Fig 2b, n = 9-12); the equivalent exper¬
iment without AA failed to show the initial rapid rise and
was significantly lower than the AA-treated sample
throughout (p = 0.02, 2-way ANOVA, repeated measures).
An inter-sample coefficient of variation of 0.18 (18%) was
calculated from the control data obtained. From these
data, it was determined that t = 1.5 min was an appropri¬
ate point at which to compare free radical generation
between control and NSAID-treated PGHS-1, given that
spin-adduct generation in response to AA had peaked -
subsequent adduct formation was at an equivalent rate in
control and AA-treated samples and was likely to be due
to non-specific auto-oxidation of CPH.
Inhibitory effect of aspirin and salicylic acid
The impact of pre-incubation of PGHS-1 with different
concentrations of aspirin that spanned the known thera¬
peutic range (10 pM - 1 mM) is shown in Fig 3. Our
results indicate that aspirin concentrations of 100 pM and
1 mM caused significant inhibition of spinTadduct forma¬
tion at the 1.5 min time-point (to 72 ± 11 and 100 + 16%
of control respectively; P < 0.05 for both compared to con¬
trol, 1-way ANOVA followed by Dunnet's post-hoc analy¬
sis).
Parallel experiments with salicylic acid (SA, 10 pM - 1
mM; n = 6) showed that a 10 min pre-incubation with SA
failed to significantly inhibit generation of the spin-
adduct, even at the highest concentration (P > 0.05).
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(a) Sample EPR spectra obtained in the absence (control;
PGHS + AA) and presence of aspirin (100 |±M or I mM) after
correction for background autoxidation. EPR settings: B0-
field, 3356 gauss; sweep width; 50 Gauss, sweep time, 30 sec;
modulation amplitude, I 500 mGauss; microwave power, 20
mW. (b) Mean data for development of EPR signal intensity
(AU) with time in the absence (control; PGHS + AA) and
presence of aspirin (100 pM). In both cases, substrate (AA)
was added at t = 0 min. P = 0.02, 2-way ANOVA, repeated
measures: n = 9-I 2.
Comparative pharmacology of PGHS-1 and PGHS-2
inhibitors
Equivalent concentrations (100 pM) of the recognized
non-selective PGHS inhibitors, aspirin and indomethacin
both significantly (P < 0.05 and P < 0.01 respectively)
inhibited generation of the EPR-detectable spin adduct at
1.5 min (72 ±11 and 114 ± 10% inhibition of control
response respectively), but the PGHS-2-selective inhibi¬
tor, NS398 had no effect (P > 0.05) on this assay of PGHS-
1, despite its use at a concentration which is in excess of
that required to significantly inhibit PGHS-2 [29] (Fig 4).
Discussion
Here we have validated a new, quick, simple and repro¬
ducible method for detecting PGHS-1 activity and inhibi¬
tion in vitro. The principle of the assay was based on the
concomitant oxidation which occurs with the reduction
of PGG, by the peroxidase element of PGHS [2]. This oxi¬
dation can be exploited in the absence of antioxidant glu¬























Effect of aspirin and salicylic acid (10 pM - I mM) on EPR sig¬
nals generated from PGHS-1 after treatment with substrate
(AA). In each case, incubations with aspirin or SA were for
10 min prior to the baseline EPR reading (t = -2 min, not
shown). AA was added at t = 0 min and readings shown were
taken at t = 1.5 min. *P < 0.05, **P < 0.01; I -way ANOVA
with Dunnett's post-hoc test vs. control: n = 8— I 0.
adduct, CP which generates a characteristic 3-line EPR
spectrum. The amplitude of the EPR signal is proportional
to the amount of adduct generated.
Our results indicated that oxidation of CPH by the iso¬
lated PGHS-1 enzyme upon addition of the enzyme sub¬
strate, AA, was sufficient to be easily detectable by EPR.
The initial peak in the detected signal recorded at the first
reading, had by the subsequent time-points slowed to a
rate that was equivalent to the signal generation from sub¬
strate-free enzyme, most likely due to autoxidation of the
spin trap. The loss of specific enzyme-mediated radical
generation is unsurprising, given the well-recognised sui¬
cidal nature of activated PGHS-1 [3], From these time-
course experiments, we selected a 1.5 min time-point for





















Comparative effects of SA and recognized NSAIDs (all 100
pM) on EPR signal intensity measured at t = 1.5 min. *P <
0.05, **P < 0.0 I; I -way ANOVA with Dunnett's post-hoc
test vs. control: n = 6-10.
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AA-dependent free radical generation was complete but
the signal was not significantly enhanced by autoxidation
of the spin trap.
Aspirin pretreatment (10 min) was shown to have a con¬
centration-dependent inhibitory effect in the published
range [30], but the acetyl-free counterpart, SA, failed to
significantly inhibit enzyme activity. The lack of effect of
SA indicates that aspirin-mediated inhibition of the
enzyme is dependent on the acetyl group, the moiety
involved in PGHS inhibition, and not due to a non-spe¬
cific antioxidant effect. SA was not expected to have any
effect in this assay because it is known not to affect PGHS-
1 or 2 activity [31] except in intact cells [30], possibly by
suppressing PGHS-2 transcription in response to exoge¬
nous stimuli [32]. Furthermore, the reversible, non-spe¬
cific PGHS inhibitor, indomethacin [33] was
demonstrated to have a powerful inhibitory effect, whilst
the PGHS-2 specific inhibitor, NS398 at a concentration
known to inhibit PGHS-2 [29] failed to do so. Signal
intensities shown in the figures are after subtraction of an
AA-free control from a parallel experiment to account for
autooxidation of the spin trap. A negative signal (as
observed with indomethacin for example) therefore indi¬
cates that the control value was greater than the AA-treated
sample, which might suggest that AA has a slight antioxi¬
dant effect on its own.
These results confirm that the assay is relevant for NSAIDs
with different modes of inhibitory action. As purified
PGHS-2 is now available commercially (Sigma), it maybe
possible to adapt this assay system to help determine the
specificity of novel PGHS-2 inhibitors.
This assay provides a convenient screening method for
inhibitors of the PGHS enzyme. Whilst various tech¬
niques exist to assay the activity of PGHS isoforms, each
has its own disadvantages. For instance, recording the oxy¬
gen uptake by PGHS is an option to measure its activity
but this requires high enzyme concentrations and also
accurate control of the initial oxygen concentrations [24].
Optical techniques are prone to interference from col¬
oured assay constituents (such as haematin) and require
high AA concentrations. Techniques recording uptake of
radiolabeled substrate [25] can be complex and expen¬
sive. Our technique provides quick inexpensive results
that give real-time determination of COX-inhibition. Data
obtained, as demonstrated by percentage inhibition of
control response achieved with aspirin, is comparable to
other in vitro techniques [34-3.6],
The technique described in the present study also offers a
simpler alternative than previous EPR techniques where
generated radicals are detected following complex radical
stabilization steps [26,27] and thereby providing poten¬
tial for less loss of signal. Tsai et al. [26] used dry ice and
liquid nitrogen to stop the reaction and trap the radical.
The recording of spectra was then carried out under liquid
nitrogen. By comparison, our method uses direct oxida¬
tion of a spin-trap to generate an adduct that is sufficiently
stable to allow successive time-point readings to be taken
without the need to freeze the sample at the required
time-point. The method by Schreiber et al. [27] did use a
spin-trap, but required the use of glutathione to reduce an
amine radical to the parent amine, liberating a thiyl radi¬
cal which was trapped by DMPO. In our method, the spin-
trap is oxidised directly, thus reducing the potential for
loss of signal. Furthermore, there is some evidence of
rapid signal decay in the Schreiber method; the spectra
show a decrease of the DMPO-thiyl signal during the
course of the measurement, whereby the spectral lines no
longer conform to the expected 1:2:2:1 ratio. By compari¬
son, the EPR signal generated in the present technique is
much more resilient and does not decay during the time-
course of experiments.
It is important to recognize the potential limitations of
this assay. Its reliance on the oxidation of CPH might pre¬
clude its use in cells, given that the cellular environment
is usually very rich in antioxidants such as GSH, and its
presence at intracellular concentrations (~5 mM) could
effectively compete out the spin-trap and nullify the assay.
The susceptibility of polyunsaturated fatty acids such as
AA to peroxidative attack by reactive oxygen species may
impact on the recorded level of radical if radicals are con¬
sumed by free AA in the samples [37,38], Furthermore, it
is important to recognize that the in vitro nature of the
assay does not account for any absorption, metabolic or
availability issues that might relate to applied NSAIDs.
Conclusion
In summary, we have validated a new, simple, EPR-based
assay for detecting PGHS-1 activity and inhibition. We
have demonstrated it to be sensitive to the inhibitory
effects of conventional NSAIDs (aspirin and indometh¬
acin) and not to SA or a PGHS-2 specific inhibitor. In
principle, this assay should be equally applicable to meas¬
uring PGHS-2 activity in isolated enzyme. As such, this
assay might prove to be a useful research tool in the ongo¬
ing search for novel PGHS inhibitors of both isoforms of
the enzyme.
Abbreviations
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Therapeutic effects of nitric
oxide-aspirin hybrid drugs
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This review examines the therapeutic potential and mechanisms of action of
drugs known as nitric oxide (NO)-aspirins. Drugs of this class have an
NO-releasing moiety joined by ester linkage to the aspirin molecule. NO-aspi-
rins have the capability to release NO in addition to retaining the cyclooxyge-
nase-inhibitory action of aspirin. The protective nature of NO led to the
development of NO-aspirins in the hope that they might avoid the gastric
side effects associated with aspirin. However, it has become apparent that
the drug-derived NO instils potential for a wide range of added beneficial
effects over the parent compound. In this review, the authors focus on the
analgesic, anti-inflammatory, cardiovascular and chemopreventative actions
of compounds of this emerging drug class.
Keywords: analgesia, anti-inflammatory, aspirin, cancer, cardiovascular, gastrotoxicity, nitric oxide,
NO-aspirin, NSAID, platelet
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1. Introduction
1.1 Nitric oxide
Nitric oxide (NO) is an ubiquitous signalling messenger molecule involved in diverse
physiological and pathophysiological processes, including vasodilatation, inhibition of
platelet activation and inflammatory cell adhesion (1-6). Furthermore, NO functions as
a neurotransmitter at non-adrenergic, non-cholinergic neurons [7].
The enzyme soluble guanylate cyclase (sGC) is the primary target for NO. NO
binds sGC with high affinity, prompting it to undergo a conformational change,
resulting in a 400-fold increase in the rate of enzyme catalytic activity [8]. Activated
sGC converts guanosine-5'-triphosphate (GTP) to 3', 5'-cyclic guanosine mono-
phoshate (cGMP) [9-11). There are a number of cGMP-dependent effector pathways
that involve cGMP-dependent protein kinases, cGMP-regulated phosphodiesterases
and cGMP-gated ion channels. Low levels of NO acting primarily via these
pathways are responsible for several protective physiological processes including
vasodilation, antithrombotic effects and anti-inflammatory actions.
1.2 Aspirin
Aspirin (acetylsalicylic acid) was first synthesised in 1899 and was the first example
of the family of NSAIDs, Its therapeutic uses include the treatment of headache,
rheumatic pain and inflammation; low-dose aspirin is also an effective prophylactic
against thrombotic events in the cardiovascular system.
Aspirin causes irreversible inhibition of the cyclooxygenase (COX) family of
enzymes by selectively and rapidly acetylating a serine residue (Ser 530) near the
C-terminus of the protein, forming an impediment to the binding of AA [12-14], The
acetylation evokes a requirement for new COX to be synthesised for subsequent pro¬
duction of prostaglandins, which are derived from arachidonic acid in a COX-medi-
ated process. There are two structurally similar COX isoforms named COX-1 and
COX-2, which are encoded by different genes. The expression of the COX isozymes
varies between tissues and aspirin is more selective for COX-1 than COX-2. Other
10.1517/14728222.10.6.xxx © 2006 Informa UK Ltd ISSN 1472-8222 1
Therapeutic effects of nitric oxide-aspirin hybrid drugs
Figure 1. Structural formula of NO-aspirin, NCX4016.
NSAIDs, such as naproxen and ibuprofen, reversibly bind at
the active site of COX and have different selectivity profiles to
aspirin for the different COX isoforms [15].
1.3 Why make an NO-aspirin?
The long-term use of aspirin for pain and inflammation asso¬
ciated with conditions such as rheumatism and arthritis is
limited due to its serious side effects in the gastrointestinal
tract, which are reported to cause 16,000 deaths each year in
the US [16]. The first evidence for gastric damage caused by
aspirin was presented in 1938 [17] and there is now clear evi-:
dence for an association between gastric and duodenal ulcers
and NSAID use [18-22].
NSAIDs cause gastric mucosal injury through their topical
irritant effect and, more importantly, thrdugh suppression of
gastric prostaglandin synthesis [23,24], Many components of
mucosal defense rely on prostaglandins, including mucus and
bicarbonate secretion, blood flow [25,26], epithelial cell turn¬
over and repair, as well as mucosal immunocyte function. It is
believed, therefore, that inhibition of prostaglandin synthesis
by aspirin depresses these defences, providing an opportunity
for further damage by endogenous agents, such as acid, pepsin
and bile salts [22].
1.4 Overcoming gastrotoxicity
NO-aspirins are hybrid drugs that have been designed to
combine the cytoprotective effects of NO with aspirin, with a
view to their use as 'gastric-friendly' NSAIDs [27,28],
NO has various effects on the gastric mucosa which might
contribute to enhanced mucosal defense. It increases blood
flow in the gastric mucosa, promoting repair and removal of
toxins [29]. It also increases secretion of protective gastric
mucus [30] and is thought to promote healing of gastric ulcers
by promoting angiogenesis [31]. NO from NO-aspirins can
inhibit neutrophil adhesion to the blood vessel wall in a sim¬
ilar fashion to prostacyclin (PGI2) [32]. It is, therefore, plausi¬
ble that NO could replace aspirin-inhibited PGI2 as an
inhibitor of neutrophil adherence and also of mucosal
vasodilatation [16]. Wallace et al. documented the role of
neutrophils in gastropathy [33]. They reported neutrophil
adherence to the vascular endothelium of the gastric
microcirculation as one of the earliest events following
NSAID administration to laboratory animals [34]. Further¬
more, they showed, with the use of antibodies, that
by preventing neutrophil adherence, mucosal injury was
avoided [35]. As NO is known to prevent neutrophil adhe¬
sion, the idea of combining an NO group with an NSAID
was suggested to prevent gastropathy [33].
Given that some of the gastrotoxic effects of aspirin have
been suggested to be due to actions of the carboxylic acid
moiety [36], it would be expected that esterification at this
group might reduce such an outcome. NO-aspirin hybrids
have been shown to have reduced acute gastric toxicity,
thought to be primarily via prevention of the carboxylic acid
effect, rather than a direct protective effect of NO, although
the latter may contribute [27]. It is worth noting, however, that
under the acid conditions of the stomach, aspirin will exist
primarily in the non-ionised form and would not, therefore,
be expected to significantly affect the pH through ionisation
at the carboxylic acid.
1.5 NO-aspirins
Two main subtypes of NO-aspirins have so far been developed:
the nitro-oxy ester derivatives and the furoxan derivatives.
The first NO-aspirin hybrid drugs to be released were the
NicOx compounds, NCX4016 (2 acetoxy-benzoate
2-(2-nitroxymethyl)-phenyl ester; Figure l) and the related,
NCX4215 [37]. Both are nitro-oxy ester (organic nitrate)
derivatives of aspirin, often referred to as nitroaspirins.
NCX4016 consists of an aspirin molecule linked by an
ester bond to a molecular spacer, which, in turn, is linked to a
nitro-oxy ester group [38]. NCX4016 has been demonstrated
not to be ulcerogenic at equivalent concentrations to those of
aspirin that are capable of inducing ulcers. Furthermore, it
causes a dose-dependent protection against gastric lesions
induced by hydrochloric acid/ethanol mix in rats [39].
More recently, another series of NO-aspirin hybrid drugs
have been developed with a furoxan NO-donor moiety [27,40],
These drugs link the NO-donating furoxan group by ester
linkage to the aspirin molecule (Figure 2). These compounds
also appear to overcome the problem of gastric lesions [27],
although the precise mechanism and the possible role of NO
has not yet been fully determined.
The NO release mechanism of the different NO-aspirin
drugs varies. The ester linkage of NCX4016 requires enzymatic
cleavage, as has been identified for other organic nitrates, such as
glyceryl trinitrate [41]. In contrast, the furoxan derivatives appear
to release NO intracellularly on encountering antioxidant
species glutathione and ascorbate [40). ■ .
In addition to their intended ■ use as gastric-sparing
NSAIDs, NO-aspirins have been demonstrated to bring
about various therapeutic effects, which are explored
throughout this review.
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Figure 2. General structural formula of a furoxan-aspirin
hybrid drug and structural formulae of two typical
examples (B8 and B7).
2. Anti-inflammatory and analgesic effects
NO-aspirins have the potential to be anti-inflammatory
through the actions of both the NO-moiety and the parent
compound. The anti-inflammatory effects of aspirin are well
covered in the literature (see [42-47] for reviews). Both major
types of NO-aspirin have been shown to retain an inhibitory
action on COX-1 in vitro [40,48] and, thus, have the potential
to retain the anti-inflammatory, analgesic and antithrombotic
actions of the parent compound, aspirin.
The analgesic effect of aspirin is brought about through
suppression of prostaglandin E2 and 12 production via inhibi¬
tion of COX. These prostaglandins, whether synthesised dur¬
ing inflammation or in the spinal cord, play a role in firing of
nociceptors (for review see [49]). NO-aspirins have the poten¬
tial to be analgesic through COX-mediated inhibition of
prostaglandin production, but the impact of the NO moiety
is more difficult to predict due to the impact of NO on pain
pathways apparently varying with the type, location and cause
of pain [50-52]. A study into the antinociceptive properties of
NCX4016 revealed that in models of inflammatory pain,
such as carrageenan-induced hindpaw hyperalgesia and acetic
acid-induced abdominal constrictions, as well as acute pain
(tail flick), NCX4016 demonstrated a very similar antinocice¬
ptive profile to aspirin itself [53]. Both furoxan—aspirin hybrids
and NCX4016 cause similar anti-inflammatory effects to
aspirin in the carrageenan model of inflammation [27,53,54],
NO derived from NCX4016 inhibits the action of caspase 1
(also known as IL-1(3 converting enzyme) in lipopolysaccha-
ride (LPS)-stimulated monocytes in vitro [55]. Caspases are a
family of proteases that are involved in cytokine release and
apoptosis [56]. Caspase 1 is upregulated in inflammatory dis¬
eases and is responsible for the generation of IL-ip and IL-18,
which themselves are responsible fdr stimulating formation of
further pro-inflammatory cytokines such as TNF-a and IL-8.
The anti-inflammatory effects of NCX4016 are due to inhibi¬
tion of the formation of these pro-inflammatory cytokines
through 5-nitrosylation of a cysteine residue in caspase 1 [57].
A similar effect on caspase 1 has also been suggested to be
responsible for the gastric-sparing property of NCX4016.
Inhibition of gastric caspase activity in rats was determined to
occur through both cGMP-dependent and -independent path¬
ways^]. Furthermore, NO-aspirins have also been reported to
inhibit the release of inflammatory cytokines, such as TNF
from LPS-stimulated macrophages [59.60]. This anti-TNF-a
action by the NO-aspirins may provide clinical benefit in
inflammatory diseases such as arthritis, Crohn's disease
and asthma [61-64].
Rheumatoid arthritis is a chronic inflammatory autoim¬
mune disorder characterised by inflammation of the lining
(synovium) of joints. Joint deterioration, together with the
pain associated with synovial inflammation can lead to sub¬
stantial loss of mobility. Pro-inflammatory cytokines are
abundant in the joints of sufferers [64]. Anti-TNF-a drugs
have been recently licensed for use in arthritis to limit the
contribution of the cytokine to inflammation [62]. Treatment
of arthritis with drugs of the NSAID class is severely limited
due to the gastric side effects associated with the high doses
and chronic nature of the treatment required. However, it is
hoped that NO-aspirins might offer a preferable alternative to
therapy with conventional NSAIDs; the dual action of the
COX-mediated aspirin action and the anti-TNF-a response,
together with their resistance to gastrotoxic effects mediated
by NO, is a promising antiarthritic profile for this target.
It is now widely accepted that inflammation is a key element
in atherogenesis and atherosclerotic plaque rupture that leads to
acute cardiovascular events (myocardial infarction or stroke) [65].
Given its potential to prevent the gastrotoxicity associated with
aspirin, NO-aspirin hybrids might be a useful means of chronic
delivery of aspirin, not only to help prevent thrombosis associ¬
ated with vascular disease, but also to limit progression of
disease itself. The potential of NO-aspirins in cardiovascular
disease is explored in the following section.
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3. Cardiovascular effects
NO-aspirins have the potential to bring about cardiovascular
benefit through both the aspirin and the NO moieties.
There are extensive protective effects of NO in the vascular
system to complement those of aspirin. NO is a powerful
endogenous vasodilator [66], which acts to keep the vascula¬
ture in an active state of dilatation by stimulating
cGMP-mediated relaxation of vascular smooth muscle cells.
NO also opposes the adherence of monocytes to the vessel
wall [67]. The reduction of endogenous NO synthesis or
availability is heavily implicated as a key factor in the initia¬
tion and progression of atherogenesis [68-71]. Furthermore,
NO displays antithrombotic actions through its ability to
inhibit platelet adhesion [4,72] and aggregation [3,73,74].
3.1 Antiplatelet action
The antithrombotic action of aspirin comes about through
its ability to inhibit the action of platelet COX-1-derived
thomboxane A-, (TxA2). TxA-, exerts its effect by action on
G-protein-coupled TP receptors, which activate phospho-
lipase C to bring about Ca2+-mediated platelet shape change
and aggregation [75].
The inhibition of platelet COX-1 by aspirin occurs
through a selective and rapid acetylation as outlined above.
The acetylation causes irreversible COX inhibition and a
requirement for new COX to be synthesised for subsequent
production of prostaglandins. As platelets are widely thought
to lack the necessary cellular machinery to synthesise new pro¬
teins, the effect of aspirin will last for the lifetime of the plate¬
let (~ 10 days). An overall recovery of COX activity by 10%
per day has been observed, in line with platelet turnover [76].
Following aspirin-mediated COX inhibition, there is a cumu¬
lative reduction in platelet TxA2 production [77], leading to a
prolonged antithrombotic effect.
The NO element of the hybrids instils potential for a sec¬
ondary antithrombotic effect. NO-mediated inhibition of
platelet aggregation occurs primarily via stimulation of cGMP,
although cGMP-independent signalling mechanisms have
also been identified [71,78-81].
The mechanism of NO release can impact on the ability of
the clinical effectiveness of the drug. For instance, NCX4016
is a nitro-oxy ester (organic nitrate) that relies upon enzymatic
breakdown to yield NO [82]. The metabolism of both
N.CX4016, and the organic nitrate compound, glyceryl trini¬
trate, has been reported to occur through identical mecha¬
nisms [41]. Due to the poor capability of platelets to release
NO from organic nitrates [83], an NO-mediated antiplatelet
effect of NO is not detected in vitro [40]. This lack of ability of
platelets to release NO from NCX4016 is demonstrated in its
lack of antiplatelet effects in plasma [40]. Antiplatelet effects
with organic nitrate hybrids have been demonstrated in
washed platelets [37,84,85], but it is likely that these occur
through the aspirin moiety [40], Furthermore, antiplatelet
effects of NCX4016 have been demonstrated ex vivo, in
animals and humans [86-89], presumably through remote
nitro-oxy ester activation in vascular cells other than platelets
(e.g., smooth muscle cells); a rather inefficient method of NO
delivery specifically to platelets.
In contrast to NCX4016, the NO release mechanism of
furoxans is dependent on the presence of intracellular anti¬
oxidants glutathione and acorbate [40] and, therefore, furoxans
release NO without the requirement for the same cellular
machinery as that for organic nitrates. The reliance of furo-
xan-hybrids upon such endogenous agents to catalyse decom¬
position may instil potential for primarily intracellular
delivery of NO, on account of the differential distribution of
glutathione and ascorbate within cells compared with plasma
and extracellular fluid. The antiplatelet effects of the furoxan
compounds have been demonstrated in vitro and have been
shown to display a degree of NO-mediated antiplatelet effects
to complement those of the aspirin moiety [40].
3.2 Vasodilatory effects
In healthy blood vessels, NO is synthesised by endothelial NO
synthase in response to shear stress, hypoxia and endogenous
mediators [90-92], whereupon it acts directly up on the adjacent
smooth muscle cells to bring about local vasodilatation.
NO-induced vasorelaxation is almost exclusively
cGMP-dependent; NO acts on soluble guanylate cyclase to
increase cGMP, which results in a reduction of intracellular cal¬
cium in smooth muscle cells and thereby relaxation [1,2,92-95].
NO also has a range of effects on COX activity (see [96] for
review). Although it has no impact on purified COX-1 and
can suppress LPS-induced COX-2 expression [97,98], it has been
demonstrated to stimulate PGI2, production in endothelial
cells possibly by a cGMP-independent mechanism [99]. Given
that PGI2 is a potent vasodilator, this may be another means by
which NO causes vasodilation.
An interesting situation arises with regard to the role of the
NO-aspirin moiety in the vasculature. The dual inhibition by
aspirin in the COX-generation of the vasoconstricting agent,
TXA2 [ioo], and the vasodilatory substance, PGI2 [101,102],
raises uncertainties as to whether aspirin will cause vasodilata¬
tion or vasoconstriction. TXA., acts through specific TP
receptors leading to phospholipase C activation, release of
inositol triphosphate and an increase in the intracellular Ca2+
level, thus triggering smooth muscle contraction [103,104]. The
source of vasoconstricting TXA2 is platelet COX-1 [105] and,
due to their anucleate nature, full TXA2 recovery will only
take place as a function of platelet turnover following aspirin
inhibition [ 106]. In contrast, in the vasculature, PGI-, is pre¬
dominantly COX-2-derived and the main source is endothe¬
lial cells [ 107]. PGI2 brings about endothelium-dependent
vasodilatation through activation of IP receptors [108] and
the consequent stimulation of adenylyl cyclase to generate
cAMP [108,109]. Interestingly, studies with cultured vascular
smooth muscle cells demonstrate that the vasodilator PGI2 is
produced only on stimulation by thrombin [110,111] or when
in co-culture with platelets [112], suggesting that PGI-, is
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produced endogenously to overcome the vasoconstrictive
effects of TXA2. It was further shown that following treat¬
ment with aspirin, PGI2 is restored within only a couple of
hours [ill]. The reason behind the recent withdrawal of the
COX-2-specific inhibitors valdecoxib and rofecoxib [107,113] is
their instigation of an inbalance between vascular PGI-, and
platelet TXA2, ultimately resulting in an increased risk of
stroke. This is most likely due to inhibition of COX-2 in
endothelial cells and the resultant loss of the antithrombotic
and vasodilator agent, PGI2, whereas COX-l-derived TXA2
remains unaffected [107]. It is generally accepted that in vivo,
aspirin treatment will result in a vasodilatory effect due to the
predominant inhibition of platelet-derived TXA2 over that of
endothelium-derived PGI2. Due to platelets only possessing
COX-1 [114] and aspirin being nearly 170-fold more selective
for COX-1 than COX-2 [43], low-dose aspirin that is effective
at inhibiting platelet COX-l-derived TXA, without affecting
endothelial COX-2-derived PGI2 [115,116] can be administered.
These facts, combined with the ability of endothelial cells to
restore PGR production quickly [110,117], suggest that aspirin
will bring about a vasodilatory action. It is worth noting, how¬
ever, that some reports suggest that very high concentrations
of PGI2 can paradoxically act as a vasoconstrictor [118,119].
The vasorelaxant effects of the nitro-oxy ester, NCX4016,
have been investigated in vitro. Unlike platelets, vascular
smooth muscle cells are able to metabolise NCX4016 to
release NO and thus this class of compound has the poten¬
tial for NO-mediated vasodilatory effects. NCX4016 causes
vasodilatation in noradrenaline-preconstricted rat tail arter¬
ies in a process that relies on cGMP and not the aspirin
moiety [120]. The lack of platelets in the isolated preparation
likely excludes a vasodilatory role for the aspirin moiety in
such a system. Interestingly, NCX4016 does not have a sig¬
nificant impact on blood pressure at therapeutically relevant
concentrations on account of the slow release of NO [121]
avoiding rapid vasodilation [122]. The furoxan—aspirin hybrid
drugs have also been demonstrated to cause NO-mediated,
cGMP-dependent vasodilatation in isolated rat aortae
(unpublished data).
3.3 Restenosis
Restenosis is the reocclusion through vascular remodelling ofO O
a blood vessel after a procedure such as angioplasty. Aspirin is
commonly given following angioplasty to prevent thrombotic
events [123], but it carries the risk of gastric ulceration outlined
above. The lack of endothelium-derived NO has been impli¬
cated in restenosis [124] and administration of NO or its pre¬
cursor, L-arginine, can help prevent its progression [125-128].
NCX4016, but not aspirin, reduced experimental restenosis
in aged rats, an effect attributed to a reduction in vascular
smooth muscle cell proliferation [129]. The use of NCX4016
was demonstrated to significantly reduce restenosis when
compared with aspirin in hypercholesterolaemic mice [130].
The effect was also shown to be greater than that achieved
with an NO-donor [130].
3.4 Myocardial ischaemia and infarction
NCX4016 has been shown to reduce damage to the myocar¬
dium in an NO-dependent manner following ischaemia—reper-
fusion in a rabbit model [131]. It was further shown to reduce
infarct size caused by myocardial ischaemia-reperfusion in
pig [89] and anesthetised rat models [132]. The beneficial effects
have been attributed to the release of NO preventing inflamma¬
tion, obstruction of the coronary microcirculation, arrhythmias
and myocardial necrosis [132].
4. Cancer therapy
The use of aspirin is reported to reduce the risk of several
cancers, including colorectal, oesophageal, breast, lung and
bladder cancer (for review see [133-136]) via inhibition of
prostaglandin synthesis [13".138;. Colon cancer has been asso¬
ciated with high COX-derived prostaglandin output,
particularly PGE2 [139], which enhance tumour growth [140].
It is thought that these prostaglandins are derived from
COX-2 [137,141], giving rise to the perceived benefits of
COX-2 inhibitors in cancer prevention [141-143].
However, the use of NO-aspirin compounds would ide¬
ally inhibit the cancer-promoting prostaglandins to the same
extent as aspirin, but would avoid gastrotoxicity and the car¬
diovascular risk of the specific COX-2 inhibitors [107,142].
Indeed, in an in vitro model using colon cancer cell lines, an
NO-aspirin that shares many of the molecular characteristics
of NCX4016 was up to 250-fold more potent than aspirin
at inhibiting the growth of cancer cells [144]. The NO-aspirin
was also determined to be more potent than the parent com¬
pound in pancreatic, prostate, lung, skin, leukaemia and
breast cancer cell lines, in some cases up to 6000-fold more
effective [144]. The increase in potency over the parent com¬
pound is likely an effect of the structural change [145]. Inter¬
estingly, a further nitro-oxy ester hybrid, NCX 4060, has
been shown to have benefit in human prostate cancer cell
systems [146], an area where the effect of the parent
compound is unclear [147,148].
In vivo, NCX4016 has been demonstrated to reduce cancer
growth in a rat model of colonic adenocarcinoma to a greater
extent than aspirin [149]. The beneficial effect of the
NCX4016 appears not to be related to COX-inhibition [149]
and, thus, may be due to as yet undetermined effects of the
NO and not the aspirin moiety.
5. Type 2 diabetes
NiCox are soon to initiate Phase II trials on NCX4016 in
Type 2 diabetes. The company claims that previous clinical
studies with the drug show an increased sensitivity to insulin
in patients with Type 2 diabetes [201]. Interestingly, it is inti¬
mated that the effect is due to release of salicylic acid with
high dose treatment, perhaps acting synergistically with NO
to increase insulin sensitivity. These data do not appear to
have yet been published, although some of them were
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presented at the American Heart Association meeting in
2005. This approach represents an interesting new angle in
development of this compound in particular; here it is being
used as a vector for delivery of high concentrations of salicylic
acid rather than aspirin. The protective effects of NO facili¬
tate delivery of sufficient salicylic acid to have a therapeutic
effect without inducing gastric side effects.
6. Expert opinion and conclusion
It has become apparent that compounds of the so-called
NO-aspirin drug class have beneficial effects that exceed their
intended use as 'gastric-friendly' alternatives to aspirin. The
drugs have been demonstrated to retain the COX-inhibitory
effect of the aspirin moiety, thus providing analgesic,
anti-inflammatory and antithrombotic effects on a par with the
parent compound. The introduction of the NO moiety does
not prevent these actions and provides at least the potential for
a beneficial range of anti-inflammatory and cardiovascular
effects to complement those of the aspirin moiety.
Despite being the most commonly used drugs over the past
century, there have been few advances in measures to reduce the
gastroenteropathy associated with NSAIDs (for review see [33]).
The search for gastric-friendly NSAIDs has recently encoun¬
tered a major setback with the withdrawal of some
COX-2-specific inhibitors due to mounting evidence of
increased risk of stroke [107]. Clearly, there is still a market for a
safer alternative to aspirin and it is possible that NO-aspirin
drugs may fulfil such a requirement.
NO-aspirins have been demonstrated to have potent
antiplatelet, vasodilatory and anti-inflammatory actions con¬
tributed to by both moieties of the hybrid. It is hoped that
such actions, along with their favourable gastric profile, will
enable them to replace aspirin as a prophylactic against
thrombotic events or for use as an anti-inflammatory agent in
patients with arthritis. Furthermore, data obtained with
NO-aspirins are leading to more speculative applications to
those envisaged for them and it is likely yet more will arise as
future studies are carried out. Such applications include anti¬
cancer therapy where the nitro-aspirin family has been dem¬
onstrated to have beneficial effects in vitro [144] and Type 2
diabetes, where NCX4016 is soon to enter Phase II trials. The
latter is a particularly interesting divergence for this com¬
pound because, in this setting, it is believed to be acting as a
precursor for salicylic acid rather than aspirin per se. Never¬
theless, the protective properties of NO in the gastric mucosa
remain important and the developments in this setting will be
watched with interest.
A further possible application is in atherosclerosis and the
associated thrombosis, although the complexity of the disease
poses a number of challenges. NO-aspirins may provide some
clinical benefit through their antiplatelet and anti-inflamma¬
tory actions, but as NO-related species have been linked to
smooth muscle cell necrosis [150], it is difficult to predict the
actions of the NO-aspirins in an established plaque. Future
studies utilising the Apo-E model [151] could help to clarify
whether or not the drugs will be of benefit in this setting.
The in vitro experimental data using drugs of this class
should be viewed with a degree of caution. The results of
some studies may not translate into clinical effects on the
basis that the drug concentrations used are unrealistically
high and if such doses were to be used in vivo, the high
plasma concentrations may result in toxic effects such as liver
and kidney damage, inhibition of de novo protein synthesis
associated with high aspirin dose [152.153], or the mutagenic
effects associated with high doses of NO [154],
Both families of NO-aspirin hybrid drugs discussed
throughout this review have their drawbacks. NCX4016 has
limited NO-mediated antiplatelet effects due to the organic
nature of its NO moiety. Its antiplatelet effects in vitro are
almost exclusively aspirin mediated and in plasma are
non-existent, most likely due to instability of the acetyl
group [40], The fact that antiplatelet effects have been dem¬
onstrated ex vivo [58,86,88.89] suggests that NO can be released
from the compounds in vivo, probably through remote acti¬
vation of the organic nitrate group — an inefficient method
of delivering NO if platelets constitute the primary target in
this therapeutic setting.
A further drawback to NCX4016, and perhaps one more
likely to limit its use, is the probability of tolerance with
long-term or high-dose use; there is no evidence to suggest
that NCX4016 will not be susceptible to the tolerance prob¬
lems associated with long-term or high dosage use of
traditional organic nitrates (for review on tolerance see [155]).
The stability of the acetyl group is a problem that appears
to affect the aspirin-like action of both NCX4016 and the
furoxan NO-aspirins in plasma. Further chemical modifica¬
tions arc necessary in order that an aspirin function is retained
in plasma, although it is perhaps the instability of the aspirin
moiety in plasma which has been turned to advantage in the
use of NCX4016 in diabetes.
For a drug to be classed as a hybrid drug, it is reasonable to
presume that both components of the drug contribute to its
clinical effect. There are examples of furoxan derivatives (B8)
where dominance of the NO moiety suggests that it acts
almost exclusively as an NO-donor, rather than a true
NO-aspirin hybrid. The furoxan NO-aspirin B7, has a better
balance between the NO and aspirin moieties and, therefore,
has greater potential as a hybrid drug [40], It is likely
that chemical modification may be necessary to drugs of the
furoxan NO-aspirin family in order that both elements
remain active, otherwise the co-administration of an
NO-donor with aspirin may be a more suitable option. The
nitro-oxy ester compound NCX4016 is also affected by
'balance' problems and thus does not necessarily act as a true
hybrid. Its effect in platelets is limited to an aspirin-only
mediated action due to lack of NO release [40], at least in vitro.
The effects of the novel furoxan hybrids have not been as
extensively examined as NCX4016 and further study is
required before fair comparisons can be made. However, the
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furoxan class appears to be a competitive alternative to
NCX4016. The NO-release mechanism does not rely on
enzymatic degradation and their specific release in the pres¬
ence of cellular antioxidants instils potential for targeted cellu¬
lar delivery of NO [40]. The furoxan NO moiety is not
nitro-oxy ester and does not require the same enzyme-medi¬
ated mechanism to release NO, and so their long-term use
would not be expected to be limited by tolerance, although
this remains to be tested. Data obtained with NO-aspirins so
far definitely warrant further research into this class of drugs.
From a gastric safety perspective, the results seem promising
and drugs of this class may offer an effective alternative to
COX-2 inhibitors. However, further work is needed to perfect
the art of hybrids in this arena, particularly with respect to bal¬
ancing NO release with COX activity, stabilising the com¬
pounds in plasma to retain the acetyl group and looking for
alternatives to nitro-oxy esters that would avoid tolerance
issues for long-term and/or high-dose arthritis treatment.
Bibliography
Papers of special note have been highlighted as
either of interest (•) or of considerable interest
(••) to readers.
1. GRUETTER CA, GRUETTER DY,
LYON JE, KADOWITZ PJ,
IGNARRO LJ: Relationship between cyclic
guanosine 3':5'-monophosphate formation
and relaxation of coronary arterial smooth
muscle by glyceryl trinitrate, nitroprusside,
nitrite and nitric oxide: effects of methylene
blue and methemoglobin./. Pharmacol.
Exp. Ther. (1981) 219( 1): 181 -186.
2. IGNARRO LJ, BUGA GM, WOOD KS,
BYRNS RE, CHAUDHURI G:
Endothelium-derived relaxing factor
produced and released from artery and vein
is nitric oxide. Proc. Natl. Acad. Sci. USA
(1987) 84(24):9265-9269.
3. RADOMSKI MW, PALMER RM,
MONCADA S: The anti-aggregating
properties of vascular endothelium:
interactions between prostacyclin and
nitric oxide. Br. J. Pharmacol. (1987)
92(3):639-646.
4. RADOMSKI MW, PALMER RM,
MONCADA S: The role of nitric oxide and
cGMP in platelet adhesion to vascular
endothelium. Biochem. Biophys. Res.
Commun. (1987) 148(3):1482-1489.
5. AHLUWALIA A, FOSTER P,
SCOTLAND RS et al.: Antiinflammatory
activity of soluble guanylate cyclase:
cGMP-dependent down-regulation of
P-selectin expression and leukocyte
recruitment. Proc. Natl. Acad. Sci. USA
(2004) 101 (5):1386-1391.
6. DE CATERINA R, LIBBY P, PENG HB
et al.: Nitric oxide decreases
cytokine-induced endothelial activation.
Nitric oxide selectively reduces endothelial
expression of adhesion molecules and
proinflammatory cytokines.
J. Clin. Invest. (1995) 96(l):60-68.
7. RAND MJ: Nitrergic transmission: nitric
oxide as a mediator of non-adrenergic,
non-cholinergic neuro-effector
transmission. Clin. Exp. Pharmacol. Physiol.
(1992) 19(3): 147-169.
8. STONE JR, MARLETTA MA: Spectral
and kinetic studies on the activation of
soluble guanylate cyclase by nitric oxide.
Biochemistry (1996) 35(4): 1093-1099.
9. ISHII K, CHANG B, KERWIN JF Jr etal.:
Formation of endothelium-derived relaxing
factor in porcine kidney epithelial LLC-PK1
cells: an intra- and intercellular messenger for
activation of soluble guanylate cyclase.
J. Pharmacol. Exp. Ther. (1991) 256(l):38-43.
10. MORO MA, RUSSEL RJ, CELLEK S
et al.: cGMP mediates the vascular and
platelet actions of nitric oxide: confirmation
using an inhibitor of the soluble guanylyl
cyclase. Proc. Natl. Acad. Sci. USA (1996)
93(4): 1480-1485.
11. WOLIN MS, WOOD KS, IGNARRO LJ:
Guanylate cyclase from bovine lung.
A kinetic analysis of the regulation of the
purified soluble enzyme by protoporphyrin
DC, heme, and nitrosyl-heme.
J. Biol. Chem. (1982) 257(22):13312-13320.
12. DEWITT DL, SMITH WL: Primary
structure of prostaglandin G/H synthase
from sheep vesicular gland determined from
the complementary DNA sequence.
Proc. Natl. Acad. Sci. USA (1988)
85(5): 1412-1416.
13. ROTH GJ, MAJERUS PW:
The mechanism of the effect of aspirin
on human platelets. I. Acetylation of
a particulate fraction protein.
J. Clin. Invest. (1975) 56(3):624-632.
14. ROTH GJ, STANFORD N,
MAJERUS PW: Acetylation of
prostaglandin synthase by aspirin.
Proc. Natl. Acad. Sci. USA (1975)
72(8):3073-3076.
15. GARCIA RODRIGUEZ LA,
VARAS-LORENZO C, MAGUIRE A,
GONZALEZ-PEREZ A: Nonsteroidal
antiinflammatory drugs and the risk of
myocardial infarction in the general
population. Circulation (2004)
109(24):3000-3006.
16. KEEBLE JE, MOORE PK:
Pharmacology and potential therapeutic
applications of nitric oxide-releasing
non-steroidal anti-inflammatory and
related nitric oxide-donating drugs.
Br. J. Pharmacol. (2002) 137(3):295-310.
17. DOUTHWAITE AH, LINTOTT GAM:
Gastroscopic observation of the effect of
aspirin and certain other substances on
the stomach. Lancet (1938) 2:1222-1224.
18. NO AUTHORS LISTED: AMIS:
a randomized, controlled trial of aspirin
in persons recovered from myocardial
infarction. JAMA (1980) 243(7):661-669.
19. LEVY M: Aspirin use in patients with
major upper gastrointestinal bleeding and
peptic-ulcer disease. A report from the
Boston Collaborative Drug Surveillance
Program, Boston University Medical
Center. N. Engl. J. Med. (1974)
290(21):1158-1162.
20. SILVOSO GR, IVEY KJ, BUTT JH et al.:
Incidence of gastric lesions in patients with
rheumatic disease on chronic aspirin
therapy. Ann. Intern. Med. (1979)
91 (4):517-520.
21. SUN DC, ROTH SH, MITCHELL CS,
ENGLUND DW: Upper gastrointestinal
disease in rheumatoid arthritis.
Am.]. Dig. Dis. (1974) 19(5):405-410. ■
22. WOLFE MM, LICHTENSTEIN DR,
SINGH G: Gastrointestinal toxicity of
nonsteroidal antiinflammatory drugs.
N. Engl. J. Med. (1999) 340(24):1888-1899.
23. RAINSFORD KD, WILLIS C:
Relationship of gastric mucosal damage
induced in pigs by antiinflammatory drugs
to their effects on prostaglandin production.
Dig. Dis. Sci. (1982) 27(7):624-635.
Expert Opin. Ther. Targets (2006) 10(6) 7
Therapeutic effects of nitric oxide-aspirin hybrid drugs
24. WALLACE JL, MCCAFFERTY DM,
CARTER L, MCKNIGHT W,
ARGENTIERI D: Tissue-selective
inhibition of prostaglandin synthesis in rat
by tepoxalin: anti-inflammatory without
gastropathy? Gastroenterology (1993)
105(6): 1630-1636.
25. ASHLEY SW, SONNENSCHEIN LA,
CHEUNG LY: Focal gastric mucosal
blood flow at the site of aspirin-induced
ulceration. Am. J. Surg. (1985)
l49(l):53-59.
26. GANA TJ, HUHLEWYCH R, KOO J:
Focal gastric mucosal blood flow in
aspirin-induced ulceration.
Ann. Surg. (1987) 205(4):399-403.
27. CENA C, LOLLI ML, LAZZARATO L
et al.: Antiinflammatory, gastrosparing, and
antiplatelet properties of new NO-donor
esters of aspirin. J. Med. Chem. (2003)
46(5):747-754.
• A detailed introduction to the furoxan
NO-aspirin class.
28. DEL SOLDATO P, SORRENTINO R,
PINTO A: NO-aspirins: a class of new
anti-inflammatory and antithrombotic
agents. Trends Pharmacol. Sci. (1999)
20(8):319-323.
29. WALLACE JL, MILLER MJ: Nitric oxide
in mucosal defense: a little goes a long way.
Gastroenterology (2000) 119(2):512-520.
30. BROWN JF, KEATES AC, HANSON PJ,
WHITTLE BJ: Nitric oxide generators and
cGMP stimulate mucus secretion by rat
gastric mucosal cells. Am. J. Physiol. (1993)
265(3 Pt 1):G418-G422.
31. MA L, WALLACE JL: Endothelial nitric
oxide synthase modulates gastric ulcer
healing in rats. Am. J. Physiol. Gastrointest.
Liver Physiol. (2000) 279(2):G34l-G346.
32. LEFER AM, LEFER DJ: The role of nitric
oxide and cell adhesion molecules on the
microcirculation in ischaemia-reperfusion.
Cardiovasc. Res. (1996) 32(4):743-751.
33. WALLACE JL: Nonsteroidal
anti-inflammatory drugs and
gastroenteropathy: the second
hundred years. Gastroenterology { 1997)
112(3): 1000-1016.
• Detailed revjew on the gastrotoxicity .
of NSAIDs.
34. ASAKO H, KUBES P, WALLACE J,
WOLF RE, GRANGER DN: Modulation
of leukocyte adhesion in rat mesenteric
venules by aspirin and salicylate.
Gastroenterology (1992) 103(1): 146-152.
35. WALLACE JL, MCKNIGHT W,
MIYASAKA M et al.: Role of endothelial
adhesion molecules in NSAID-induced
gastric mucosal injury. Am. J. Physiol.
(1993) 265(5 Pt 1):G993-G998.
36. RAINSFORD KD, WHITEHOUSE MW:
Gastric irritancy of aspirin and its
congeners: anti-inflammatory activity
without this side-effect. J. Pharm.
Pharmacol. (1976) 28(7):599-601.
37. WALLACE JL, MCKNIGHT W,
DEL SOLDATO P, BAYDOUN AR,
CIRINO G: Anti-thrombotic effects of a
nitric oxide-releasing, gastric-sparing aspirin
derivative./ Clin. Invest. (1995)
96(6):2711-2718.
• Introduction to the effects of nitro-oxy
derivatives of aspirin.
38. FIORUCCI S, DEL SOLDATO P:
NO-aspirin: mechanism of action and
gastrointestinal safety. Dig. Liver Dis.
(2003) 35(Suppl. 2):S9-S19.
39. TAKEUCHI K, SUZUKI K,
YAMAMOTO H et al.: Cyclooxygenase-2
selective and nitric oxide-releasing
nonsteroidal anti-inflammatory drugs and
gastric mucosal responses. J. Physiol.
Pharmacol. (1998) 49(4):501 -513.
40. TURNBULL CM, CENA C,
FRUTTERO R et al.: Mechanism of action
of novel NO-releasing furoxan derivatives of
aspirin in human platelets. Br. J. Pharmacol.
(2006) 148(4):517-526.
41. GROSSER N, SCHRODER H:
A common pathway for nitric oxide release
from NO-aspirin and glyceryl trinitrate.
Biochem. Biophys. Res. Commun. (2000)
274(l):255-258.
42. AMANN R, PESKAR BA:
Anti-inflammatory effects of aspirin and
sodium salicylate. Eur. J. Pharmacol. (2002)
447(1): 1-9.
43. VANE JR, BOTTING RM:
Mechanism of action of antiinflammatory
drugs. Int. J. Tissue React. (1998) 20(1):3-15.
44. GILROY DW: The role of aspirin-triggered
lipoxins in the mechanism of action of •
aspirin. Prostaglandins Leukot. Essent.
Fatty Acids (2005) 73(3-4):203-210.
45. KAPOOR M, SHAW O, APPLETON I:
Possible anti-inflammatory role of
COX-2-derived prostaglandins:
implications for inflammation research.
Curr. Opin. Investig. Drugs (2005)
6(5):46l-466.
46. FIORUCCI S, ANTONELLI E:
Cyclo-oxygenase isoenzymes.
Structural basis for selective inhibition of
cyclo-oxygenases by anti-inflammatory
agents. Dig. Liver Dis. (2001)
33(Suppl. 2):S2-S7.
47. FIERRO IM, SERHAN CN:
Mechanisms in anti-inflammation and
resolution: the role of lipoxins and
aspirin-triggered lipoxins. Braz. J.
Med. Biol. Res. (2001) 34(5):555-566.
48. CORAZZIT, LEONE M, MAUCCI R,
CORAZZI L, GRESELE P: Direct and
irreversible inhibition of cyclooxygenase-1
by nitroaspirin (NCX 4016)./. Pharmacol.
Exp. Ther. (2005) 315(3): 1331-1337.
49. FERREIRASH: Peripheral analgesia:
mechanism of the analgesic action of
aspirin-like drugs and opiate-antagonists.
Br. /. Clin. Pharmacol. (1980)
10(Suppl. 2):237S-245S.
50. HOHEISEL U, UNGER T, MENSE S:
The possible role of the NO-cGMP
pathway in nociception: different spinal and
supraspinal action of enzyme blockers on
rat dorsal horn neurones. Pain (2005)
117(3):358-367.
51. SEMOS ML, HEADLEY PM: The role of
nitric oxide in spinal nociceptive reflexes in




52. LUO ZD, CIZKOVA D: The role of nitric
oxide in nociception. Curr. Rev. Pain (2000)
4(6):459-466.
53. AL-SWAYEH OA, CLIFFORD RH,
DEL SOLDATO P, MOORE PK:
A comparison of the anti-inflammatory and
anti-nociceptive activity of nitroaspirin and
aspirin. Br. J. Pharmacol. (2000)
129(2):343-350.
54. WALLACE JL, REUTER B, CICALA C
et al.: Novel nonsteroidal anti-inflammatory
drug derivatives with markedly reduced
ulcerogenic properties in the rat.
Gastroenterology (1994) 107(1 •): 173-179.
55. FIORUCCI S, SANTUCCI L, CIRINO G
et al.: IL-1 beta converting enzyme is a
target for nitric oxide-releasing aspirin:
new insights in the antiinflammatory
mechanism of nitric oxide-releasing
nonsteroidal antiinflammatory drugs.
J. Immunol. (2000) l65(9):5245-5254.
56. CREAGH EM, MARTIN SJ: Caspases:
cellular demolition experts. Biochem.
Soc. Trans. (2001) 29(Pt 6):696-702.
8 Expert Opin. Ther. Targets (2006) 10(6)
Turnbull, Rossi & Megson
57. DIMMELER S, HAENDELER J,
NEHLS M, ZEIHER AM: Suppression of
apoptosis by nitric oxide via inhibition of
interleukin-1 beta-converting enzyme
(ICE)-like and cysteine protease protein
(CPP)-32-like proteases./. Exp. Med.
(1997) 185(4):601-607.
58. FIORUCCI S, ANTONELLI E,
SANTUCCI L et al.\ Gastrointestinal safety
of nitric oxide-derived aspirin is related to
inhibition of ICE-like cysteine proteases
in rats. Gastroenterology (1999)
116(5): 1089-1106.
59. MINUZ P, DEGAN M, GAINO S et aL.
NCX4016 (NO-Aspirin) has multiple
inhibitory effects in LPS-stimulated human
monocytes. Br. J. Pharmacol. (2001)
134(4):905-911.
60. TURNBULL CM, CENA C,
FRUTTERO R et aL A novel hybrid
aspirin-nitric oxide donor drug inhibits
TNF-a release from LPS-activated human
macrophages in vitro. From the BPS Winter
Meeting, December 2005: Proceedings ofthe
British Pharmacological Society (2005).
61. RUSSO C, POLOSA R: TNF-alpha as
a promising therapeutic target in chronic
asthma: a lesson from rheumatoid arthritis.
Clin. Sci. {Lond) (2005) 109(2): 135-142.
62. SIDDIQUI MA, SCOTT LJ: Spotlight on
infliximab in Crohn disease and rheumatoid
arthritis. BioDrugs (2006) 20(l):67-70.
63. CARROCCIO A, DI PRIMA L,
PIRRONE G et aL. [Anti-TNF (infliximab)
treatment in Crohn disease: safety profile].
RecentiProg. Med. (2006) 97(2): 108-112;
quiz 122.
64. CHRISTODOULOU C, CHOY EH:
Joint inflammation and cytokine inhibition
in rheumatoid arthritis. Clin. Exp. Med.
(2006) 6(1):13-19.
65. ROSS R: Atherosclerosis-an inflammatory
disease. N. Engl. J. Med. (1999)
340(2):115-126.
66. PALMER RM, FERRIGE AG,
MONCADA S: Nitric oxide release
accounts for the biological activity of
endotheliurn-derived relaxing factor.
Nature (1987) 327(6l22):524-526.
67. TSAO PS, WANG B, BUITRAGO R,
^
SHYY JY, COOKE JP: Nitric oxide
regulates monocyte chemotactic protein-11.
Circulation (1997) 96(3):934-940,
68. ANDERSON TJ, GERHARD MD,
MEREDITH IT et al.\ Systemic nature of
endothelial dysfunction in atherosclerosis.
Am. J. Cardiol. (1995) 75(6):71 B-74B.
69. MAXWELL AJ: Mechanisms of
dysfunction of the nitric oxide pathway in
vascular diseases. Nitric Oxide (2002)
6(2):101-124.
70. SHAUL PW: Endothelial nitric oxide
synthase, caveolae and the development
of atherosclerosis. J. Physiol. (2003)
547(Pt l):21-33.
71. TREPAKOVA ES, COHEN RA,
BOLOTINA VM: Nitric oxide inhibits
capacitative cation influx in human platelets
by promoting sarcoplasmic/endoplasmic
reticulum Ca2+-ATPase-dependent refilling of
Castores. Circ. Res. (1999) 84(2):201-209.
72. RADOMSKI MW, PALMER RM,
MONCADA S: Endogenous nitric oxide
inhibits human platelet adhesion to vascular
endothelium. Lancet (1987)
2(8567):1057-1058.
73. PASQUI AL, CAPECCHI PL,
CECCATELLI L et al.: Nitroprusside
in vitro inhibits platelet aggregation and
intracellular calcium translocation.
Effect of haemoglobin. Thromh. Res. (1991)
61 (2):113-122.
74. RADOMSKI MW, PALMER RM,
MONCADA S: An L-arginine/nitric oxide
pathway present in human platelets
regulates aggregation. Proc. Natl. Acad.
Sci. USA (1990) 87(13):5193-5197.
75. BRASS LF, SHALLER CC,
BELMONTE EJ: Inositol
1,4,5-triphosphate-induced granule
secretion in platelets. Evidence that the
activation of phospholipase C mediated by
platelet thromboxane receptors involves
a guanine nucleotide binding
protein-dependent mechanism distinct
from that of thrombin./ Clin. Invest.
(1987) 79(4):1269-1275.
76. ALTMAN R, LUCIARDI HL,
MUNTANER J, HERRERA RN:
The antithrombotic profde of aspirin.
Aspirin resistance, or simply failure?
Thromh. J. (2004) 2(1 ):1.
77. PATRIGNANI P, FILABOZZI P,
PATRONO C: Selective cumulative
inhibition of platelet thromboxane
production by low-dose aspirin in
healthy subjects. J. Clin. Invest. (1982)
69(6):1366-1372.
78. CRANE MS, ROSSI AG, MEGSON IL:
A potential role for extracellular nitric
oxide generation in cGMP-indepcndent
inhibition of human platelet aggregation:
biochemical and pharmacological
considerations. Br. J. Pharmacol. (2005)
l44(6):849-859.
79. GORDGE MP, HOTHERSALL JS,
NORONHA-DUTRA AA: Evidence for a
cyclic GMP-independent mechanism in the
anti-platelet action of S-nitrosoglutathione.
Br. J. Pharmacol. (1998) 124(1): 141-148.
80. HOMER KL, WANSTALL JC:
Inhibition of rat platelet aggregation by
the diazeniumdiolate nitric oxide donor
MAHMA NONOate. Br. J. Pharmacol.
(2002) 137(7):1071-1081.
81. SOGO N, MAGID KS, SHAWCA,
WEBB DJ, MEGSON IL: Inhibition of
human platelet aggregation by nitric oxide
donor drugs: relative contribution of
cGMP-independent mechanisms.
Biochem. Biophys. Res. Commun. (2000)
279(2):412-419.
82. WALLACE JL, IGNARRO LJ,
FIORUCCI S: Potential cardioprotective
actions of no-releasing aspirin. Nat. Rev.
DrugDiscov. (2002) 1 (5):375-382.
83. WEBER AA, NEUHAUS T, SEUL C et al.:
Biotransformation of glyceryl trinitrate by
blood platelets as compared to vascular
smooth muscle cells. Eur. J. Pharmacol.
(1996) 309(2):209-213.
84. LECHI C, ANDRIOLI G, GAINO S etaL
The antiplatelet effects of a new
nitroderivative of acetylsalicylic acid-an
in vitro study of inhibition on the early
phase of platelet activation and on TXA2
production. Thromb. Haemost. (1996)
76(5):791-798.
85. MINUZ P, LECHI C, TOMMASOLI R
et al.\ Antiaggregating and vasodilatory
effects of a new nitroderivative of
acetylsalicylic acid. Thromb. Res. (1995)
80(5):367-376.
86. FIORUCCI S, MENCARELLI A,
MENEGUZZI A et aL Co-administration
of nitric oxide-aspirin (NCX-4016) and
aspirin prevents platelet and monocyte
activation and protects against gastric
damage induced by aspirin in humans.
J.Am. Coll. Cardiol. (2004) 44(3):635-641.
87. FIORUCCI S, SANTUCCI L,
GRESELE P et al.\ Gastrointestinal safety of
NO-aspirin (NCX-4016.) in healthy human,
volunteers: a proof of concept endoscopic
study. Gastroenterology (2003)
124(3):600-607.
88. MOMI S, PITCHFORD SC,
ALBERTI PF etal.: Nitroaspirin plus
clopidogrel versus aspirin plus clopidogrel
against platelet thromboembolism and
intimal thickening in mice.
Thromb. Haemost. (2005) 93(3):535-543.
Expert Opin. Ther. Targets (2006) 10(6) 9
Therapeutic effects of nitric oxide-aspirin hybrid drugs
89. WAINWRIGHT CL, MILLER AM,
WORK LM, DEL SOLDATO P:
NCX4016 (NO-aspirin) reduces infarct
size and suppresses arrhythmias following
myocardial ischaemia/reperfusion in pigs.
Br. J. Pharmacol. (2002) 135(8): 1882-1888.
90. ARNET UA, MCMILLAN A,
DINERMAN JL, BALLERMANN B,
LOWENSTEIN CJ: Regulation of
endothelial nitric-oxide synthase during
hypoxia. / Biol. Chem. (1996)
271 (25): 15069-15073.
91. HORI N, WIEST R, GROSZMANN RJ:
Enhanced release of nitric oxide in response
to changes in flow and shear stress in the
superior mesenteric arteries of portal
hypertensive rats. Hepatology (1998)
28(6):1467-1473.
92. RAPOPORT RM, DRAZNIN MB,
MURAD F: Endothelium-dependent
relaxation in rat aorta may be mediated
through cyclic GMP-dependent protein
phosphorylation. Nature (1983)
306(5939):174-176.
93. LIU SF, CRAWLEY DE, ROHDE JA,
EVANS TW, BARNES PJ: Role of
nitric oxide and guanosine 3',5'-cyclic
monophosphate in mediating
nonadrenergic, noncholinergic relaxation
in guinea-pig pulmonary arteries.
Br. J. Pharmacol. (1992) 107(3):861-866.
94. MILLER MR, MEGSON IL,
ROSEBERRY MJ et al.\ Novel
S-nitrosothiols do not engender vascular
tolerance and remain effective in glyceryl
trinitrate-tolerant rat femoral arteries.
Eur. J. Pharmacol. (2000) 403(1-2): 111-119.
95. COLLINS P, GRIFFITH TM,'
HENDERSON AH, LEWIS MJ:
Endothelium-derived relaxing factor alters
calcium fluxes in rabbit aorta: a cyclic
guanosine monophosphate-mediated effect.
J. Physiol. (1986) 381:427-437.
96. O'DONNELL VB, FREEMAN BA:
Interactions between nitric oxide and lipid
oxidation pathways: implications for
vascular disease. Circ. Res. (2001)
88( 1): 12-21.
97. HABIB A, BERNARD C, LEBRET M
et al.\ Regulation of the expression of
cyclooxygenase-2 by nitric oxide in rat
peritoneal macrophages./. Immunol. (1997)
158(8):3845-3851.
98. MINGHETTI L, POLAZZI E,
NICOLINI A, CREMINON C, LEVI G:
Interferon-gamma and nitric oxide
down-regulate lipopolysaccharide-induced
prostanoid production in cultured rat
microglial cells by inhibiting
cyclooxygenase-2 expression.
J. Neurochem. (1996) 66(5): 1963-1970.
99. DAVIDGE ST, BAKER PN,
LAUGHLIN MK, ROBERTS JM:
Nitric oxide produced by endothelial cells
increases production of eicosanoids through
activation of prostaglandin H synthase.
Circ. Res. (1995) 77(2):274-283.
100. HAMBERG M, SVENSSON J,
SAMUELSSON B: Thromboxanes: a new
group of biologically active compounds
derived from prostaglandin endoperoxides.
Proc. Natl. Acad. Sci. USA (1975)
72(8):2994-2998.
101. BUNTING S, GRYGLEWSKI R,
MONCADA S, VANE JR: Arterial walls
generate from prostaglandin endoperoxides
a substance (prostaglandin X) which relaxes
strips of mesenteric and coeliac ateries
and inhibits platelet aggregation.
Prostaglandins (1976) 12(6):897-913.
102. DUSTING GJ, MONCADA S, VANE JR:
Prostacyclin (PGX) is the endogenous
metabolite responsible for relaxation of
coronary arteries induced by arachindonic
acid. Prostaglandins {1977) 13(1):3-15-
103. HABIB A, VEZZA R, CREMINON C,
MACLOUF J, FITZGERALD GA: Rapid,
agonist-dependent phosphorylation in vivo
of human thromboxane receptor isoforms.
Minimal involvement of protein kinase C.
/. Biol. Chem. (1997) 272(11):7191-7200.
104. NARUMIYA S, SUGIMOTO Y,
USHIKUBI F: Prostanoid receptors:
structures, properties, and functions.
Physiol. Rev. (1999) 79(4):1193-1226.
105. PATRONO C, GARCIA
RODRIGUEZ LA, LANDOLFI R,
BAIGENT C: Low-dose aspirin for the
prevention of atherothrombosis.
N. Engl. J. Med. (2005) 353(22):2373-2383.
106. BURCH JW, STANFORD N, MAJERUS
PW: Inhibition of platelet prostaglandin
synthetase by oral aspirin./ Clin. Invest.
(1978) 61 (2):314-319.
107. FITZGERALD GA: Coxibs and
cardiovascular disease. N. Engl. J. Med.
(2004) 351 (17):1709-1711.
108. COLEMAN RA, SMITH WL,
NARUMIYA S: International Union of
Pharmacology classification of prostanoid
receptors: properties, distribution, and
structure of the receptors and their
subtypes. Pharmacol. Rev. (1994)
46(2):205-229.
109. HALUSHKA PV, MAIS DE,
MAYEUX PR, MORINELLI TA:
Thromboxane, prostaglandin and
leukotriene receptors. Ann. Rev.
Pharmacol. Toxicol. (1989) 29:213-239.
110. WEKSLER BB, LEY CW, JAFFE EA:
Stimulation of endothelial cell prostacyclin
production by thrombin, trypsin, and the
ionophore A 23187./ Clin. Invest. (1978)
62(5):923-930.
111. WHITING J, SALATAK, BAILEY JM:
Aspirin: an unexpected side effect on
prostacyclin synthesis in cultured vascular
smooth muscle cells. Science (1980)
210(4470):663-665.
112. WEKSLER BB, MARCUS AJ, JAFFE EA:
Synthesis of prostaglandin 12 (prostacyclin)
by cultured human and bovine endothelial
cells. Proc. Natl. Acad. Sci. USA (1977)
74(9):3922-3926.
113. BROPHY JM: Celecoxib and cardiovascular
risks. Expert Opin. DrugSaf. (2005)
4(6): 1005-1015.
114. PATRONO C: Aspirin as an antiplatelet
drug. N. Engl. J. Med. (1994)
330( 18): 1287-1294.
115. FITZGERALD GA: Cardiovascular
pharmacology of nonselective nonsteroidal
anti-inflammatory drugs and coxibs: clinical
considerations. Am. ]. Cardiol. (2002)
89(6A):26D-32D.
116. PATRONO C, COLLER B, DALEN JE
et al.: Platelet-active drugs : the
relationships among dose, effectiveness,
and side effects. Chest (2001)
119(1 Suppl.):39S-63S.
117. FUSTER V, DYKEN ML, VOKONAS PS,
HENNEKENS C: Aspirin as a therapeutic
agent in cardiovascular disease.
Special Writing Group. Circulation (1993)
87(2):659-675.
118. WILLIAMS SP, DORNGW II,
RAPOPORT RM: Prostaglandin 12
mediates contraction and relaxation of
vascular smooth muscle. Am. J. Physiol.
(1994) 267(2 Pt 2):H796-H803.
119. YANG BC, LAWSON DN, MEHTA JL: ''
' Role of eicosanoids in rat aortic ring
response to agonists and acetylcholine
with special reference to the biphasic
effects of prostacyclin. Eicosanoids (1992)
5(3-4): 135-139.
120. ROSSONI G, MANFREDI B,
DEL SOLDATO P, BERTI F: NCX 4016,
a nitric oxide-releasing aspirin, modulates
adrenergic vasoconstriction in the perfused
rat tail artery. Br. J. Pharmacol. (2002)
137(2):229-236.
10 Expert Opin. Ther. Targets (2006) 10(6)
Turnbull, Rossi & Megson
121. CARINI M, ALDINI G, STEFANI R,
ORIOLI M, FACINO RM:
Nitrosylhemoglobin, an unequivocal index
of nitric oxide release from nitroaspirin:
in vitro and in vivo studies in the rat by
ESR spectroscopy. ]. Pharm. Biomed. Anal.
(2001) 26(4):509-518.
122. CHIROLI V, BENEDINI F, ONGINI E,
DEL SOLDATO P: Nitric oxide-donating
non-steroidal anti-inflammatory drugs:
the case of nitroderivatives of aspirin.
EurJ. Med. Chem. (2003) 38(4):44l-446.
123. AWTRY EH, LOSCALZO J: Aspirin.
Circulation (2000) 101 (10): 1206-1218.
124. MYERS PR, WEBEL R, THONDAPU V
et al.: Restenosis is associated with decreased
coronary artery nitric oxide synthase.
Int. J. Cardiol. (1996) 55(2): 183-191.
125. LE TOURNEAU T, VAN BELLE E,
CORSEAUX D et al.: Role of nitric oxide
in restenosis after experimental balloon
angioplasty in the hypercholcsterolemic
rabbit: effects on neointimal hyperplasia
and vascular remodeling. J. Am. Coll.
Cardiol. (1999) 33(3):876-882.
126. NIEBAUER J, SCHWARZACHER SP,
HAYASE M et al.: Local L-arginine delivery
after balloon angioplasty reduces monocyte
binding and induces apoptosis. Circulation
(1999) 100( 17): 1830-1835.
127. SCHWARZACHER SP, LIM TT,
WANG B et al.: Local intramural delivery
of L-arginine enhances nitric oxide
generation and inhibits lesion formation
after balloon angioplasty. Circulation (1997)
95(7): 1863-1869.
128. LEE JS, ADRIE C, JACOB HJ etal.:
Chronic inhalation of nitric oxide inhibits
neointimal formation after balloon-induced
arterial injury. Circ. Res. (1996)
78(2):337-342.
129. NAPOLI C, ALDINI G, WALLACE JL
et al.: Efficacy and age-related effects of
nitric oxide-releasing aspirin on
experimental restenosis. Proc. Natl. Acad.
Sci. USA (2002) 99(3): 1689-1694.
130. NAPOLI CCIRINOG, DEL SOLDATO P
et al.: Effects of nitric oxide-releasing
aspirin versus aspirin on restenosis in
hypercholesterolemic mice. Proc. Natl.
Acad. Sci. USA (2001) 98(5):2860-2864.
131. ROSSONI G, BERTI M, COLONNA VD
et al.: Myocardial protection by the
nitroderivative of aspirin, NCX 4016:
in vitro and in vivo experiments in the
rabbit. Ital. Heart J. (2000) 1 (2): 146-155-
132. ROSSONI G, MANFREDI B,
COLONNA VD, BERNAREGGI M,
BERTI F: The nitroderivative of aspirin,
NCX 4016, reduces infarct size caused by
myocardial ischemia-reperfusion in the
anesthetized rat. J. Pharmacol. Exp. Ther.
(2001) 297(l):380-387.
133. BARON JA: Aspirin and cancer.
Prev. Med. (1995) 24(2):121-124.
134. MARNETT LJ: Aspirin and related
nonsteroidal anti-inflammatory drugs as
chemopreventive agents against colon
cancer. Prev. Med. (1995) 24(2): 103-106.
135. DUBOIS RN, SMALLEY WE:
Cyclooxygenase, NSAIDs, and colorectal
cancer.J. Gastroenterol. (1996)
31(6):898-906.
136. WANG D, DUBOIS RN: Prostaglandins
and cancer. Gut (2006) 55(1): 115-122.
137. SANO H, KAWAHITO Y, WILDER RL
et al.: Expression ofcyclooxygenase-1 and -2
in human colorectal cancer. Cancer Res.
(1995) 55(17):3785-3789.
138. ROSENBERG L, PALMER JR,
ZAUBER AG et al.: A hypothesis:
nonsteroidal anti-inflammatory drugs
reduce the incidence of large-bowel cancer.
J Natl. Cancer Inst. (1991) 83(5):355-358.
139. KARIM SMM, RAO B: Prostaglandins
and tumours. Adv. Prostaglandin Res.
(1976):303-325.
140. LUPULESCU A: Prostaglandins, their
inhibitors and cancer. Prostaglandins Leukot.
Essent. Fatty Acids (1996) 54(2):83-94.
141. LIM JW, KIM H, KIM KH: Nuclear
factor-kappaB regulates cyclooxygenase-2
expression and cell proliferation in human
gastric cancer cells. Lab. Invest. (2001)
81(3):349-360.
142. YONA D, ARB ER N: Coxibs and cancer
prevention./. Cardiovasc. Pharmacol.
(2006) 47(Suppl. 1):S76-S81.
143. SINICROPE FA: Targeting
cyclooxygenase-2 for prevention and
therapy of colorectal cancer.
Mol. Carcinog. (2006) 45(6):447-454.
144. KASHFI K, RIGAS B: Molecular targets of
nitric-oxide-donating aspirin in cancer.
Biochem. Soc. Trans. (2005) 33(Pt
4):701-704.
145. KASHFI K,.BORGOS, WILLIAMS JL
et al.: Positional isomerism markedly affects
the growth inhibition of colon cancer cells
by nitric oxide-donating aspirin in vitro and
in vivo. J. Pharmacol. Exp. Ther. (2005)
312(3):978-988.
146. ROYLE JS, ROSS JA, ANSELL I et al.:
Nitric oxide donating nonsteroidal
anti-inflammatory drugs induce apoptosis
in human prostate cancer cell systems and
human prostatic stroma via caspase-3.
J. Urol. (2004) 172(l):338-344.
147. MAHMUD S, FRANCO E, APRIKIAN A:
Prostate cancer and use of nonsteroidal
anti-inflammatory drugs: systematic review
and meta-analysis. Br. J. Cancer (2004)
90(l):93-99.
148. NORRISH AE, JACKSON RT,
MCRAE CU: Non-steroidal
anti-inflammatory drugs and prostate
cancer progression. Int. J. Cancer (1998)
77(4):5ll-515.
149. BAK AW, MCKNIGHT W, LI P et al.:
Cyclooxygenase-independent
chemoprevention with an aspirin derivative
in a rat model of colonic adenocarcinoma.
Life Sci. (1998) 62(23):PL367-PL373.
150. SHAW CA: The effects of nitric oxide and
nitric oxide-related species on the viability
of cell types critical to atherosclerosis:
obligatory role of peroxynitrite in cell death.
PhD thesis, University of Edinburgh
(2006).
151. JOHNSON JL, JACKSON CL:
Atherosclerotic plaque rupture in
the apolipoprotein E knockout mouse.
Atherosclerosis (2001) 154(2):399-406.
152. OMERB, ONERP, BAYSALK, OZH:
Effect of acetylsalicylic acid on liver plasma
membrane Ca2+ ATPase activity. Pol. J.
Pharmacol. Pharm. (1990) 42(5):441-446.
153. KWON G, HILL JR, CORBETT JA,
MCDANIEL ML: Effects of aspirin on
nitric oxide formation and de novo protein
. synthesis by RINm5F cells and rat islets.
Mol. Pharmacol. (1997) 52(3):398-405.
154. LI CQ, TRUDEL LJ, WOGAN GN:
Nitric oxide-induced genotoxicity,
mitochondrial damage, and apoptosis in
human lymphoblastoid cells expressing
wild-type and mutant p53. Proc. Natl. Acad.
Sci. USA (2002) 99 (16): 10364-1
155. MUNZEL T, DAIBER A, MULSCH A:
Explaining the phenomenon of nitrate
tolerance. Circ. Res. (2005) 97(7):6l8-628.
Website
201. http://www.nicox.cpm/updatc/NCX40 ] 6.html
Nicox (2006).






Typical volume drawn ~160ml
Chapter 6
LA
LtJ
Dextran Sedimentation
Chapter 7
